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SPECIFIC AIMS 
Uterine fibroids are benign tumors of the myometrium that occur in 70 to 80% of women 
by menopause.
1
 Fibroids are the leading cause of hysterectomy in the United States, are 
associated with increased healthcare costs, increased risk of irregular vaginal bleeding and 
abdominal pain, and also with increased risk of pregnancy and birth-related complications.
2,3,4, 5,6,7
 
In the first trimester of pregnancy, 11% of women have fibroids detectable via ultrasound.
8
 
Though some groups have reported on number, size, and types of fibroids identified in pregnant 
cohorts, the impact of these characteristics on symptoms during pregnancy is poorly 
characterized.  
No single fibroid characteristic is commonly used as a measure of disease severity. 
Multiple factors likely interact to influence risk of pregnancy complications or symptoms among 
women with fibroids. The lack of clear (e.g., linear or consistent) relationships between specific 
fibroid characteristics and outcome risks has limited our ability to fully understand the impact and 
etiology of this disease. A number of measures may be good surrogates for severity—including 
fibroid volume or number of tumors. Changes in fibroid volume may also merit consideration as 
an indicator of disease severity, but during pregnancy, the extent to which fibroids change in size 
is thought to vary from tumor to tumor within an individual as well as between women.
9,10,11,12
 
Furthermore, fibroid and maternal characteristics (such as body mass index, BMI) influencing 
growth during pregnancy are not adequately describe. This makes it difficult to understand 
growth as a measure of fibroid disease severity with the potential to influence complications or 
symptoms.  
Right from the Start: A study of early pregnancy health (RFTS, 2000-2012) is a 
prospective community-based cohort that enrolled a racially diverse group of women who were 
newly pregnant or trying to become pregnant.
13
 We aimed to capture the full range of fibroid 
disease in reproductive-aged women in this cohort. Using standardized research protocol, all 
participants had a transvaginal ultrasounds in the first trimester to determine the presence or 
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absence of fibroids, as well as document fibroid position, type, and size (as small as 0.5 
centimeters).
8
 RFTS has first trimester imaging information for 4,392 participants whose data is 
used in this dissertation; a subset of women had additional ultrasound examinations in each 
trimester of pregnancy (n=216).  All of these women also completed interviews during the first 
trimester detailing bleeding episodes and pain experiences. RFTS data is uniquely suited to help 
me address the research objectives for my dissertation: to better characterize fibroid severity and 
changes in severity during pregnancy and to describe its relationship with bleeding and pain 
symptoms.  
 
My specific Aims were:   
1. To determine whether first trimester vaginal bleeding is associated with measures of 
fibroid severity such as total volume or number of tumors. Among all participants in the 
RFTS cohort who had live births, logistic and polytomous logistic regression models were used to 
determine the independent association of fibroid severity with risk of self-reported bleeding.  
 
2. To ascertain whether first trimester abdominal pain is associated with measures of 
fibroid severity such as total volume or number of tumors. Among the same population 
described in the first Aim, logistic and polytomous logistic regression models were used to 
determine the independent association of fibroid severity with risk of self-reported pain (with and 
without vaginal bleeding accompanying it). 
 
3. To identify associations between maternal characteristics and fibroid growth during 
pregnancy. Information from repeated ultrasounds among a subcohort of women in RFTS was 
used in this Aim. Multilevel logistic regression was used to describe the associations between 
percent change in total volume during pregnancy or change in number of fibroids and factors 
associated with the presence of fibroids (e.g., maternal age and race). 
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CHAPTER I  
SIGNIFICANCE 
Impact of fibroids on public health 
Fibroids greatly impact the United States healthcare system and burden women 
differentially by race. They are the leading cause of hysterectomy—accounting for 30% of 
hysterectomies among reproductive aged women.
3,14
 Wu and colleagues used a nation-wide 
sample of inpatient data and found that hysterectomies due to fibroids were more often performed 
for Black women (70% of hysterectomies) than for White women (33%).
3
 Hysterectomy rates in 
the United States are highest in the South.
3,14
 This may be due to variation in the prevalence of 
fibroids, healthcare utilization, physician practices, or likely, a combination of these factors. The 
unique burden of fibroids in Black women is described later.  
Other treatments for fibroids, such as myomectomy (surgical removal) or uterine artery 
embolization (UAE; closing off blood vessels) may influence subsequent fertility, pregnancy 
health, and method of delivery.
15,16
 For example, a trial of labor may not be recommended for 
women with uterine incision scars, such as those from a myomectomy, due to risk of uterine 
rupture.
15,17
 Myomectomy is also associated with pelvic adhesive disease (scarring in the 
pelvic/abdominal cavity), which can lead to fertility problems.
17
 
An Agency for Healthcare Research and Quality review on the management of fibroids 
noted that current evidence regarding the “benefit, harm, or relative costs” of treatment choices 
for fibroids is inconclusive, especially for women planning a future pregnancy.
18
 By nature, most 
treatments for symptomatic fibroids (i.e., those that cause bleeding or pelvic discomfort) may be 
contraindicated during pregnancy (e.g., gonadotropin-releasing hormone analogs, oral 
contraceptives, endometrial ablation, UAE, and often, myomectomy).
19
 Accordingly, most fibroid 
treatments will happen prior to, between, or after pregnancies. Those during pregnancy, may only 
be palliative—for example, treatments for pelvic pain in pregnancy may include: rest, exercises, 
massage, acupuncture, and non-steroidal anti-inflammatory drugs (NSAIDs)   at certain stages.
20
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Hartmann and colleagues used a nation-wide administrative database to estimate that 
women with symptomatic fibroids have excess direct healthcare and work loss-related costs of 
$4,624 per year (95% confidence interval (CI): $4,132–$5,042) compared to women without 
fibroids (adjusted for age, region of residence, health plan type, and comorbidities).
2
 It is also 
estimated that fibroids are responsible for over two billion dollars in total healthcare costs.
21
 This 
includes surgeries, physician costs, outpatient and inpatient care, medications, and diagnostic 
testing. By 2050, fibroids will impose a significant financial burden on the United States 
healthcare system if fibroid-associated hospitalizations increase by 23%, as predicted by Wechter 
and collaborators in 2011.
22
 When considering these costs with work loss-related costs, personal 
expenses (sanitary products, over-the-counter drugs), and quality of life impairment, the burden 
of fibroids is such that they should be considered one of the key concerns in women’s health. Yet, 
little is understood about their general etiology or their affects during pregnancy.  
 Fibroids are widely believed to increase risks of cesareans, preterm birth, 
malpresentation, and abruptio placentae—increasing morbidity, mortality, and healthcare costs 
for mothers and infants.
4,9,23,24,25
 Most of the studies identifying these risks however, did not 
prospectively ascertain fibroid status (billing or diagnostic codes were often used)
24
 or were set 
among hospital-based populations (where women with larger, more symptomatic fibroids are 
more likely to be identified).
9,23,25
 These methods increase the chance of exposure 
misclassification, inflate risk estimates (especially for common outcomes, when a reported odds 
ratio is not a good approximation of a risk ratio), and limit the generalizability of their results.
26
 
Arguably though, these studies most strongly inform our understanding of fibroids and pregnancy 
health—as there are very few population-based studies and to my knowledge, only Right from the 
Start (RFTS; a prospective community based pregnancy cohort) prospectively screened all 
participants to determine the presence or absence of fibroids.  
Fibroids are also associated with bleeding and pelvic pain in gynecologic populations.
27
 
However, few studies have looked at these symptoms in pregnant women. Those that have are 
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unlikely to report associations between symptoms and disease severity (e.g., total volume, 
number of fibroids). This is likely due to small sample sizes, difficultly in modeling fibroid 
volume or number (both are unlikely to be normally distributed within a study population), or a 
lack of information on these characteristics. These studies are discussed further in subsequent 
sections.  
Increasing fibroid size is thought to correlate with increased risks of symptoms or 
pregnancy complications, which is important to note because fibroids are also known to change 
size.
23, 25,28
 Growth rates during pregnancy are not well-measured and growth as a measure of 
disease severity, contributing to the development complications or symptoms, needs to be 
explored. Studies that examined fibroid growth during pregnancy (n=9) have not used 
multivariable modeling, have had small sample sizes (largest n=104), are often performed in 
clinic-based populations, may limit their populations to women with one fibroid, or do not fully 
describe their study populations.
9,10,11,12,29,30,31,32,33
 
In order to better describe fibroid disease during pregnancy and tailor clinical 
recommendations for treatment in women planning pregnancies, it is necessary to fill these gaps 
in knowledge left by the current literature.  
Which fibroids have “clinical significance?” 
It has been suggested that 25% of fibroids are “clinically relevant.”19 However, this 
estimate does not represent women who manage their fibroid symptoms without the aid of a 
physician, nor is it an estimate of clinical relevance during pregnancy. When investigating 
pregnancy complications, larger fibroids or fibroids located near the placenta may increase risk of 
placental abruption.
15
 Koike and associates found women whose largest fibroid was greater than 
six centimeters (cm) were more likely to deliver smaller infants and at an earlier gestational age 
than women with smaller tumors.
34
 In a RFTS analysis, women with larger total fibroid volumes 
(≥33 cubic centimeters (cc), analogous to a spherical tumor of 4cm or larger in diameter) were at 
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increased risk for cesarean birth compared to women with no fibroids and those with smaller 
ones.
28
 There is also a general consensus that submucous fibroids are associated with vaginal 
bleeding, while subserosal fibroids cause pelvic pressure and discomfort.
35
 These fibroid 
classifications are discussed shortly. 
It is appealing to examine severity of this disease in the context of characteristics such as 
increasing size or number and perhaps increased rate of growth. For example, it is reasonable to 
hypothesize that increased total fibroid volume may be associated with symptoms of pain or 
pressure, especially in pregnant women, as a larger uterus will put pressure on the surrounding 
organs and blood vessels. Fibroids may interfere with muscle contractility or reorganize blood 
flow within the uterus as well, leading to any number of complications or symptoms such as 
bleeding and pain. This is plausibly exacerbated for a pregnant woman, whose uterus is 
undergoing dramatic hormonal, volumetric, and vascularization changes.  
Fibroid symptoms and severity during pregnancy: importance and implications 
Research on fibroids and pregnancy often centers on fecundity, fertility, and pregnancy 
complications or the impact of fibroid treatments on subsequent pregnancy health. The 
experience of pregnancy may be differentially shaped by pain, bleeding, and medication needs for 
women with fibroids compared to those without fibroids, but this is not well described. Nor do we 
understand whether tumor changes (conformational, position) during pregnancy influence the 
experience. Fibroid severity may not be constant during pregnancy; the extent to which fibroids 
change in size is not agreed upon because of scant literature, nor is the clinical significance of any 
growth known.
9,10,11,12
  
Symptoms may be affected by disease severity (size, number, type), so it would be 
advantageous to better describe the relationship between these outcomes and measures of 
severity. Understanding severity changes during pregnancy and identifying maternal risk factors 
associated with this may allow patients and their care providers to anticipate healthcare needs or 
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pregnancy complications. It may be possible to prevent unnecessary prophylactic surgery to 
remove fibroids if we can better understand which ones are likely to lead to problems during 
pregnancy.  
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CHAPTER II 
INNOVATION 
Right from the Start is a prospective community-based cohort designed to investigate 
pregnancy health. From 2000 to 2012, the study enrolled women from Texas, Tennessee, and 
North Carolina who were newly pregnant or trying to become pregnant. The cohort’s population 
includes women not often represented in previous studies: Black and White women from the 
same base population (urban and suburban areas in the southeastern United States) who receive 
care in a range of settings from private practice to health department clinics and not 
predominately tertiary care settings.  
Prior studies have used routine first or second trimester imaging to retrospectively 
identify women with fibroids, but in these situations, the identification and measurement of any 
fibroids may not be standardized across all participants. Additionally, the size criteria used to 
determine whether a woman has fibroids or “clinically relevant” fibroids, vary across institutions, 
making fibroid assessment and “exposed” populations disparate across studies. In other instances, 
the approach developed by Muram and colleagues to identify fibroids is used, but this was 
developed under the constraints of now outdated imaging technologies.
29
  
Our cohort allows for an examination of the full range of fibroid severity among pregnant 
women; all participants were examined for the presence or absence of fibroids with transvaginal 
ultrasonography in the first trimester. The position, type, and size of each fibroid (as small as 
0.5cm in maximum diameter) were documented by trained sonographers and confirmed by a 
physician.
8
 Women with small fibroids may be undetected or underreported in other studies, as 
some studies only have documentation of “large” fibroids. Among RFTS participants, risk of 
misclassification is minimized; by following women prospectively, we had the opportunity to 
systematically measure potential confounders and also conduct standardized ultrasound 
screenings to determine the fibroid status of all participants—while using uniform methods to 
document characteristics of identified fibroids. 
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CHAPTER III 
BACKGROUND 
What are uterine fibroids? 
Uterine leiomyomata (also called fibroids or leiomyomas) are benign tumors of the 
uterine smooth muscle (myometrium).
36
 They are a ubiquitous gynecologic health concern: most 
women will be affected by the time of menopause, but a fibroid diagnosis is rarely made before 
puberty because of their association with increased estrogen exposure.
1, 37
 More than one in ten 
women have fibroids detectable via ultrasound in the first trimester of pregnancy.
8
 Women may 
have multiple fibroids of varying sizes, histopathology, and clinical relevance. 
  Fibroid tumors are of monoclonal origin (arising from a single cell), exhibit a sensitivity 
to steroid hormones such as estrogen, and also an abnormal regulation of blood vessels and 
extracellular matrix.
36,37
 They are often referred to as “fibroids” because of a visibly fibrous 
texture resulting from their high collagen content.
38
 While the exact cause of fibroid formation is 
unclear, it is likely multifactorial: influenced by interactions between genes and the environment 
(hormones, growth factors).
37
 A variety of hypotheses have been put forth to explain their origins 
and all may play a role: growth factors such as transforming growth factor beta (TGF-beta) may 
be dysregulated in women with fibroids; fibroids may arise from mutated cells that for some 
reason, begin to function like myometrial cells during pregnancy; or perhaps they develop as 
repercussions from chronic inflammation.
39,40,41
 
Risk factors and growth factors 
Genetic mutations that alter hormone and growth factor production or regulation may 
explain the higher risk for developing fibroids among African American women or those with a 
family history of fibroids.
38
 It is often cited that tissue-level chromosomal abnormalities are found 
in 60% of fibroids, but the original study that reported this used 13 fibroid samples from women 
aged 38-45.
42,43
 There is conflicting evidence regarding the magnitude of the association between 
10 
 
chromosomal abnormalities and fibroid size; this relationship may be influenced by underlying 
study population characteristics, medication use, and tumor type.
44, 45
 Underlying genetic causes 
may differ in younger, reproductive-aged women or with tumor position, type, or size. However, 
several ubiquitous genetic risk factors have been identified. Research from Vanderbilt University 
confirmed associations between fibroids and germline single nucleotide polymorphisms in and 
near the blocked early in transport 1 homolog gene (BET1L) and the trinucleotide repeat 
containing 6B gene (TNRC6B) among White women; these associations were previously 
identified among a Japanese cohort.
46,47
 These genes are implicated in numerous health events 
including age at menarche and the development of prostate cancer and diabetes.
46
 Somatic 
mutations in the mediator complex subunit 12 gene (MED12) are found in most fibroids; this 
gene helps regulate transcription and can influence activity of the aforementioned cytokine, TGF-
beta.
48,49
 TGF-beta plays an important role in many processes, including cell growth, 
angiogenesis, and the regulation of the extracellular matrix.
50
 In addition to fibroids, changes in 
the regulation of TGF-beta are associated with fibrotic conditions like liver cirrhosis and keloid 
scarring.
50
 Papers by Ciarmela and colleagues and N. Chegini provide an excellent summary of 
the relationship between cytokines like TGF-beta and fibroid development.
50,51
 I did not analyze 
biomarkers or genetic risk factors in this dissertation and only briefly discuss them. The risk 
factors for fibroids that I investigated are discussed in and below Table 1. 
Steroid hormones like estrogen and progesterone perhaps most heavily influence the 
development and growth of fibroids. Accordingly, the tumors are found very infrequently in girls 
before menarche or women after menopausal.
38
 These hormones can affect levels of growth 
factors such as vascular endothelial growth factor, insulin-like growth factor, and TGF-beta.
50,51
 
Differential regulation of all of these molecules have been implicated in fibroid formation 
because of their influence on angiogenesis and cell growth, differentiation, and proliferation.
51
  
Increased exposure to estrogen is associated with incidence of fibroids. Therefore, earlier 
age at menarche and obesity have been identified as risk factors, while smoking may be 
11 
 
protective.
37,52
  Smoking is considered to have anti-estrogenic properties—the compounds in 
cigarette smoke can change steroidogenesis, leading to lower levels of estrogen and 
progesterone.
53
  Obese women may produce more estrogen in their adipose tissue and perhaps 
less progesterone during certain phases of their menstrual cycle; they are also at increased risk of 
anovulation, which can lead to a prolonged release of estrogen with lower progesterone levels.
54,55
 
Smoking is also associated with lower BMI, but may be linked to central adiposity in heavy 
smokers.
56
 Alcohol use also can alter estrogen and progesterone levels during pregnancy.
57
  
However, it is progesterone, not estrogen, that is argued to be both necessary and 
sufficient to support fibroid growth.
35
 Estrogen may help facilitate the development of 
progesterone receptors on myometrial cells, which in turn allows for the activation of 
progesterone pathways (some of which involve TGF-beta). These pathways lead to increased 
cellular proliferation and survival and increased formation of extracellular matrix.
35
 This 
progesterone-fibroid relationship is of special interest during pregnancy because progesterone 
levels dramatically increase to help with the “structural remodeling” of the uterus and the 
prevention of contractions.
58
 A Finnish maternity cohort study examining serum biomarkers 
found that progesterone levels tend to increase throughout early pregnancy.
59
 They also noted that 
older women had higher progesterone levels in pregnancy, while multiparous mothers (versus 
nulliparous) had 9% lower levels and smokers (versus non-smokers) had 10% lower levels.
59
  
A variety of traits are associated with increased risk of fibroids including increasing age, 
Black race/ethnicity, having a higher BMI, and possibly alcohol use.
27
 Increased parity and 
smoking are generally thought to lower risk, or be protective against fibroid formation.
27,60
 
Evidence is less clear regarding associations with diabetes and hypertension, sometimes due to 
confounding by medications use, but they are often considered risk factors for fibroids.
27
 The 
basic characteristics that are known to be associated with the presence of fibroids (among 
pregnant and non-pregnant populations) are shown in Table 1 along with suspected associations 
with disease severity, if known. Studies describing these relationships are listed and I discuss 
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them below. The lack of knowledge regarding risk factors for fibroid growth will become 
apparent. 
 
Table 1. Investigated risk factors for uterine fibroid presence and severity  
Characteristic Presence of 
Fibroids 
Tumor 
Volume 
Number of 
Tumors 
Growth of 
tumors 
Selected References 
Age x  x x 
1,8,61,62,63 
African American race x x x x 
1,8,61, 63,64 65,66,67,68 
BMI x   x 
10,63,67,68 69,70,71 
Parity x   x 
10,62,67,72,73,74,75 
Diabetes x x   
52,55,76 
Hypertension x    
52,77,78 
Smoking x    
69,73,79, 68,67 
Alcohol use x    
79,80 
BMI=body mass index 
 
 Increasing age increases the risk for fibroids, though this relationship is modified by 
maternal race and the incidence of fibroids may decline after menopause.
1,8
 Baird and colleagues 
used ultrasound and medical record data to show that the cumulative incidence of fibroids by age 
50 was 70-80%--with Black women being more likely to develop them.
1
 Disease severity (as 
defined by having an enlarged uterus, at least on tumor ≥4cm diameter, or at least one 
submucosal fibroid) also increased with age and was more prevalent among Black women.
1
 
Women in this study were at least 35 years old, so any increasing incidence among reproductive 
aged women is not reflected here. However, a previous study used RFTS data to show that a 
similar relationship between increasing incidence and age for younger women existed and was 
modified by maternal race.
8
 The percentage of women with more than one fibroid also increased 
with age in RFTS, but only among Black women.
8
 Other groups have reported similar increases 
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in fibroid incidence with age, but few studies comment on disease severity—increasing volume, 
number of tumors, or tumor growth.
61,62
 Peddada and colleagues performed longitudinal analyses 
of fibroid growth in non-pregnant women and noted that growth rates decreased with age, but 
most evidently among White women.
63
 Reproductive aged women (less than 35 and not pregnant) 
had similar growth rates by race.
63
 De Vivo and co-authors, who looked at fibroid growth in 
pregnancy, reported that increasing age was protective against increases in fibroid volume 
between the first and third trimesters (odds ratio (OR) 0.55, CI 0.35, 0.86 unadjusted), but not 
between other time points.
10
 
 In considering age as a risk factor for fibroids, we saw that Black women are more likely 
to have fibroids, have larger and more numerous tumors at younger ages, and have rates of 
growth that may not decline with age.
8,63,65,66,67
 Many other studies have confirmed the differences 
in fibroid prevalence between races. Researchers using Nurses’ Health Study II data reported that 
age standardized incidence rates for fibroids were higher among Black women (37.9 , CI 32.3, 
43.6) than among White, Hispanic, or Asian women, for whom rates were all less than 15 per 
1000 woman-years.
61
 The reasons for these differences in disease occurrence and severity are 
multifactorial; genetic and environmental/behavioral risk factors likely play a role. By looking at 
genetic markers associated with African ancestry, Wise and colleagues identified a higher 
percentage of African ancestry among women with fibroids in the Black Women’s Health Study, 
than among women without fibroids (age-adjusted mean difference between women with and 
without fibroids was −1.76%, CI −2.40, −1.12).64 The differences in African ancestry remained, 
even after adjusting independently for age and stratifying by age, parity, or BMI—which seems to 
indicate that underlying biologic differences between races affect fibroid formation.
64
 
Perplexingly, results from one study—a matched case-control study that interviewed women 
across the United States via telephone—implied that African American race was protective 
against fibroids (OR 0.60, CI 0.3, 1.20 adjusted).
68
 However, this population contained only 201 
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women with fibroids, 16 of whom were Black. For more information on race and fibroid severity, 
see the section entitled “Does fibroid severity vary by race?” 
Increasing BMI is also associated with the presence of fibroids.
27
 Due to the previously 
mentioned influence of body fat on steroid hormone levels, many groups have studied the 
relationship between fibroids and BMI—most finding modest or increased risks with increasing 
BMI.
67,69,70,71
 Faerstein and colleagues interviewed and reviewed medical records for 409 
premenopausal women from Baltimore with fibroid diagnoses and their frequency matched 
controls. They found that women in their population’s upper quartile of BMI, versus the lowest 
quartile, had a two-fold increase in risk for fibroids (OR 2.3, CI 1.4, 3.8 adjusted for age, clinic, 
and race).
67
 For women with BMI of 24 or higher, Marshall and colleagues report 15-36% 
increases in the risk of having fibroids that were self-reported and confirmed by medical records 
(adjusted; risks varied with the level of their categorical BMI variable).
69
 This study used data 
from the Nurse’s Health Study II; other groups have used this same data to show that increasing 
waist-to-hip ratios increased risk of fibroids after adjustment for age, but this trend did not hold 
after adjustment for other potential confounders.
71
 Data from the Black Women’s Health Study 
also support the idea that increasing BMI may increase fibroid risk (for BMI between 25 and 32 
at least), but not the idea that increasing waist-to-hip ratios do.
70
 The above mentioned case-
control study that found no association between fibroids and race, also found no increased risk for 
fibroids among “heavy” versus “lean” women.68 Ultimately, comparing these studies is difficult, 
because BMI is categorized differently and few studies provide descriptions of how they assessed 
the linearity of the relationship between increasing BMI and fibroid risk. Even fewer studies 
comment on the role of BMI and fibroid severity—likely because many rely on self-reported 
fibroid status.  
Two groups looking at fibroid growth investigated the influence of BMI.
10,63
 Peddada and 
colleagues’ study of individual tumors in non-pregnant women noted no differences in mean 
growth rates across BMI categories.
63
 However, a study following individual tumors in pregnant 
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women showed that increasing continuous pre-pregnancy BMI was a risk factor for increases in 
tumor growth between the first and second trimester (OR 1.2, CI 1.01, 1.5 unadjusted) and 
protective against them (OR 0.78, CI 0.67, 0.91 unadjusted) between the second and third.
10
 BMI 
may influence growth in two ways: 1) increased hormone levels in early pregnancy could lead to 
tumor growth during this period, and this growth may be modified by BMI and 2) larger BMI 
could cause difficulties in visualizing fibroids as pregnancy progresses (see section entitled 
“Fibroid Assessment”). 
Parity is thought to have a relationship with fibroids due to the differential ability of the 
parous versus nulliparous uterus to restructure itself. Uterine involution after pregnancy may 
influence fibroid reduction and perhaps future fibroid size changes; this idea is discussed briefly 
in the “Fibroid Growth” section below and also by Laughlin and colleagues.60,81 Faerstein and 
colleagues’ case-control study from Baltimore, did not find an association with parity after 
adjustment, but these researchers used a 5-level categorical variable to describe parity.
67
 Perhaps 
any prior completed pregnancy is protective relative to nulliparity (e.g., a dichotomous variable). 
Wise and colleagues also found no association between increasing parity and fibroids in the Black 
Women’s Health Study, but presumably used a 5-level categorical variable as well.74 Most other 
studies have found that parity is protective against fibroid development. In a hospital based case-
control study where the presence or absence of fibroids was determined by examination of 
surgically removed uteri or ultrasonography, parity was protective against fibroids (OR 0.75, CI 
0.57, 0.98, adjusted for history of fibroids and age).
62
 It was not clear however, if this measure of 
parity was continuous or dichotomous. Nurses’ Health Study II data have been used to 
demonstrate that being parous offered a statistically significant 33% reduction in the risk of 
having fibroids (adjusted for age, race, marital status, age at menarche, body mass index, age at 
first birth, years since last birth, age at first oral contraceptive); this association remained 
protective even when stratifying on a history of infertility.
72
 The study listed in Table 1 by Terry 
and colleagues, used this same population and reported similar findings.
75
 Finally, a case-control 
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study from an Italian University hospital noted that after adjustment, being parous was very 
protective against histologically confirmed fibroids documented in medical records (risk 
reductions of 40-60% with increasing parity; n=621 cases).
73
 
For the remaining risk factors listed in Table 1, the evidence for associations with 
fibroids is less convincing—though diabetes, hypertension, smoking, and alcohol use are posited 
to be associated because of their causing cytokine and steroid hormone dysregulation. To my 
knowledge, the paper by Baird and associates is the only to describe fibroid severity in the 
context of these characteristics.
76
 Most studies rely on self-reported diagnosis of fibroids—when 
severity information is often unknown.  
Diabetes may increase risk for fibroids, but the literature does not support this assertion 
well. In The Sister Study, which focused on the diabetes status of its participants’ mothers, 
daughters incurred a 54% increased risk of reporting fibroids when their mothers had pre-
pregnancy or gestational diabetes (CI 0.95, 2.49); White women had a two-fold increased risk 
associated with their mothers having pre-pregnancy diabetes.
82,83
 Often, studies examining 
diabetes and fibroids are limited by small sample sizes. This may have been the case for Faerstein 
and colleagues when they observed no association between fibroids and diabetes or taking 
diabetes medication.
52
 Though treatment for diabetes doubled risk estimates, there were only nine 
women among approximately 700 who used anti-diabetic medications (CI 0.4, 12.6 adjusted).
52
 
The incidence of fibroids was increased among women with diabetes who used medication in the 
Black Women’s Health Study (incidence rate ratio 0.77, CI 0.60, 0.98 adjusted), but it was not 
elevated among those who had diabetes and did not use medication (incidence rate ratio 0.91, CI  
0.64,1.28 adjusted).
55
 This suggests possible modification by medication use or by severity of 
diabetes. These drugs may influence the hormone and cytokine activity that can lead to the 
formation of fibroids. Baird and colleagues used data from the National Institute of 
Environmental Health Sciences’ Uterine Fibroid Study and found that generally, increased levels 
of insulin were inversely related to fibroid prevalence—especially among Black women (based 
17 
 
on one-time measurements from blood samples).
76
 Specifically, high insulin levels may be 
protective against the development of large fibroids in Blacks (a 16% reduction in prevalence of 
fibroids ≥4cm in diameter).76 In this study, diabetes itself was protective against fibroids among 
Black women (OR 0.50, CI 0.25, 1.02 adjusted for age, age of menarche, parity after age 24, 
BMI, and physical activity), but not among White women (OR 0.83, CI 0.21, 3.38 adjusted).
76
 No 
associations were observed between gestational diabetes and fibroids and modification by 
medication use was not explored.
76
 These authors note that “vascular dysfunction is part of the 
pathogenesis of diabetes and could inhibit tumor [fibroid] development.”76 
 Boynton-Jarrett and co-authors suspect an association between fibroids and hypertension 
exists because higher blood pressures can cause “hemodynamic stress” or injury to muscle 
cells—which then initiates an inflammatory response in the tissues during which, cytokines like 
TGF-beta are recruited into action.
77
 Using data from the Nurses’ Health Study, these researchers 
report a 10% (7–13%) and 8% (5–11%) increase in the risk of having fibroids for every 10 
millimeters (mm) of mercury diastolic blood pressure increase among hypertension medication 
users and nonusers, respectively (adjusted).
77
 In the Baltimore-based case-control study of women 
seeking gynecologic care, a history of hypertension appeared to be related to the presence of 
fibroids after adjustment for age, clinic, ethnicity, and historical BMI (OR 1.7, CI, 1.0-2.8).
52
 
Treatment for hypertension increased this risk (OR 2.1, CI, 1.1-4.1).
52
 The associations between 
treatment and fibroids were strongest when the participant was prescribed the medications at a 
young age (<35 years) or had been using them for at least five years, but there was no clear 
increasing trend between years since hypertension diagnosis and risk of fibroids.
52
 However, 
differences in hypertension severity between those who do and do not require medications may 
actually be the modifying factor. Among Black women in the Black Women’s Health Study, both 
treated (incidence rate ratio 1.08, CI 1.00, 1.16) and untreated hypertension (incidence rate ratio 
1.09, CI 0.99, 1.20) were associated with the presence of fibroids after adjustment for potential 
confounders (not including baseline blood pressure).
78
 This study also tested whether these effects 
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were modified by BMI, but evidence did not support this.
78
 
 Smoking is considered to have anti-estrogenic properties—the compounds in cigarette 
smoke can change steroidogenesis, leading to lower levels of estrogen and progesterone.
53
 
Parazzini and associates’ hospital-based case-control study reported that ever smokers had a 30% 
decreased risk of having fibroids compared to never smokers (CI 0.5, 0.8).
73
A similar protective 
effect was reported by researchers who interviewed a nation-wide cohort by telephone (those 
researchers who found that race was not associated with fibroid status).
68
 Faerstein and colleagues 
(using the clinic-based population from Baltimore) did not find associations between fibroids and 
smoking, number of pack years, or duration of smoking, but did report that the OR for risk of 
fibroids due to smoking 20 or more years versus never smoking was 0.6 (CI 0.4, 1.1).
67
 The 
Nurses’ Health Study II did not find any association between the presence of fibroids and current 
smoking, recent quitting of smoking, or cigarettes smoked per day (each exposure adjusted for 
age, race, marital status, age at menarche, BMI, age at first birth, years since last birth, history of 
infertility, and age at first oral contraceptive use).
69
 However, their models adjusted for a history 
of infertility; it could be possible that fibroids severe enough to impact fertility are those more 
likely to be sensitive to the hormonal effects of smoking. Wise and colleagues showed no 
association between smoking and reporting fibroids in the Black Women’s Health Study, though 
the magnitude of their adjusted incidence rate ratios suggested protective effects for most 
smoking exposures relative to non-smokers (e.g., exposures like former/current smoker, number 
of pack-years, age at first smoke).
79
  
 This group also explored the effect of alcohol use on fibroid risk—one of the few to do 
so. Similar to their smoking results, most estimates for alcohol exposures (e.g., former/current 
drinker, years of drinking, type of alcohol) were not statistically significant, but did have 
magnitudes in the same direction—specifically, alcohol use suggested an increased risk of having 
fibroids.
79
 There was a trend for fibroid incidence increasing with number of beer servings per 
week, with seven or more drinks per week posing the greatest risk (incidence rate ratio 1.57, CI 
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1.17, 2.11 adjusted).
79
 In a study of Japanese women (n=285), the risk for having fibroids was 
almost 3-fold higher among those who had high alcohol consumption, compared to those who did 
not, but the cross-sectional measurement of alcohol use makes it difficult to tell whether the use 
predates the formation or diagnosis of a fibroid (as is the case in other studies).
80
 These 
researchers did replicate the findings by Wise and colleagues: greater beer consumption was 
associated with having fibroids (OR 2.75, CI 1.30, 5.83 adjusted for age, BMI, smoking, number 
of live births, and age at menarche).
80
 
Does fibroid severity vary by race? 
As discussed above, Black women of reproductive age are disproportionately affected by 
fibroids compared to White women.
1,8,61
 Eighteen percent of Black and eight percent of White 
women have fibroids detectable via ultrasound in the first trimester of pregnancy.
8
 Black women 
are also more likely to have more severe fibroid disease: more numerous and larger tumors and 
fibroid diagnoses at a younger ages.
1,8,65,61,66
 Tumor growth and symptom severity are suggested 
to vary by race, but little is known about these differences during pregnancy.
63,65
 Peddada and 
colleagues used mixed effect models to assess fibroid growth in Black and White women outside 
of pregnancy and they found that growth was similar between races in women younger than 35, 
but rates of growth declined with age only in White women.
63
  
In accordance with this increased burden of disease, Black women aged 15 to 54 also 
have increased rates and risks of hospitalization, hysterectomy, and myomectomy compared to 
White women (unadjusted RR: 3.5, 2.4, and 6.8, respectively).
22
 Black women are also more 
likely to have a myomectomy or hysterectomy at an earlier age.
21
 Data from the “Finding Genes 
for Fibroids” study indicate that Black race was a risk factor for more severe fibroid disease (OR 
5.30 1.92-14.7, adjusted)—when “severe” disease was defined by earlier age at diagnosis, 
menstrual cycle symptoms, and history of fibroid-related surgeries.
65
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After adjustment for age, education, and birth order, D’Alosio and co-authors identified 
several risk factors associated with self-reported onset of disease before age 30 among Black 
women: being taller and thinner at age ten, having any hypertensive disorder, being born first to a 
young mother, having low birth weight, and being from a multiple birth (especially 
monozygotic).
82
 Increased risks associated with being breastfed or having gestational diabetes 
were suggested, but not statistically significant. Multiple birth, hypertensive disorders, height and 
weight in childhood, and low birth weight did not have as strong associations among White 
women in the cohort, while associations with lower socioeconomic status were found primarily 
among White women.
82,83
 Data from the Black Women’s Health Study suggests that (self-
reported) polycystic ovarian syndrome, which is more prevalent in Blacks, is also a risk factor for 
fibroids (even after adjusting for diabetes, BMI, parity, age, and alcohol and tobacco use).
55
 All of 
these findings point to underlying differences in fibroid etiology between the two races. 
Aside from differences in severity, symptoms, and risk factors, genetic studies have 
provided further evidence that fibroid disease is modified by race. Mutations linked to BET1L 
and TNRC6B are associated with fibroids in White and Japanese women, but these associations 
were not replicated among Black women.
46,47,64
 
Uterine anatomy 
The uterus is comprised of both fibrous and muscular tissues and is located in the female 
pelvis between the rectum (posterior) and the bladder (anterior).
84
 The body of the uterus is called 
the corpus, while the lower portion connected to the vagina is known as the cervix. The fallopian 
tubes and ovaries lay on either side of and are connected to the fundus (the area above the 
junction of the uterus and fallopian tubes; see Figure 1). Parity and estrogen levels influence the 
shape and weight of uterus. In an adult, the uterus is approximately seven cm long and five cm 
wide (at the fundus) and the ovaries are two-and-a-half to five cm in length.
84
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 The muscular wall of the uterus, the myometrium, surrounds the endometrial cavity. 
Lining the inner surface of the myometrium is a mucosal layer known as the endometrium; it is 
the outermost portion of this tissue that is shed during the menstrual cycle.  Serosal tissue covers 
the pelvic surface outside of the uterus within the peritoneal cavity (see Figure 1).
84
 
 
Figure 1. Uterine Anatomy  
 
 
 
Fibroid classification  
Fibroids are often classified according to their position in the uterus. The tumors can be 
located within the uterine fundus (top of the uterus), uterine corpus (body of the uterus), cervix 
(bottom of uterus, next to the vagina), anterior (front of the uterus, near the bladder), and 
posterior (back of the uterus, near the coccyx; Figure 2). Fibroids may encompass one or more of 
these areas of the uterus (e.g., a large fibroid arising in the lower corpus may also grow into the 
cervix).   
22 
 
Fibroid type refers to where within the muscle the tumors are located. For example, 
intramural fibroids are located completely within the myometrium (See Figure 2). Submucous 
fibroids are located in the muscle, but near the uterine cavity—distorting the cavity or 
immediately adjacent to the endometrium. They may also be classified by the degree to which 
they distort the endometrium (i.e., type 0, type I, type II), but the application of these 
classifications in pregnancy is not clear and they were not used in these analyses.
85
 Other fibroid 
types include: subserosal (in the muscle, near to or distorting the outer contour of the uterus and 
the serosal layer) and pedunculated (attached to any part of the uterus via a stalk).
8
  
 
Figure 2. Examples of fibroid positions and types  
 
 
Fibroid assessment 
Previous studies have identified women with fibroids by manual examination (palpation), 
imaging (e.g., ultrasound, MRI), self-report, and visual confirmation during surgery. Research 
from RFTS and Uterine Fibroid Study shows that self-report has low sensitivity, but high 
specificity as a measure for determining fibroid status (when confirmed by ultrasound).
86
 These 
authors also found that age, parity, education, fibroid size, and race jointly influenced the 
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sensitivity of self-report. The highest agreement between self-report and ultrasound diagnosis of 
fibroids was for women aged 18 to 29 years, especially among those who were White—which are 
often groups with the lowest fibroid prevalence.
86
 
Transvaginal ultrasonography is typically used to identify fibroids because it is cost-
efficient, non-invasive, and across most ultrasound studies, offers good sensitivity and 
specificity.
87,88
 Variation in its effectiveness may be related to the heterogeneity of study 
designs—both how a fibroid diagnosis was confirmed (e.g., surgery, hysteroscopy) and the 
characteristics of a study population can alter the usefulness of sonography. There is some 
evidence to suggest that ultrasounds may be less accurate in detecting submucous fibroids or 
fibroids in obese or very pregnant patients.
88,89,90
 
As a pregnancy progresses, a sonographer may need to lower the sound wave frequency 
used during an examination; lower bandwidths provide poorer image resolution, but are necessary 
to penetrate the increasing size of the pregnant uterus.
90
 Visualization may also be impeded 
among patients who are obese, but this is mitigated by use of transvaginal sonography.
89
 The 
obstruction presented by the growing fetus or adipose tissue, coupled with the potential for poorer 
image resolution, may alter the ability to reliably detect and measure fibroids via ultrasound. This 
may be more concerning with transabdominal versus transvaginal probes, the former provides 
images of the uterus viewed from the abdomen surface (like Figure 1) as the sound waves 
penetrate the abdomen; the ability to visualize the anterior uterus is generally acceptable, but 
posterior views are more challenging as a pregnancy progresses. Three studies following fibroids 
throughout pregnancy noted these visualization difficulties, in addition to conformational changes 
in the tumors associated with the stretching of the uterine muscle.
12,30,33
 
Fibroids and pregnancy 
Pregnancy may be considered a “hyperestrogenic state” for a woman’s body; the levels of 
progesterone also dramatically rise.
91
 Estrogen and progesterone production are first centered in 
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the ovaries, but by seven weeks gestation, the majority of estrogen is made by the placenta.
91
 
Certain health problems may affect the extent to which estrogen is produced by the placenta: fetal 
death, trisomy 21, adrenal disorders, and use of glucocorticoids.
91
 
The uterus will reach a size such that its volumetric capacity is 500 to 1000 times greater 
than its previous state by the end of pregnancy.
92
 Both hormones and fetal growth act on the 
uterine muscle, leading to increases in muscle cell size and the production of fibrous and elastic 
tissues.
92
  Uterine stretching during pregnancy likely affects fibroid positioning and capability for 
tumor growth. The fundus and the portion of the uterus in contact with the placenta will likely 
enlarge the most, and the walls of the fundus and corpus thin to only a few centimeters by the end 
of pregnancy.
92
  
Fibroid-associated symptoms 
Overview 
Fibroid volume or number of tumors may be considered markers of disease severity 
because they are thought to lead to adverse health outcomes. These measures are associated with 
surgical intervention, symptoms such as pain and bleeding, and pregnancy complications. 
However, it is not clear if the associations between increasing severity and bleeding or pain exist 
during pregnancy. The definition of “severe” fibroid disease may change when examined in the 
context of these symptoms during pregnancy. 
Fibroids are most often described in the gynecologic literature as causing heavy 
menstrual bleeding and pelvic pressure or discomfort.
27
 In their efforts to create an electronic 
daily diary to characterize fibroid symptoms, Deal and associates held focus groups and 
interviews among women of mixed races, aged 18 to 49, the majority having had some college 
education or higher, and all had symptomatic fibroids.
93
 They found that several symptoms were 
consistently important to these women: abnormal bleeding, pain, menstrual cramping, and 
fatigue.
93
 While pain was identified as a concern by these women, the importance of specific pain 
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types varied (e.g., abdominal, during intercourse, migraine)—implying an experience specific to 
each woman or unique to the location and size of her fibroids.
93
  
Zimmermann and colleagues used an international internet-based survey and noted that 
women with a diagnosis of fibroids were more likely to report irregular and more severe episodes 
of bleeding, pressure on the bladder, pelvic pain, and painful intercourse compared to women 
without this diagnosis.
7
 The symptoms for these women were such that over half of the 
respondents with a fibroid diagnosis felt that their symptoms negatively impacted their everyday 
life. Their sexual life was the primary aspect affected, followed by work performance, and their 
“relationship and family.”7  
A United States-based survey study found that women who self-reported symptomatic 
fibroids had similar concerns to those identified by Deal, Zimmermann, and their colleagues.
94
 
These women (64% White, 28% Black, and 8% other race groups) reported that their fibroid-
related symptoms led to missed work and negatively influenced their career growth.
94
 Younger 
women in this study (<40 years) particularly felt that their fibroids interfered with physical and 
social activities and left them feeling “tired.”94 
Factors associated with vaginal bleeding 
Vaginal bleeding may be considered “abnormal” during menstrual cycles if it occurs 
throughout the cycle, or is particularly heavy or long in duration.
95
 During pregnancy, many 
women experience spotting, but vaginal bleeding can be an indicator for miscarriage. Often, 
progesterone-containing medications are used to minimize bleeding both in and outside of 
pregnancy.
95
 Risk factors for pregnancy and fibroid-related bleeding are discussed below, but 
several important risks for vaginal bleeding can be mentioned here. First, among women of 
reproductive age, the prevalence of bleeding is generally thought to increase with age due to 
increasing lifetime exposures to sexually transmitted infections and greater risk of having 
fibroids—although the risks for these infections likely decline in a woman’s thirties.96 Endocrine 
26 
 
disorders (including diabetes), polycystic ovarian syndrome, obesity, hormonal disorders, trauma, 
infection, and medications can all lead to endometrial/vaginal bleeding.
96
 Finally, smoking can 
cause immediate changes in blood flow and pressure, but the extent to which it can affect arteries 
within the uterus is uncertain.
53
 
Pregnancy-related bleeding 
Bleeding episodes in the first month of pregnancy are not unusual, but can be incorrectly 
identified as menstruation.
97
 Abnormal uterine bleeding affects 10% to 30% of reproductive aged 
women and occurs in 15% to 20% of ongoing pregnancies.
96
 During pregnancy, bleeding may be 
related to implantation spotting, miscarriage, ectopic pregnancy, or infection. First trimester 
bleeding may indicate threatened abortion or ectopic pregnancy and can be particularly 
concerning for women.
98
 Bleeding later in pregnancy may be related to placenta previa, 
abruption, or infection.
5
  
 In RFTS, over a quarter of women reported first trimester bleeding; the majority had only 
one episode and only eight percent of women reporting bleeding described it as “heavy.”5 
However, women who had a miscarriage were included in the population used for these analyses 
and bleeding may herald an impending miscarriage. In this paper, Hasan and colleagues tested all 
of their risk factors of interest in one regression model and removed them in a stepwise procedure 
to arrive at a parsimonious model of predictors. The researchers identified age (being 28 to 34 
years), more years of education, long or short cycle length, infection, gestational diabetes, 
nulliparity, history of miscarriage, past therapeutic abortions, and fibroids as risk factors.
5
 Most 
variables in their model had statistically significant effects or ones that approached significance 
(at alpha=0.05). BMI, race, marital status, poverty level, smoking, vitamin use, alcohol use, 
caffeine intake, gravidity, and history of preterm birth were risk factors were removed from the 
model. Predictors in their model for heavy bleeding included age, education, cycle length, self-
reported first trimester infection, gestational diabetes, smoking, alcohol use, parity, history of 
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miscarriage, past therapeutic abortions, and fibroids. However, only alcohol use and history of 
miscarriage were associated with heavy bleeding.
5
  
 Several other studies describe risk factors for early-pregnancy bleeding among their 
cohorts. A Danish nation-wide medical record review found women with cardiovascular disease 
had a two-fold greater risk (unadjusted) for first trimester bleeding without miscarriage, but they 
did not find an association between diabetes and bleeding.
99
 The large China Anhui Birth Defects 
and Child Development cohort described the following risk factors for bleeding (either requiring 
or not requiring a physician visit): being older than 25 years, living in an urban rea, history of 
surgical abortion, having gynecological inflammation, and having more stress in early pregnancy 
(proportions were compared via chi-square tests between women with and without bleeding).
100
 
The Pregnancy, Infection, and Nutrition Study from North Carolina collected self-reported 
information on bleeding in pregnancy and increased risks of having multiple bleeding episodes or 
having longer episodes were suggested for women of older ages (≥35); no effects for active 
smoking on bleeding were noted; and history of multiple induced abortions was related to heavy 
bleeding and bleeding in the first trimester (as opposed to second).
101
 Lastly, Wittels and 
colleagues reviewed emergency room visits for vaginal bleeding in pregnancy across the United 
States and noted that visitation rates were higher among Black and Hispanic women than among 
Whites.
102
 Younger women (<35 years) visited emergency rooms more than older women (the 
population rate was six times higher); the authors theorize that this could be due to careful 
monitoring of older pregnant patients by obstetricians and primary care providers and a higher 
prevalence of private insurance holders in this group that would facilitate this closer care.
102
  
Bleeding and fibroids 
Bleeding for some women may mean needing to use more sanitary products and 
accidental spotting on clothes or bed linens.
27
 Very heavy bleeding can cause anemia and any 
amount of bleeding can make women anxious.
27
 The bleeding that accompanies fibroids for many 
28 
 
women is thought to be associated with abnormal regulation of vascular growth in the uterus.
36
 
As previously mentioned, a variety of growth factors that help generate new blood vessels or alter 
vessel size are differentially expressed in fibroids: basic fibroblast growth factor, vascular 
endothelial growth factor, heparin-binding epidermal growth factor, platelet derived growth 
factor, TGF-beta, parathyroid hormone-related protein, and prolactin.
36,51
 This change in 
vascularization likely affects blood supply to fibroids. A relationship between fibroids and 
vaginal bleeding may exist if large fibroids distort the endometrium or if an increased localization 
of hormonally-regulated growth factors leads to increased proliferation of the endometrium or 
size changes in the spiral arteries feeding it. 
In the survey done by Zimmermann and colleagues, women with a fibroid diagnosis 
reported having more frequent menstruation (less than 24 days, 28% versus 15%, p<0.001), 
longer periods (5.6 ±3.1 days versus 5.2 ±2.4 days, p<0.001), bleeding in between periods (33% 
versus 14%, p<0.001), and heavier bleeding (60% versus 37%, p<0.001) than women who did not 
have a fibroid diagnosis.
7
 In a Uterine Fibroid Study analysis performed by Wegienka and 
associates, having a previous diagnosis of fibroids was not associated with increased reporting of 
bleeding, when the diagnosis was incidental and not related to fibroid-associated symptoms (RR 
1.1, CI 0.9-1.4, adjusted for size, submucous type, BMI, and parity).
103
 Women in the Uterine 
Fibroid Study self-reported a previous diagnosis of fibroids and the presence of fibroids at the 
time of the study was confirmed via ultrasound within the last five years. Women whose previous 
diagnosis resulted from seeking medical care for symptoms like bleeding (who likely tracked 
subsequent bleeding problems more vigilantly) were excluded from their analyses; by limiting to 
those who had incidental diagnoses, it is possible these risk estimates could be biased toward a 
null association. In another analysis among this same group of women, Wegienka and co-authors 
studied 564 non-pregnant women with fibroids and found increasing tumor size was associated 
with increased risk of self-reported heavy bleeding (RR ranging from 1.4 to 1.9, adjusted for BMI 
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and parity).
104
 The effect of fibroid size overshadowed risk due to fibroid type; the risk of 
bleeding due to submucous masses was similar to those of other types given similarity in size.
104
  
 Researchers for the Seveso Women’s Health Study did not identify a relationship 
between fibroids and menstrual cycle length or heaviness (OR for “scanty” flow 1.9, CI 0.8–4.3; 
OR for “heavy” flow 1.3, CI 0.7–2.5; relative to moderate flow after adjusting for age, smoking, 
BMI, parity, and past contraceptive use).
105
 Nor was any association found when examining 
fibroid severity (number, volume, type, or position; age adjusted).
105
 Small sample sizes (73 
women with fibroids) within this study and potential dioxin exposures may influence these 
findings, as dioxin is an endocrine disruptor and researchers theorize that it influences 
endometriosis risk.
106
 
Research suggests that fibroids also play a role in pregnancy-related bleeding. In a paper 
by Hasan and associates (discussed further in the next section), fibroids were selected as a 
predictor in their explanatory models for self-reported first trimester bleeding and amount of 
bleeding. After adjustment for suspected predictors, there was evidence to suggest that fibroids 
increased risk of any bleeding (OR 1.3, CI 1.0-1.6) or light bleeding/spotting (OR 1.2, CI 1.00-
1.54), but not heavier flow.
5
 Women who had miscarriages were also included in this study 
population. To contrast, a study that used Washington state hospital discharge records found a 
87% in the odds of first trimester bleeding for women with fibroids who had singleton live births, 
compared to those without (adjusted for age and weight gain during pregnancy).
24
 
Factors associated with abdominal and pelvic pain 
 As with bleeding, factors associated with the presence of fibroids may also influence the 
prevalence or reporting of pain. Firstly, pain has a relationship with hormones like estrogen—
numerous studies show sex-related differences in pain and among women, variations in pain 
throughout the menstrual cycle and during menopause.
107
 However, the exact relationship 
between estrogen levels and pain is still uncertain.
107
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 The national survey report by Borah and colleagues indicated that women with 
symptomatic fibroids who were under the age of 40 were more likely have menstrual pain and 
painful intercourse compared to women with fibroids who were in their forties.
94
 Pain threshold is 
thought to increase with age, but this is likely stimuli-dependent and more apparent among the 
elderly.
108
 As such, age may not be a particularly strong confounder of the fibroid severity and 
pain relationship among a group of reproductive aged women. 
 Black women responding to this survey were much more likely than White women to 
report abdominal bloating or pressure (adjusted RR 2.14; CI 1.43-3.21) and abdominal pain or 
cramping (adjusted RR 1.79; CI 1.21-2.65).
109
 Both sociocultural and biologic characteristics 
complicate the relationship between race and pain. Black women may be predisposed to 
conditions associated with pain like hypertension and larger fibroids.  Furthermore, race is often 
associated with socioeconomic status (SES) and lower SES may mean a woman is less likely to 
seek care for her pain (affordability, fear of prejudice).
110
 Chronic stress, discrimination, or even 
fibroid experiences of relatives can also change how women respond to pain—for example, how 
anxious it makes them feel or whether or not they decide to treat it.
110
 An interesting study from 
the University of Florida (111 male and female students) indicated that White people are 
perceived to have and be more likely to report pain than Black or Hispanic people.
111
 This 
suggests that there are sociocultural expectations about how one should experience and report 
pain. Additionally, as Black women are more likely to have fibroid-associated hysterectomies or 
hospitalizations, one could infer that Black women have different expectations for their disease 
experience than White women (see section entitled “Does fibroid severity vary by race?”).  
 Higher BMI and conditions influenced by it, like diabetes and hypertension, are generally 
considered to be risk factors for pain. Stone and colleagues interviewed over one million United 
States residents and found risks for pain increased with BMI, compared to women with low or 
normal BMI (ORs ranging from 1.2-3.54, adjusted for age, gender, race, education, smoking, and 
healthcare use).
112
 Painful neuropathy may occur with diabetes and it is more common and may 
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manifest at an earlier age among women with type II diabetes.
113
 Although often associated with 
limbs or extremities, autonomic neuropathy within abdominal organs can develop.
113
 
Hypertension has a complex relationship with pain. Generally, hypertension is associated with an 
increased pain threshold for acute pain, but in the long term may actually lead to experiencing 
more chronic pain.
114
 
 Parity may also influence pain perception and expectations. Women with prior 
pregnancies may feel less anxious or worried about pain than nulliparous women and therefore 
report it less.  During pregnancy, most studies of pain center on pelvic-girdle pain. Pain in the 
pelvis is not unexpected in pregnancy due to the enlargement of the uterus and increased 
mobilization of joints by the hormone, relaxin. There is conflicting evidence as to whether 
number of prior pregnancies, age, or race increase risk of pelvic-girdle pain.
115
 Likely, these 
factors interact or exhibit non-linear relationships with pain—both situations being often 
overlooked in studies.
115
   
Pelvic and abdominal pain in pregnancy  
Generally, acute pain in the lower abdomen and pelvis can be a symptom of numerous 
conditions including appendicitis, irritable bowel syndrome, gastroenteritis, Mittelschmerz 
(ovulation pain), ovarian torsion, pelvic inflammatory disease, tumors, and trauma. During 
pregnancy, miscarriage or ectopic pregnancy may also lead to acute pain.
116
 Chronic abdominal 
and pelvic pain can also be caused by irritable bowel syndrome, pelvic inflammatory disease, and 
tumors (including fibroids). Poor posture, muscle strain, endometriosis, and physical or sexual 
abuse may be culprits as well.
116
  
The pelvic and low back pain (pelvic girdle pain) that often occurs in pregnancy typically 
begins in the second trimester and may be most intense between 24 and 36 weeks gestation, but it 
can begin earlier and if chronic, continue throughout pregnancy.
115
 This pain has been described 
as “stabbing,” “dull,” “burning,” or even “shooting,” the myriad responses likely reflect upon the 
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unique manifestation of pregnancy-related pain for each woman.
115
 Lower back pain during 
pregnancy may also be related to changes in posture and joint flexibility.
92
 In their review, Wu 
and colleagues found that the median prevalence of pregnancy-related pelvic girdle pain across 
studies was 49%, but ranged from 4% to 90%.
115
 These authors determined that strenuous activity 
and previous pelvic pain experiences were the strongest risk factors for pregnancy related pelvic 
and lower back pain.
115
 Across studies, evidence of association between pain and maternal age, 
weight, and parity was weak or conflicting and likely masked by residual confounding.
115,117
  Bed 
rest, exercises, acupuncture, and NSAIDs are often used to treat pregnancy-related pelvic-girdle 
pain, but the risk of pregnancy complications may limit the use of NSAIDs at certain points 
during pregnancy.
117
  
Pain and fibroids 
Investigating symptoms of bleeding and pelvic pain independently is difficult. Many 
studies report on each symptom, but rarely are they commented upon in conjunction (i.e., painful 
bleeding episodes). In previous RFTS research, 28% of women who experienced light bleeding in 
the first trimester of pregnancy and 54% of those with heavier bleeding also reported pain.
5
 
Likely, etiologies for bleeding and pain are shared and these symptoms may be non-specific to an 
array of conditions.  
Fibroid-related pain may be masked by pregnancy-related pelvic and low back pain, may 
manifest as this type of pain, or may even exacerbate it. Fibroids can exert pressure on organs 
adjacent to the uterus; this may cause changes in urinary frequency, constipation, low back pain, 
or bloating.
27
 The pain related to these problems is generally not characterized as “sharp.” 27 
Fibroids can cause “sharp” pain for women in several situations: when a fibroid outgrows its 
available blood supply (degeneration or infarction) or when a pedunculated fibroid twists on its 
stalk, obstructing blood supply.
27
 When degeneration occurs, the pain may be localized.
16
 
Degeneration may necessitate bed rest and use of pain medications (even opiates) and 
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antibiotics.
118
 When these treatments are limited in effectiveness, some have suggested the use of 
surgery to remove a degenerated fibroid during pregnancy.
16,119
  
For Zimmermann and colleagues, women who self-reported a fibroid diagnosis and 
symptoms described having more pressure on the bladder (33% versus 15%, p<0.001) and 
chronic pelvic pain (15% versus 3%, p<0.001) than women without fibroids.
7
 A diagnosis was 
also coincided with a higher prevalence of mid-cycle and during-menstruation pain, but no 
difference in the reporting of pre-menstrual abdominal cramping was found.
7
  
After adjusting for age and gravidity, investigators in the Seveso Women’s Health Study 
found that among women with ultrasound-detected fibroids (n=96), fibroids were not associated 
with self-reported noncyclic pelvic pain or painful periods.
6
 However, the trends for increasing 
severity across both pain types were statistically significant.
6
 Larger total fibroid volumes, 
volume of a woman’s largest fibroid, and number of tumors were not associated with increasing 
degree of noncyclic pelvic pain or painful intercourse. The researchers also observed that women 
with intramural and/or fundal fibroids more frequently reported pain than study participants with 
other fibroids.
6
 The unique exposures of women in this study (dioxin) may limit the 
generalizability of these findings. 
In their study among pregnant women with only one fibroid (n=434), Exacoustos and 
Rosati noted that a fibroid in the uterine fundus or isthmus or those larger than 200cc were 
associated with pelvic pain during pregnancy.
120
 They also observed that women with fibroids 
were more likely to experience pelvic pain during pregnancy that required hospitalization and 
prescription of narcotic pain medications than women without fibroids (13% versus 0.1%, 
p<0.001; women who had a miscarriage were included in these analyses).
120
 In a retrospective 
chart review from Duke University Medical Center, a quarter of pregnant patients with fibroids 
five cm or larger (n=39) required narcotic analgesics for their pelvic pain (none did among their 
age, race, and parity matched control group).
121
 These researchers also point out that these drugs 
may be more likely to be prescribed to women with larger fibroids.
121
 In a chart review of 102 
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women with fibroids from a Japanese hospital, 28% of women with documented pain during 
pregnancy (prevalence of 16%) required prescription analgesics.
34
 Finally, a study of women in 
Maryland undergoing hysterectomy mentions that Black and White women having 
hysterectomies for fibroids were equally likely to not have symptoms, but Black women with 
fibroids were more likely to report severe pelvic pain than White women with fibroids.
66
 The 
RFTS cohort has not been used to explore the relationship between fibroids and pain. 
Is fibroid growth a measure of disease severity? 
Fibroid growth 
Aside from larger volume, changes in fibroid size may contribute to pregnancy 
complications or symptoms. Growing fibroids may lead to changes pelvic pressure or 
vascularization, which may manifest as self-reported pain and bleeding. To my knowledge, no 
study has explored fibroid growth as a measure of disease severity, although a nation-wide survey 
indicated that more than 70% of women with symptomatic fibroids are afraid that their tumors 
will grow (84% of Black women).
94,109
 Fibroids are known to change in size over time, but 
predictors for growth or reduction, especially during pregnancy, are still being identified. Study 
designs vary greatly among those measuring growth—criteria for determining change in size, 
length of follow-up and statistical methods are very disparate. Most have used ultrasounds to 
visualize fibroids.  
Several studies have examined fibroid growth outside of pregnancy. Tsuda and 
colleagues followed 70 women with fibroids for one year, performing measurements via 
ultrasound every 3 months.
122
 A change in fibroid size was defined as a ≥30% increase or 
decrease in volume from the initial scan; visualization of arteries connecting to the tumor was 
also completed. A higher proportion of fibroids increased in volume when an artery was 
detectable, regardless of the tumor’s volume.122 This may suggest that a robust blood supply 
contributes to increases in fibroid size over time.   
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Peddada and associates used mixed modeling techniques to measure growth rates of 262 
fibroids in non-pregnant women aged 24 to 54 (percent change in volume per six months, as 
detected with magnetic resonance imaging).
63
 They found that growth was greatest when there 
was only one (versus multiple) fibroid in the uterus, after adjusting for an interaction between age 
and race. Characteristics such as BMI, parity, initial fibroid volume, and fibroid type or location 
were associated with minimal changes in growth (<5%) that the study may have been 
underpowered to detect.
63
 This is perhaps the only paper to take into consideration the correlation 
of growth rates within each woman. One of the most important results from their research was the 
observation of different growth rates across fibroids within the same woman; their modeling also 
suggested that both within-woman and between-women variation were significant contributors to 
overall variance (within-woman variation was twice as large).
63
 This idea has not been explored 
in a pregnancy cohort and accordingly, I attempted to address intra-and inter-person correlation of 
fibroid growth using longitudinal modeling techniques with RFTS data. 
Another small study from the University of Iowa followed multiple fibroids in eleven 
women aged 33 to 56 over the course of two years; they also noted that fibroids grew, shrank, or 
remained stable.
123
 Unlike the research by Tsuda and Peddada, these authors looked for changes 
in average diameter and noted that average growth was 1.2cm per 2.5 years and number of 
fibroids both increased and decreased from ultrasound to ultrasound. Women who had fibroids 
disappear between scans were older than those whose fibroids remained (51 vs. 47 years, p=0.15) 
and these fibroids tended to be small (1.1cm mean diameter).
123
 
Laughlin and colleagues examined 171 RFTS participants with a single fibroid in the first 
trimester of pregnancy and followed those three to six months postpartum.
81
 By this point in time, 
36% of fibroids were no longer visible and of the remaining tumors, 79% showed a decrease in 
average diameter. The median diameter of fibroids in the first trimester was 1.9cm and between 
the first trimester and postpartum period, the median change in diameter was 0.5cm.
81
 Fibroid 
characteristics such as type, position, and size were not related to fibroid disappearance, but 
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submucous fibroids decreased in size to the greatest extent (median change of 1.8cm in 
diameter).
81
 These authors suggest that a combination of conformational restructuring and 
changes in vascularization during post-partum uterine involution contribute to fibroid reduction, 
which serves to explain why parity could be protective against risk of fibroids.
81
 In another 
article, Laughlin and colleagues assessed change in total fibroid volume between early pregnancy 
to postpartum among RFTS participants (looking for a >50% decrease).
60
Among 235 women 
who had live births, 72% showed this decrease in total volume while 12% had a change of 50% 
or less, and 16% showed an increase in total volume.
60
 Decreases in total volume were less 
common among non-Hispanic Black women, relative to non-Hispanic White women (OR 0.47, 
CI 0.25-0.88, adjusted for submucous fibroid type).
60
 
Fibroid growth during pregnancy 
Growth during pregnancy is likely influenced by great changes in the levels of hormones 
and growth factors, the physical stretching of the uterus, and vascularization changes.  In non-
pregnant women, fibroid volumetric changes are likely specific to both a tumor and an 
individual.
16,63
 Several studies have examined growth during pregnancy, but their conclusions are 
difficult to compare, owing to great heterogeneity in study design. 
I identified nine articles exploring fibroid growth during pregnancy.
9,10,11,12,29,30,31,32,33  
Summary information from these papers is presented in Appendix 1. Four of the nine studies 
were done in the United States, three in Italy, and one each in Canada and Israel. However, 
descriptions of study setting were inadequate in many papers and were inferred from author 
contact information (five studies). Inability to identify study settings and source populations 
limits the generalizability and interpretation of these studies’ results. Four studies were likely 
prospective (ultrasounds were scheduled with the intent to follow fibroid growth), but this was 
not always explicitly stated.
10,33,30,32
 The average number of women with fibroids in each study 
was 68, but ranged from 32 to 104. Four studies followed only the largest fibroid in each 
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participant or limited analyses to those with one tumor.
11,29,32,33
 The remaining studies looked at 
all fibroids, but ignored potential within-woman correlation of growth rates. Ethnicity 
information was supplied in six studies and one of these analyses was limited to White women; 
Black women comprised 7% to 89% of the other five study populations, conducted in the United 
States or Canada.
9,10,11,12,29,31
 
Regression techniques (logistic) were used in only one of these studies, to identify 
univariate associations between risk factors and an increase in growth (>10% change in 
volume).
10
 DeVivo and colleagues showed that between the first and second trimesters, pre-
pregnancy BMI (continuous) and the juxtaposition of a fibroid and the placenta were associated 
with growth, while multiparity (continuous) was protective. Only BMI was a risk factor for 
growth between the second and third ultrasounds. Increasing age was protective for growth over 
the entire pregnancy. Initial fibroid size or position was never a statistically significant 
predictor.
10
 
All nine studies used ultrasound to measure fibroid size. Timing of ultrasounds (e.g., 
average gestational age for first scan, average number of subsequent scans and time between 
them) was described in all but one paper.
29
 Roughly half of these studies used a measure of 
fibroid diameter to describe size changes (e.g., percent change in diameter, ≥1.0cm change in two 
out of three diameter measurements, or 10% change in average diameter).
9, 29,12,33
 The remaining 
five studies calculated fibroid volume as a sphere or an ellipsoid or did not describe their volume 
calculations.
10,11,30,31,32
 Aharoni and colleagues reported that fibroids appeared to become less 
spherical and more ellipsoid during pregnancy. The authors felt that while tumor volume was 
unaffected by these conformational changes (no data provided), comparing measurements of 
fibroid diameter over time would be inadequate for describing size changes—which favors using 
volume a better metric.
30
 If conformational changes are great, then measurement of fibroids with 
a spheroid volumetric measurement or by maximum or average diameter may not provide an 
accurate classification of tumor size, especially as pregnancy progresses. Calculating tumor 
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volume as a prolate ellipsoid (i.e., a symmetric, egg-shape) will provide a better approximation 
because it uses three unique diameter measurements; this is how RFTS calculates fibroid volume. 
 The heterogeneity in design and fibroid size measurement techniques across these studies 
makes comparisons of growth estimates difficult. Most results were reported as a proportion of 
fibroids that increased, decreased, or stayed the same size (often within 10% of initial size—be it 
tumor volume or diameter). Lev-Toaff, Rosati, Hammoud, and De Vivo and colleagues 
commented on fibroid size changes between trimesters, while others focused on the entire 
pregnancy timeframe
.9,10,11,32
 Of the studies reporting information on the latter, growth was 
observed in five percent, 20%, 22%, and 32% of fibroids.
29,30,32,33
 Overall growth was difficult to 
assess from the information presented in two papers.
12,31
  
 Muram and colleagues performed the only study in which the timing or number of 
ultrasound scans were not described.
29
 In the other studies, initiation of exams (in terms of 
estimated gestational age) was described as being first trimester, mean of 14 weeks, 11 to 14 
weeks, 16 to 20 weeks, before 20 weeks, 20 to 24 weeks, or after 20 weeks. Descriptions for 
timing between scans were similarly diverse: from two to four weeks, three to eight weeks, six to 
eight, four to 12, every two weeks until 20 weeks and monthly thereafter, approximately every 10 
weeks, up to 19 weeks then 20 to 30 weeks and 31 to 42 weeks, or one to 17 weeks with an 
average of six.  Numbers of ultrasounds performed were two to four, three, at least three, or two 
or more.
9,10,11,12,31,33
 
 Although DeVivo and co-authors commented on characteristics associated with growth 
between all trimesters, three other studies commented on fibroid growth between the first and 
second trimesters
.9,11,32
 For Hammoud and colleagues,  40% of fibroids increased by more than 
10% of their initial volume, while Rosati and co-authors found that average difference in volume 
was an eight percent increase between these time points.
11,32
 Lev-Toaff and colleagues noted that 
observed tumors grew or remained the same in diameter, but did not describe to what extent.
9
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Growth was less pronounced as pregnancies progressed.
9,11,32
 Thirty percent of “small” 
fibroids (average diameter two to six cm) and 14% of “large” ones (six to 12cm) increased in size 
for Lev-Toaff and associates within the second trimester. In the third trimester, these proportions 
were five and 12%, respectively.
9
 For Hammoud and colleagues, the percent of fibroids 
exhibiting growth decreased from 40% to 18% between the second and third ultrasounds (20 to 
30 weeks gestation and 31 to 42, respectively).
11
 The average percentage difference in volume for 
Rosati and associates went from 8% growth to 0.5% reduction over the course of pregnancy.
32
 
Decreases in fibroid volume (reduction) were most marked between the second and third 
trimesters for larger fibroids. For Hammoud and colleagues, 88% of tumors >4cm showed a 
decrease (percent change in mean diameter) whereas only 20% of smaller fibroids shrank 
(p=0.001).
11
 Lev-Toaff and co-authors also found that in the second trimester, 15% of small 
fibroids (two to six cm in diameter) decreased in size (at least 2 out of 3 diameter measurements) 
versus 48% of larger fibroids. In the third trimester, 35% of small fibroids decreased in size while 
60% of larger ones did.
9
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CHAPTER IV 
AIMS 1 AND 2: IDENTIFYING ASSOCIATIONS BETWEEN FIRST TRIMESTER 
SYMPTOMS AND UTERINE FIBROID SEVERITY 
Overview 
 Fibroids are consistently described as causing heavy or irregular menstrual bleeding and 
pelvic pressure or discomfort.
5,6,7,27,120,121
 Despite this knowledge, few studies have explored the 
association between bleeding or pain and fibroids among pregnant women.
5,24
 In the first 
trimester, symptoms such as these concern women because they are associated with threatened 
abortion or ectopic pregnancy.
98
  
 It is appealing to think that fibroid severity increases linearly with characteristics such as 
increasing size or number. For example, it is reasonable to hypothesize that larger total fibroid 
volumes may contribute to symptoms of pain or pressure—especially in pregnant women, as a 
larger uterus will put pressure on the surrounding organs and blood vessels.
27
 Fibroids may 
interfere with muscle contractility or reorganize blood flow within the uterus as well, contributing 
to symptoms such as bleeding and pain. This is plausibly exacerbated for a pregnant woman, 
whose uterus is undergoing dramatic hormonal, volumetric, and vascularization changes 
 As described in the background sections, few studies report associations between fibroids 
and symptoms during pregnancy and commenting on the role of disease severity (volume or 
number of fibroids) only occurred when pain was of interest.
5,24,120,121  
Fibroid severity and 
symptom information may be inconsistently documented in hospital records (e.g., only pain 
requiring narcotics is noted). Prior research largely relies on retrospective examination of 
pregnancy-related imaging records to identify women with fibroids—when approaches that limit 
the number and size of fibroids documented may be used. Clinical study populations typically are 
biased to include women who have “problematic” or larger fibroids. Therefore, estimates for risk 
of symptoms may be artificially high because women with small or asymptomatic fibroids are left 
out—the majority of women with fibroids.  
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The goal of these Aims was to determine whether vaginal bleeding or abdominal pain in 
the first trimester of pregnancy is associated with measures of fibroid severity such as total 
volume or number of tumors. To conduct these analyses, I used data from the Right from the Start 
pregnancy cohort. Using transvaginal ultrasonography, all participants were prospectively 
screened for the presence or absence of fibroids in the first trimester. All fibroids as small as 
0.5cm in diameter were documented and measured. Women self-reported information about 
symptoms in interviews and our reports did not rely on medical records. This approach 
minimized misclassifying a participant’s fibroids status; accurately estimating her disease 
severity; and subsequently, reduced bias when estimating the risk of fibroid-associated 
symptoms. 
The analyses for Aims 1 and 2 use information from the entire RFTS cohort with several 
exclusions, described below (n=4,392).  
Hypothesis 
Women with more severe fibroid disease (greater total volume or number) are more 
likely to report bleeding and pain episodes than women with less severe disease or those without 
fibroids.  
Methods 
Right from the Start pregnancy cohort  
Recruitment 
RFTS was initially designed to assess the influence of water disinfection by-products on 
risk of spontaneous abortion.
13
 Recruitment for RFTS began in North Carolina in 2000. When 
recruitment ended in 2011, the study had also enrolled participants from Texas and Tennessee, 
with efforts focused in several urban locations and the surrounding suburban areas. A variety of 
methods were used to advertise the study to potential participants. Both private clinics and public 
42 
 
prenatal care sites (e.g., county health departments) displayed RFTS posters and brochures, 
included study materials within informational packets, and spoke with patients about 
participation. The study also posted advertisements within a variety of community locations such 
as retail stores, fitness centers, churches, family practice offices, and worksites. Rebate coupons 
for pregnancy tests were also offered at drug stores for eligible women who expressed interest in 
the study. Finally, mass mailings and emails were sent to potential participants (e.g., new home 
owners, women who gave birth about a year prior to the mailing date). A toll-free phone number 
was provided on study materials. These recruitment methods were described in detail by 
Promislow and colleagues.
13
 
Although not advertised as a uterine fibroids research study, specific health concerns may 
have influenced a woman’s decision to enroll in RFTS. During the screening interview, women 
addressed whether or not a healthcare provider ever told them that they had uterine fibroids and if 
concern about fibroids was related to their reason for joining RFTS.  If they cited a specific 
concern as reason for participating, study personnel categorized this response as one or more of 
the following: pain, bleeding/spotting, had a previous miscarriage, not experiencing any nausea, a 
special medical condition, general anxiety, maternal age, medicine use, smoking, uterine fibroids, 
or other (free text/typed in). Only women in the last two study phases (described below) were 
asked about their history of fibroids. 
RFTS: Eligibility 
 RFTS was conducted in three study phases, each with associated eligibility requirements 
and recruitment goals.  
RFTS I: Active enrollment for this phase took place from December 2000 to July 2004. 
As mentioned, this first phase examined water disinfection by-products and spontaneous abortion 
risk. At this time, women were required to be less than 12 weeks pregnant, be 18 years or older, 
live in an area served by the water source of interest, speak English, have not used fertility 
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treatment (for the index pregnancy), and have the intention to carry to term and deliver in the 
study area.
13
 Recruitment began in Raleigh, North Carolina followed by Memphis, Tennessee and 
Galveston, Texas. 
 RFTS II: Women were actively enrolled in this phase from August 2004 to July 2007 
and enrollment after this time was limited to those who did not meet specific eligibility criteria 
for RFTS III (see below). Phase two of RFTS was designed to explore fibroids and adverse 
pregnancy outcomes. These women were eligible for enrollment if they were less than nine and 
6/7 weeks pregnant or were not pregnant but trying to become so for less than six months, spoke 
English or Spanish, were 18 years or older, had not used fertility treatment (for the study 
pregnancy), and had the intention to carry to term and deliver in the study area. Women who were 
not pregnant were able to pre-enroll in the study and were formally enrolled if they became 
pregnant within two years of the initial screening.  
RFTS III: Active enrollment began in 2007 and ended in 2011. This phase focused on 
NSAID use and pregnancy loss. Enrollment for this phase overlapped with RFTS II. Eligibility 
was similar to the other phases, but women who were planning a pregnancy and were willing to 
complete daily diaries were enrolled. These women also needed to have daily Internet access and 
commit to checking their email regularly. RFTS III participants completed daily and weekly 
electronic diaries detailing such things as medication use and experiences with pain and bleeding 
(English speakers only). If these women became pregnant within four months, they enrolled in 
the study and participated as detailed below, with the exception of continuing their diaries into the 
first trimester. If they did not become pregnant, they were converted to a pre-enrolled status in the 
second study phase (and followed for up to eight more months). Women who became pregnant 
within a month of this conversion were allowed to re-enroll in the third phase and complete 
diaries.  
 RFTS participants were allowed to enroll in the study for multiple pregnancies. However, 
only the information from the first study pregnancy for each woman was considered for the 
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analyses included in this dissertation. During the RFTS II and III, recruitment was expanded to 
Nashville, Knoxville, and Chattanooga, Tennessee and enrollment in Texas and North Carolina 
ended. 
Process of participation 
Each RFTS participant was screened for eligibility via a 10 to 15 minute computer-
assisted telephone interview (CATI), during which she was asked about contact and demographic 
information, any fertility drug use, prior contraceptive use, her previous pregnancy experiences, 
and her interest in the study. If a woman was not yet pregnant when she initially called, she was 
classified as a “pre-pregnant” enrollee. These women were sent free pregnancy tests to encourage 
early reporting of pregnancy. Women were followed for up to 12 months. If she became pregnant 
during this time, the screening interview was repeated, but contained more detailed questions 
about her previous menstrual experiences and planned prenatal care location. If a participant’s 
response was different on questions that were repeated in the second screening, the response from 
the second screening was used in these analyses.  
 Once pregnant, each participant received a transvaginal ultrasound by study-trained 
personnel in their area of residence around the sixth week of gestation, but no later than 12 and 
6/7 weeks, as calculated from each woman’s self-reported last menstrual period. Consent forms 
were also signed and obtained at this time. A subcohort of patients from the second study phase 
also received ultrasounds at 15 and 27 weeks, performed with the primary intention of 
documenting fibroids (versus fetal characteristics).  
Participants were next scheduled for a one-hour first trimester CATI, to be completed 
before 16 and 6/7 weeks gestation (targeted on 13 weeks). Most women should have completed 
the CATI after having the first trimester ultrasound. This interview included questions on 
demographics and menstrual and pregnancy history. The women were also asked about past 
health history and medication use, pain and bleeding experiences, and health behaviors to-date 
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during the index pregnancy. Women residing in Tennessee were not asked questions regarding 
paternal characteristics due to restrictions issued by an Institutional Review Board. Women who 
had pregnancy losses were given a modified interview that was reworded to acknowledge the 
loss, but identical in content to the standard first trimester CATI. These women were also 
provided with contact information for counseling services.
124
 
The subcohort asked to return for repeated ultrasounds also participated in a CATI 
around 27 weeks, but no later than 31 and 6/7 weeks gestation (the third trimester CATI). The 
women answered questions about health behaviors and bleeding and pain episodes up to that 
point in the pregnancy. At seven months gestation, all RFTS participants completed an update 
form in order to notify the study of any address, care provider, or intended birth hospital changes. 
Finally, women in RFTS were asked to call the study or fill out a one-page questionnaire 
at the end of their pregnancies. Information on pregnancy outcome and health insurance for the 
index pregnancy was obtained at this time. Medical records of each participant were also sent to 
RFTS and if applicable, data on the infant and method of delivery were abstracted. Women in the 
repeated-ultrasound cohort had a final ultrasound three months postpartum and completed a CATI 
three to six months after delivery. Some of these women also had magnetic resonance imaging 
performed; the methods for postpartum imaging were described previously.
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 A timeline detailing 
the process of participation for women in RFTS is presented in Figure 4. 
Throughout the participation process, women were given monetary reimbursement or gift 
cards for their time ($10-25, with options for an additional $100 for participation in the repeated 
ultrasound cohort, and $60 for completing electronic diaries). Small gifts such as calendars, t-
shirts, water bottles, luggage tags, and bibs were provided to those who returned the seven-month 
update and pregnancy outcome forms or referred other participants.  
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Figure 3. Timeline of events for Right from the Start participants 
 
 
 
Informed consent and study approval 
 All RFTS study participants whose data are included in these analyses gave informed 
consent. The Institutional Review Boards of the University of North Carolina, University of 
Tennessee, University of Texas, and Vanderbilt University have approved RFTS study 
procedures.  
Final population for Aims 1 and 2 
 Women whose information contributed to these analyses were enrolled in RFTS between 
December 2000 and September 2011. I used information from the first study pregnancy for each 
woman (women may enroll multiple times). During this period, there were 4,776 different 
participants who had pregnancies resulting in a live birth after 20 weeks of gestation. Women 
with other pregnancy outcomes such as miscarriage, stillbirth, ectopic, or molar pregnancies were 
excluded because these outcomes may have an etiologic relationship with bleeding and pain 
symptoms. Other exclusion criteria included multiple gestations (n=57), no study ultrasound 
(n=118), missing volume information for fibroids documented during the ultrasound (n=2), no 
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first trimester CATI (n=193), and missing responses to bleeding or pain questions (n=14). The 
resulting population of 4,392 women was uniformly screened for the presence or absence of 
fibroids. 
Determining exposure status: Fibroid measurement in RFTS 
All women in RFTS were screened for the presence or absence of the fibroids. 
Experienced pelvic sonographers determined fibroid status during first trimester transvaginal 
ultrasounds. Initially, sonographers from community-based practices (an academic site and a 
single large radiology practice) were trained to perform ultrasound exams for the study. 
Beginning in RFTS II, only a small number of sonographers were consistently used to perform 
ultrasounds. All sonographers were specifically trained to collect the research data. Study 
sonographers had at least five years of experience in pelvic and obstetric sonography and were 
certified by the American Registry for Diagnostic Medical Sonography.  
Ultrasound machines were calibrated quarterly by certified maintenance technicians. 
Medical practices that provided these exams received financial reimbursement.
13
 The ultrasound 
exams were provided at no cost. Participants were asked not to discuss their reproductive and 
medical histories during the exam and this information was not provided to the sonographers by 
RFTS. 
During the ultrasound, the sonographer measured (if visualized): uterine length and 
width, gestational sac, fetal pole, heart rate, and any fibroids. If an early pregnancy loss occurred 
between the screening interview and the scheduled six-week ultrasound, the sonographer 
documented uterine dimensions, endometrial stripe, and any fibroids. 
The position, type, and size of each fibroid (as small as 0.5cm in maximum diameter) 
were noted by the sonographers and confirmed by a study physician.
8
 Still images and video from 
the ultrasound were taken and a fibroid map was also completed during the ultrasound to indicate 
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the relative location of each fibroid. All ultrasound findings were sent to the participants’ 
healthcare providers.   
The sonographer measured three perpendicular axes for each fibroid, three separate times 
(nine total measurements). The sonographers were asked to capture an image of each fibroid and 
to document caliper markings for each of their measurements. They were instructed to then 
conduct a fetal measurement and return to measure the fibroid again, repeating this process of 
“recapturing” the fibroid image a total of three times. For each axis, an average of the three 
measurements was used to calculate a final diameter (in mm). The three final diameters were used 
to calculate fibroid volume (in cc) using the formula for an ellipsoid (Volume=(4/3)*pi*radius 
1*radius 2*radius 3). Volume was calculated for all fibroids individually and also in aggregate (a 
continuous total volume variable).  
Fibroid location within the uterus was defined as follows: fundus, corpus, cervix, 
anterior, and posterior. Fibroid types included: submucous distorting the endometrium, 
submucous not distorting the endometrium, intramural, subserosal, and pedunculated. Categories 
for type were mutually exclusive.  
Participants in the subcohort who received additional ultrasounds had their fibroids 
documented in a similar manner. The sonographer also indicated if a fibroid was located beneath 
the placenta (defined by a line passing perpendicularly through the placenta and also intersecting 
a fibroid) and measured the uterine length as a distance from the fundus to the cervix. Blood flow 
to fibroids was also assessed during the repeated ultrasounds via color Doppler and if an artery 
feeding a tumor was visualized, a resistance index was reported. Examples of forms completed by 
the sonographers during these exams are presented in the appendices (A2 and A3). 
Measurements of fibroid severity 
Two measures of disease severity were my primary exposures of interest: total volume 
and number of tumors. Total fibroid volume was calculated for each woman by adding together 
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all of her individual tumor volumes. For linearity analyses, volume was rounded to the nearest cc 
and for women who had total fibroid volumes between zero and one cc, this value was rounded 
up to one cc. Volume was eventually categorized for analyses in Aims 1 and 2. In Aim 3, 
unrounded values of volume were used to estimate percent change in volume (described later). A 
continuous total fibroid volume measure was used for descriptive purposes, but total volume was 
difficult to model continuously in all Aims. I describe the linearity assessment below, but the 
distributions provided in Figure 4 show the sparseness of the data at higher total volumes, relative 
to lower ones. This figure also shows that Black women generally had larger total volumes than 
the other race groups. A categorical variable for total volume as an exposure was ultimately used 
in Aims 1 and 2: no fibroids (reference), less than or equal to 5cc, more than 5cc and less than or 
equal to 20cc, and more than 20cc. These cutoff points correspond to the 50
th
 and 75
th
 percentiles 
for total fibroid volume among the entire population used in these Aims.   
Number of fibroids was modeled continuously because it had reasonable linear 
relationships with risk of each symptom outcome (as opposed to a quadratic one).  
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Figure 4. Distribution of total fibroid volume in the first trimester, by race 
 
Top panel: total fibroid volume distribution for non-Hispanic White women. Middle Panel: non-Hispanic 
Black distribution. Bottom panel: Other/Hispanic distribution. cc=cubic centimeters, N=number 
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Outcomes 
 During first trimester CATIs, women self-reported information about their behaviors and 
experiences around conception and up to that point in the pregnancy. This included descriptions 
of the incidence of any bleeding and abdominal pain episodes. Women reported on the incidence, 
duration, heaviness, coloring of their bleeding, incidence of abdominal pain, and incidence of any 
pain during bleeding in the first trimester CATI. These questions are presented in the appendices 
(A4-A7). 
I wanted to explore three unique symptom profiles: bleeding only, pain only, and 
bleeding AND pain. Women who reported both pain AND bleeding were treated as having a 
unique set of symptoms, different from those with bleeding only or pain only (this profile is 
called “both symptoms” hereafter). This group included women who reported pain during 
bleeding or pain AND bleeding independently. My goal was to combine these three symptom 
profiles into one non-ordinal multilevel (polytomous) outcome with the following categories: no 
symptoms (reference), bleeding only, pain only, and both symptoms. This outcome was 
successfully modeled when number of fibroids was my exposure of interest. However, effect 
modification tests (see below) revealed that for models in which total fibroid volume was an 
exposure, bleeding only should be modeled as an independent logistic regression (reference: no 
symptoms). I ran polytomous models for total volume and the remaining two symptom categories 
and these were stratified by race (reference: no symptoms). 
 Several secondary polytomous outcomes were modeled. Number of bleeding episodes 
and the total duration of bleeding (in days) were modeled after the work of Hasan and 
colleagues.
125
 These two measures were categorized as: none (reference), one, or two or more. 
Heaviness of the first bleeding episode was measured as follows: none (reference), light 
spotting/flow, and heavy flow. Levels within these multilevel outcomes were presumed to have a 
non-ordinal relationship (i.e., there was no linear relationship forced between the levels).  
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 When participants were asked about bleeding, they were given the option to comment on 
any pain occurring during bleeding episodes (not specified to be “abdominal”). Secondary 
analyses among women with pain during bleeding were performed to assess the relationship 
between pain intensity (none (reference), mild, moderate, or severe; non-ordinal) and fibroid 
severity. This group of women differed from those experiencing “both symptoms” described 
above because that outcome included both women 1) who reported pain during bleeding and 2) 
those who reported both symptoms independently. 
Measurement of potential confounders and descriptive variables  
Linearity assumptions and categorization 
A range of variables was used to display demographic information about the study 
populations and considered for inclusion in regression models as confounders. This section 
details the collection, measurement, and format of these variables. First, I discuss the formatting 
of continuous variables. 
Continuous variables are sometimes categorized to improve interpretability or facilitate 
comparison across studies. Categorizing prevents a researcher from observing the change in risk 
associated with a per unit change in a continuous variable and how this relationship changes over 
values of the continuous variable. To preserve this information, splines and polynomials are often 
employed when a variable is not normally distributed or the relationship between a variable and 
the risk for an outcome is non-linear. Using a categorical variable may be preferred to a difficult-
to-interpret higher order polynomial or spline when linearity assumptions for a continuous 
variable are not met. Interpreting effect measures for variables modeled with multiple terms (e.g., 
splines) is also difficult. All of these methods (polynomials, splines, and categorization) require 
the addition of terms to regression models and can result in overparameterization (sparse data 
within strata).  
53 
 
Categories should ideally be chosen from well-tested examples in the literature because 
of the assumption that risks within (but not necessarily between) these groupings are 
homogeneous.
126
 Improper choice of categories can lead to residual confounding and not being 
able to generalize one’s results to external populations.126 RFTS, for example, has a BMI variable 
comprised of categories that correspond to weight guidelines designed for pregnant women.
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 To examine the linearity of continuous variable-outcome relationships, predicted values 
for the risk of each outcome (symptom) for each year of age or unit of BMI were plotted—such 
that the “shapes” of the variable-outcome relationships could be seen. A cigar-shaped band is 
usually evidence of a linear relationship. The linearity of the relationship may be improved with a 
transformation. For example, if a curve is u-shaped (e.g., higher risks for younger and older 
women relative to women of “middle ages”), age could be modeled with a quadratic term to 
better explain the risks associated with maternal age. The linearity between age or BMI and risk 
of each outcome needed to be examined. Figure 5 provides an example of the relationship 
between maternal age and the “both symptoms” outcome. Predicted values from regressions in 
which age was modeled linearly, quadratically, and with a three-knot restricted cubic spline are 
overlaid as lines on the scatter plot. This figure is strictly a visual aid; the decision process for 
selecting a modeling approach is described in the following paragraphs.  
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Figure 5. Linearity of the relationship between maternal age and risk of bleeding AND pain, 
with modeling transformations 
 
 
 
It is possible that a continuous variable-outcome relationship cannot be modeled with a 
“simple” transformation or the predicted values cannot be obtained due to convergence problems 
(e.g., there are no women or no women with an outcome of interest in certain age groups). A 
priori, a decision was made to categorize age and BMI into four-level variables if they could not 
be satisfactorily modeled linearly or with “simple” transformations (e.g., natural log or cubic and 
quadratic terms). Although categorization would result in loss of statistical power, interpretability 
of the effect estimates would be gained without sacrificing further degrees of freedom to complex 
polynomial terms. These categories preserve (albeit homogeneous) risk groups with adequate 
sample size. Splines were not used because of the difficulty in obtaining interpretable effect 
estimates—which was necessary when assessing for confounding (see below). Maternal age was 
categorized into data-based quartiles determined from the study population for descriptive 
purposes and treated as a continuous linear or quadratic variable in analyses (depending on the 
outcome). For BMI, categories were be taken from World Health Organization and Institute of 
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Medicine guidelines on maternal BMI, but it was also modeled continuously and linearly.
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Categorical age and BMI were only used in regression modeling in Aim 3. 
Linearity was examined between fibroid severity (continuous total volume and number) 
and risk of each outcome. Modeling approaches were selected based on visual assessment, lowest 
Akaike’s Information Criterion (AIC), degrees of freedom, and simplicity (e.g., if linear and 
quadratic techniques produced AICs within 2 units of each other, linear modeling was used). 
Total fibroid volume was treated as a categorical variable because it had no linear relationship 
with any outcome (the symptoms), nor could other techniques be used to explain these 
relationships better (e.g., polynomials, or restricted cubic splines). Maintaining interpretability of 
exposures was paramount, so the previously described categories for total volume were used. The 
results of the linearity assessments suggested that traditional use of these characteristics in simple 
continuous forms is likely inappropriate (especially when drawing inferences about risk linearity).  
The final formats for all variables are described in Table 2. Linearity of the relationships between 
number of tumors and risk of bleeding or pain were also assessed visually and with likelihood 
ratio tests (e.g., comparing a quadratic model to a linear one). Number was modeled continuously 
and linearly.  
Variables of interest 
Descriptions and construction of the variables to be used for these analyses are presented 
in Table 2. Some variables have multiple options to convey missingness in RFTS (e.g., missing, 
unknown, don’t know, and refused options). These responses were combined into one “missing” 
category for analysis. Missing information led to dropped observations in “complete case” 
regression analyses—with the exception of hypertension missingness, which was treated as a 
viable response category. 
 In addition to variable types and operational definitions, the source of information for 
each variable is given in Table 2. Much of the demographic information for RFTS participants 
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was self-reported. Women were asked about their age, race, parity, diabetes diagnoses, alcohol 
and tobacco use, marital status, household income, and education level during telephone 
interviews. Maternal BMI was calculated from height and weight measurements obtained in-
person at the first trimester ultrasound examination using standard and calibrated scales and 
stadiometers provided by the study. During this visit, study personnel were instructed to measure 
height in inches and round to the nearest half-inch. Quarters of an inch (0.25 and 0.75) were 
rounded up to the nearest half-inch. Weight was measured on a scale during the visit (lightly 
dressed and without shoes) and rounded to the nearest pound; half pounds were rounded upward. 
When this information was incomplete or not available, the height and/or weight reported during 
the first trimester interviews were used. For analyses on fibroid growth during pregnancy (Aim 
3), maternal weight measures from 15- and 27-week ultrasound visits were used to calculate BMI 
(in conjunction with height from the first trimester ultrasound or interview).
129
   
 Race/ethnicity was obtained from vital records only if not available from the screening 
interviews. To reduce misclassification, the self-reported information from RFTS was preferred 
because the determination of race/ethnicity in vital records may be made by unknown or proxy 
sources (e.g., a nurse or spouse). Previous studies have found a high rate of agreement (94 to 
95%) between observer-reported and self-reported race, but agreement on ethnicity (e.g., 
Hispanic) varied.
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Variables denoting the type and position of each fibroid were available and dichotomous 
variables indicating the presence of any fibroids of certain types/positions were also used 
(especially in the third Aim), but are not listed in Table 2.  
In regression analyses, indicator variables were used for each level within a variable 
consisting of three or more categories (e.g., hypertension). Using one variable to represent all 
levels would presume a linear relationship existed between the levels and only one parameter 
estimate would be calculated; my goal was to obtain effect estimates for each level.  
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Table 2. Classification of and information sources for potential confounders and descriptive variables 
Characteristic RFTS Classifications Classifications for Analyses Source of Information 
Maternal Age  Continuous  Categorical: 
Primarily for descriptive purposes. 
Population-based quartiles (25-50
th
 
percentile is the reference group) 
 
Continuous or quadratic: 
Used for most analyses 
Screening CATI 
Maternal Race Non-Hispanic White 
Non-Hispanic Black 
Hispanic 
Native American/ Asian/ Other 
Refused 
Don’t Know 
Missing 
Non-Hispanic White 
Non-Hispanic Black 
Other 
Missing 
 
When testing effect modification: 
Non-Hispanic White 
Non-Hispanic Black 
 
1. Screening CATI 
2. Vital records (if RFTS information 
is missing) 
Body Mass Index Continuous  
 
Clinically Relevant Categories:
127 
Underweight (<19.8) 
Normal (≥19.8 and ≤ 26.0) 
Overweight (> 26.0 and ≤ 29.0) 
Obese (>29.0 ) 
Clinically Relevant Categories:
128 
Primarily for descriptive purposes. 
Underweight (<18.5) 
Normal (≥18.5 and <25.0) 
Overweight (≥25.0 and <30.0) 
Obese (≥30.0) 
Missing 
 
Continuous: 
Used for most analyses 
1. First trimester ultrasound visit 
2. First trimester CATI (if ultrasound 
information is missing) 
 
Weight in the second and third 
trimesters is also captured during 
repeat ultrasound visits for the 
subcohort. 
Parity Continuous 
 
Categorical: 
Nulliparous (0) 
1 
2 or more 
Missing 
Categorical: 
Nulliparous (0) 
1 
2 or more 
Missing 
First trimester CATI 
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Diabetes Status (any diagnosis, not 
limited to current pregnancy) 
No diabetes 
Type I 
Type II 
Gestational diabetes 
Multiple types 
Unknown 
Missing 
No diabetes 
Diabetes (all types) 
Missing 
First Trimester CATI 
Hypertension Status (any diagnosis, 
not limited to current pregnancy) 
No 
Yes 
Refused 
Don’t Know  
Missing 
No hypertension 
Hypertension 
Missing (included as an indicator 
variable, not dropped from “complete 
case” analyses) 
First Trimester CATI 
First trimester alcohol use Never 
Current 
Quit within 4 months of interview 
Quit more than 4 months since 
interview 
Don’t know 
Missing 
Not drinking (within 4 months of 
CATI) 
Currently drinking 
Possible exposure (recently quit 
within 4 months of CATI) 
Missing (includes “don’t know”) 
First Trimester CATI 
First trimester smoking status  Never 
Current 
Quit within 4 months of interview 
Quit more than 4 months since 
interview 
Quit but unknown when 
Missing 
Not smoking (within 4 months of 
CATI, includes “quit but unknown 
when”) 
Currently smoking 
Possible exposure (recently quit 
within 4 months of CATI) 
Missing 
First Trimester CATI 
Marital/ Partner Status Married/ Living as married single 
Other 
Refused 
Married/ Living as married single 
Other 
Missing 
1. Screening CATI 
2. First trimester CATI (if screening 
information is missing) 
Household Income <=$40,000 
$40,001-$80,000 
>$80,000 
<=$40,000 
$40,001-$80,000 
>$80,000 
Missing 
First Trimester CATI 
Insurance type Private 
Public 
None (self-pay) 
Private (includes “application 
pending, private”) 
Public (includes “application pending, 
Pregnancy Outcome Form 
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Other 
Application pending, private 
Application pending, public 
Refused 
Don’t Know 
Missing 
public”) 
None (self-pay) 
Other 
Missing (includes “don’t know” and 
“refused”) 
Maternal education completed <=High school 
Some college 
>=4 years of college 
Refused 
<=High school 
Some college 
>=4 years of college 
Missing 
Screening CATI 
RFTS=Right from the Start: a Study of Early Pregnancy Health; CATI=computer-assisted telephone interview 
Reference categories are in bold; variables without an indicated reference group are used for descriptive purposes only (no regression analyses)
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Potential confounders 
 Directed acyclic graphs (DAGs) representing the postulated causal relationships between 
fibroid severity and 1) first trimester bleeding and 2) first trimester abdominal pain were created 
from knowledge of the literature (Appendix 8, Figures 1 and 2). From these DAGs, I selected a 
minimally sufficient set of potential confounders for assessment. I considered these factors: age, 
race, parity, BMI, smoking status, alcohol use, previous hypertension, previous diabetes, and 
study site.  Having previous fibroid diagnoses was not evaluated as a confounder because not all 
women in the cohort were asked to provide this information.  The DAG representing study site’s 
role as a potential confounder is Figure 3 in Appendix 8; it possesses unique relationships with 
individual-level characteristics (symptoms and fibroid volume) and ecologic-level variables 
(largely unmeasured). A final set of confounders was determined using the procedures outlined in 
the “Assessment for confounding” section. 
Examining effect modification by race 
As discussed in the background, Black women are more likely to have severe fibroid 
disease (greater number, larger tumor volume, and diagnosis at a younger age), different genetic 
risk factors, and different utilization of fibroid-associated healthcare than White women. It is 
reasonable to hypothesize that the effects of risk factors for fibroid development or growth vary 
between Black and White women. Given similar disease severity, Black women may also 
differentially report symptoms of bleeding and pain. 
For each symptom profile, I examined effect modification between 1) maternal race and 
total fibroid volume and 2) race and number of tumors. In this process, I limited race to non-
Hispanic Black and White women. Before adjustment for confounding, regression models with 
and without an interaction term for race and the exposure of the interest were compared with a 
likelihood ratio test; a p-value cut off of 0.1 was used to test for heterogeneity of effects by race. 
A p-value cut off of 0.1 was used, such that the risk of making a type I error was increased 
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relative to an alpha of 0.05 (identifying effect modification when homogeneity is true), but the 
power to detect heterogeneity was increased (making it more difficult to reject heterogeneity 
when it actually exists). If heterogeneity was detected, the results for the corresponding models 
were stratified by race. If no modification was detected, race was treated as a potential 
confounder (and women of “other” races were included). The results of my effect modification 
tests are provided in Table 1 of the ninth appendix. There was no modification by race detected 
between number of fibroids as an exposure and any symptom outcome; there was also no 
modification between the total fibroid volume exposure and the bleeding only outcome. However, 
when total volume was the exposure of interest and the outcomes were pain only or both 
symptoms, there was modification and these models were stratified by race. 
As discussed in the third Aim, interactions between time and numerous covariates were 
examined. Due to the large number of models being run in these multilevel mixed effects 
analyses, I performed Wald tests to test interaction terms (a p-value cut-off of 0.1 was still used). 
Assessment for confounding  
Potential confounders were selected a priori from an understanding of the scientific 
literature and through modeling causal relationships with DAGs. To avoid over adjustment and 
problems with sparse data, two methods to assess for confounding were used. These data-driven 
approaches also helped me examine any uncertainty regarding the suspected causal relationships 
described below (e.g., resulting from conflicting or limited literature), with the understanding that 
these conclusions may not be generalizable beyond RFTS. The potential confounders included: 
maternal age, race, parity, BMI, alcohol use, and tobacco use, any previous diagnoses of 
hypertension or diabetes, and study site.  
First, a potential confounder had to be associated with the presence of fibroids within the 
entire cohort (Appendix 9, Table 2). Secondly, that variable also had to be associated with an 
outcome among women without fibroids (each of the three symptom profiles was treated as a 
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separate outcome during confounding assessment; A9, Table 3). Logistic regression was 
employed to identify these associations and ORs of ≤0.90 or ≥1.10 for categorical and ≤0.98 or 
≥1.02 for continuous variables were sought (regardless of statistical significance). Finally, if a 
variable met both criteria, it only remained in the final regression models if, after adjusting for 
said variable, the regression parameter for the presence of fibroids was 1% different from the 
unadjusted model’s estimate (change-in-estimate approach; see A9 Table 4). When a confounder 
is correctly specified from knowledge of the literature (i.e., it is believed to be associated with 
both the exposure and outcome), the change-in-estimate procedure can help assess the magnitude 
of the confounding effect. The selection of a change-in-estimate criterion (e.g., one percent or 
10%) is subjective and often informed by context and the magnitude of effect suggested in 
previous research.
132
 Ultimately, a 1% criterion was selected because there were no strong 
confounders in my data. Candidate confounders were tested individually for inclusion in the final 
model and not in a stepwise selection process.  
For secondary analyses, I considered potential confounding by fibroid position or type. 
The following characteristics were also examined independently: any fibroids in the uterine 
fundus, only fibroids in the fundus, any in the corpus, only in the corpus, any in the cervix, only 
in the cervix, any located anterior, any located posterior, any intramural fibroids, any submucous 
(both distorting and not distorting the endometrium), any subserosal, and any pedunculated. I 
thought these characteristics were interesting to potentially adjust for because fibroid type or 
location may influence fibroid size (e.g., cervical fibroids are likely smaller) and because there is 
a consensus that certain types of fibroids cause specific symptoms (e.g., submucous and bleeding 
or subserosal and pain).
35
 Adjusting out these effects could show if volume or number do not 
actually affect symptom risk. Only the change-in-estimate approach with a 10% criterion was 
used to determine the inclusion of fibroid characteristics in secondary adjusted models (A9, Table 
5).  
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A final list of confounders included in adjusted models (based on outcome) is provided in 
Table 3 in this chapter. Logistic models for bleeding only were adjusted for the confounders 
identified for the bleeding only outcome, whereas polytomous models were adjusted for all 
confounders identified for any of the outcome levels. Unadjusted and two sets of adjusted models 
were run (adjusted for maternal characteristics, and then secondary results adjusted for maternal 
and fibroid characteristics).  
 
Table 3. Final confounders included in adjusted models, by outcome 
Outcomes Maternal characteristics 
included in adjusted models: 
Fibroid characteristics included 
in adjusted models: 
Only bleeding  
 
Age (linear), hypertension history, 
first trimester alcohol use, study 
site 
Only in corpus, any in cervix, any 
anterior, any posterior, any 
intramural, any subserosal 
Only pain  
Age (quadratic), race, parity,  
hypertension history, first 
trimester smoking, first trimester 
alcohol use, study site 
Any in corpus, only in corpus,
1
 
any anterior 
Both symptoms (bleeding 
AND pain) 
 
Age (quadratic), race, parity,  
hypertension history, study site 
Any in corpus, only in corpus, any 
anterior, any posterior 
1When “any in corpus” and “only in corpus” were identified as confounders, the “any in corpus” variable 
was used to avoid collinearity problems 
 
Missing data 
It was anticipated that there would be nearly complete information available for exposure 
(fibroid characteristics) and outcome variables (bleeding, pain). Membership in my study 
population was conditional upon having completed both the first trimester ultrasound exam and 
interview and having a live birth. There were no large amounts of missingness among potential 
confounders that could not be explained by skip-patterns or response options within the 
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interviews (e.g., “refused to answer”). BMI and parity had the most information missing 
(approximately 30 women each). Multiple imputation methods were not used and typical 
“complete-case” regression models are presented.   
Missing data are also discussed in the context of longitudinal modeling in the third 
dissertation Aim.  
Comments on sample size 
In his textbook on regression techniques, Frank Harrell recommends a ratio of 15 subjects 
per degree of freedom (df) in a multivariable model.
133
 The number of parameters or covariates 
determines the degrees of freedom in a model. For continuous outcomes, desired sample size is 
the total number of subjects; for binary outcomes, sample size is the number of subjects 
experiencing an event. For example, the categorical BMI variable has four levels; three 
dichotomous indicator variables (leaving the reference level out) would be needed to model BMI 
and would take up three df. Accordingly, I would need 45 study subjects experiencing pain in a 
model regressing only BMI on a dichotomous “any pain” (yes or no) outcome.  
 If age, BMI, total volume, and number of fibroids were modeled as simple continuous 
variables (making no transformations for linearity or normality), including all previously 
mentioned covariates of interest in any model would use many df. They would be allocated thus: 
age (1 degree of freedom), race (2), BMI (1), parity (2), diabetes status (1), hypertension status 
(2), tobacco use (2), alcohol use (2). For the exposure variables: any fibroids (1), continuous total 
fibroid volume (1), categorical total volume (3), continuous number of fibroids (1), categorical 
number of fibroids (2). For a model with 15 df, at least 225 (i.e., 15*15) subjects experiencing 
each symptom profile would be required for the primary polytomous logistic regression model. 
There were at least 300 women in each symptom profile. However, when stratifying by race, only 
59 non-Hispanic Black women experienced “bleeding only.” Models focusing on bleeding in this 
group were likely underpowered and had problems with sparse data.  
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Primary analyses 
Maternal characteristics were compared between women with and without fibroids using 
Pearson’s chi-square test for categorical factors and Wilcoxon rank-sum tests for continuous 
measures (alpha=0.05). Among women with fibroids, fibroid characteristics were compared 
between women with and without symptoms also using chi-square or rank-sum tests.   
Multinomial logistic regression, as opposed to ordinary logistic regression, is used when 
outcome variables contain more than two categories. Using a single regression model for these 
variables facilitates comparisons between categories (not only to the reference group).
134
 I used 
polytomous regression for these analyses, a type of multinomial logistic regression, because my 
primary outcome of interest contained four mutually exclusive categories:  no symptoms in the 
first trimester (reference), bleeding only, pain only, and bleeding AND pain. In polytomous 
regression, an odds ratio for each level of an outcome is reported—as beta estimates for a given 
independent variable are computed for and allowed to vary between each level of the outcome.
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Each odds ratio represents a comparison between the given level of the outcome and the reference 
category.
135
 Although an ordinal relationship between levels of a variable such as number of 
bleeding episodes is reasonable to infer, ordering between categories was not presumed for any 
polytomous outcome. Accordingly, odds ratios for fibroid severity measures and all confounders 
included in the regression models were reported for each outcome level. Reporting odds ratios for 
each level of an outcome can also show any trends in effect size across the levels.
135
   These ORs 
can be understood as a surrogate for a risk ratio (RR) when the prevalence of the outcomes is low 
(i.e., less than 10%). The (p/1-p)/(p/1-p) formula for an OR will reduce to p/p (a RR) when p (risk 
of disease) is small.
26
 Bleeding only was the only symptom with a prevalence of less than 10% 
among White and Black women. Accordingly, interpretation of ORs as RRs should not be done, 
even if “risk” and “odds” are used interchangeably in this dissertation. 
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Software 
 All analyses were completed using Stata SE, version 12. (StataCorp LP, College Station, 
Texas). 
Results 
Among the 4,392 women, 465 had one or more fibroid (11%). Table 4 describes maternal 
characteristics compared by fibroid status. Women with fibroids, compared to those without, 
were more likely to be older (≥29), black, overweight or obese, and non-smokers. They were also 
more likely to have a history of hypertension, a higher household income, and to have completed 
at least four years of college. 
 
 
Table 4. Maternal characteristics in relation to fibroid status: Right from the Start, 2000-
2011  
 
 
Characteristics 
No fibroids 
(n=3927) 
Fibroids 
(n=465) 
 
P 
 n % n %  
Age (y)      <0.001 
    <26 1300 33.1 75 16.1  
    ≥26 and <29 952 24.3 82 17.6  
    ≥29 and <32 867 22.1 123 26.5  
    ≥32 807 20.6 185 39.8  
    Missing 1  0   
Race/Ethnicity     <0.001 
    Non-Hispanic White 2880 73.4 262 56.3  
    Non-Hispanic Black 611 15.6 155 36.3  
    Other (Includes Hispanic) 432 11.0 48 10.3  
    Missing 4  0   
BMI      <0.001 
    Underweight  100 2.6 10 2.2  
    Normal weight 2167 55.5 196 42.3  
    Overweight  897 23.0 133 28.7  
    Obese 738 18.9 124 26.8  
    Missing 25  2   
Parity      0.554 
    0 1868 47.9 222 48.2  
    1 1362 34.9 152 33.0  
    2+ 668 17.1 87 18.9  
    Missing 29  4   
Diabetes     0.184 
    No  3825 97.4 448 96.3  
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    Yes 102 2.6 17 3.7  
    Missing 0  0   
Hypertension     <0.001 
    No 2137 54.4 282 60.7  
    Yes 127 3.2 28 6.0  
    Missing
1
 1663 42.4 155 33.3  
First trimester smoking      0.004 
    Non-smokers/quit prior to first trimester/ unknown when 
quit  
3443 87.7 431 92.7  
    Current smokers 139 3.5 13 2.8  
    Possible first trimester use (quit within 4 months of 
interview) 
345 8.8 21 4.5  
    Missing 0  0   
First trimester alcohol use     0.061 
    Non users/quit prior to first trimester  1696 43.2 223 48.0  
    Current users 134 3.4 20 4.3  
    Possible first trimester use (quit within 4 months of 
interview) 
2096 53.4 222 47.7  
    Missing 1  0   
Household Income     0.007 
    ≤ $40,000 1175 30.9 111 24.6  
    $40,000-80,000 1461 38.4 175 38.7  
    ≥$80,000 1171 30.8 166 36.7  
    Missing  120  13   
Education Level     0.008 
    ≤High school 674 17.2 54 11.6  
    Some college 712 18.1 84 18.1  
    ≥4 years college 2541 64.7 327 70.3  
    Missing  0  0   
Study Site     <0.001 
    North Carolina 2204 56.1 304 65.4  
    Texas 304 7.7 9 1.9  
    Tennessee 1419 36.1 152 32.7  
    Missing  0  0   
 n=number; y=years; BMI=body mass index; wk=weeks 
1
Women with unknown hypertension status were included as a distinct category in regression analyses. 
Women missing information for other variables were dropped from pertinent “complete case” analyses. 
 
 Thirty-one percent of the total population in these Aims experienced no symptoms. The 
most common symptom was only pain (43%), followed by both symptoms (18%), and bleeding 
(8%; results not shown). The fact that bleeding only was a rare outcome was surprising; it appears 
that most women will experience pain regardless of having bleeding. White and Black women 
had almost identical prevalences of symptoms (results not shown): 31-33% had no symptoms, 8% 
had bleeding only, 42-43% had pain only, and 18% had both symptoms. 
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Table 5 shows fibroid characteristics by symptom profile. No woman had more than 
seven tumors and total fibroid volume ranged from one to more than 900cc. The prevalence of 
fibroids by symptom type were similar: 9% of women with no symptoms, 10% of those with 
bleeding only, 11% of those with pain only, and 13% of those experiencing both symptoms had 
fibroids. There were no major differences in the distribution of volume or number of tumors 
between women with and without symptoms.  
 
Table 5. Fibroid characteristics in relation to first trimester symptoms: Right from the Start, 
2000-2011 
 
Fibroid 
Characteristics
1
 
 
None
2
 
(n=126) 
 
Only Pain 
(n=204) P 
 
Only 
Bleeding 
(n=35) 
P 
 
Both 
Symptoms 
(n=100) 
P 
 n % n % n % n % 
Number             
    median  
    [range]   
1 
[1-6] 
1 
[1-7] 
0.244 1 
[1-7] 
0.876 1 
[1-6] 
0.180 
            
Total volume (cc)
 
            
    median  
    [range]   
5 
[1-297] 
5 
[1-378] 
0.667 10 
[1-421] 
0.391 4 
[1-987] 
0.993 
            
Categorical     0.800   0.754   0.904 
    <14cc 63 50.0 108 52.9  15 42.9  53 53.0  
    ≥14 and < 33 31 24.6 44 21.6  10 28.6  23 23.0  
    ≥33 32 25.4 52 25.5  10 28.6  24 24.0  
Fibroid 
Characteristics  
     
      
Any subserosal     0.874   0.324   0.888 
    No 73 57.9 120 58.8  17 48.6  57 57.0  
    Yes 53 42.1 84 41.2  18 51.4  43 43.0  
Any submucous, 
distorting 
endometrium 
    
 
 
0.504 
   
 
0.409 
   
 
0.449 
    No 108 85.7 180 88.2  28 80.0  82 82.0  
    Yes 18 14.3 24 11.8  7 20.0  18 18.0  
Any submucous, 
not distorting 
    
 
0.901 
   
0.513 
   
0.887 
    No 119 94.4 192 94.1  32 91.4  94 94.0  
    Yes 7 5.6 12 5.9  3 8.6  6 6.0  
Any intramural     0.856   0.031   0.649 
    No 68 54.0 108 52.9  26 74.3  57 57.0  
    Yes 58 46.0 96 47.1  9 25.7  43 43.0  
Any pedunculated     0.211   0.654   0.196 
    No 121 96.0 189 92.7  33 94.3  92 92.0  
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    Yes 5 4.0 15 7.4  2 5.7  8 8.0  
Any anterior     0.198   0.095   0.388 
    No 52 41.3 99 48.5  20 57.1  47 47.0  
    Yes 74 58.7 105 51.5  15 42.9  53 53.0  
Any posterior     0.522   0.334   0.125 
    No 62 49.2 93 45.6  14 40.0  39 39.0  
    Yes 64 50.8 111 54.4  21 60.0  61 61.0  
Any in cervix     0.302   0.051   0.063 
    No 113 89.7 175 85.8  27 77.1  81 81.0  
    Yes 13 10.3 29 14.2  8 22.9  19 19.0  
Any in fundus     0.557   0.619   0.771 
    No 77 61.0 118 57.8  23 65.7  63 63.0  
    Yes 49 38.9 86 42.2  12 34.3  37 37.0  
Any in corpus     0.138   0.973   0.513 
    No 50 39.7 98 48.0  14 40.0  44 44.0  
    Yes 76 60.3 106 52.0  21 60.0  56 56.0  
n=number; cc=cubic centimeters 
1 
This table is limited to women who had fibroids 
2
 Each group of women reporting symptoms was compared to women without symptoms 
 
 The primary goal of Aims 1 and 2 was to model symptom type (polytomous) due to 
fibroid severity (volume categories or increasing number). Effect modification analyses indicated 
that models containing fibroid volume should be stratified by race only when my outcomes 
included women with only pain or both symptoms. Table 6 contains the results of an unstratified 
logistic regression model for total volume and bleeding only. In Table 7, the results for total 
fibroid volume and a polytomous outcome for symptom type (none, pain only, and both 
symptoms) are stratified by maternal race. And finally, in Table 8, I show my unstratified model 
for total number of fibroids and a polytomous outcome for symptom type (none, bleeding only, 
pain only, and both symptoms). I focus on unadjusted models and models adjusted for maternal 
characteristics here; models adjusted for both maternal and fibroid characteristics are described 
here, but shown in the secondary analyses (Appendix 10, Tables 1-3).  
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Table 6. Odds Ratios for bleeding due to fibroid volume among all race groups 
  
All Race Groups 
(n=1,715) 
n Unadjusted Adjusted
1
 
OR 95% CI OR 95% CI 
No Symptoms 
(reference) 
(n=1,381) 
No 
Fibroids  
1255 REF - - - 
Fibroid 
Volume  
     
≤5 63     
>5 and ≤20 31     
 >20 32     
       
 
No 
Fibroids 
299 REF - - - 
Bleeding Only 
(n=334) 
Fibroid 
Volume  
     
≤5 15 1.00 0.56, 1.78 0.82 0.45, 1.47 
>5 and ≤20 10 1.35 0.66, 2.79 1.43 0.68, 3.00 
>20 10 1.31 0.64, 2.70 1.31 0.63, 2.74 
       
REF=reference group, n=number 
1
 Adjusted for age (linear), hypertension history, alcohol use, and study site  
 
There was no association between total fibroid volume and risk of bleeding only (Table 
6); the magnitude of the ORs did not consistently increase or decrease after adjustment and small 
sample sizes may contribute to wider confidence intervals. After adjustment for confounding by 
maternal characteristics, White women with small fibroid volumes were more likely to report 
having bleeding and pain (both symptoms) than women without fibroids (OR 1.84; CI 1.16, 2.92; 
Table 7). There was no association between total fibroid volume and any symptom among Black 
women, though OR magnitudes generally became less protective with increasing total volume 
(after adjustment). In the race-stratified models of Table 7, adjustment generally increased or 
didn’t change OR magnitudes among White women, but decreased them among Black women. 
This may suggest that there is a different causal relationship between fibroid volume and 
symptoms for each race group or that my confounders more strongly influence the crude OR 
among Blacks. Despite CIs that overlap the null value, small sample sizes mean my results are 
not well-suited to distinguish whether fibroid volume (in categories) has no relationship with 
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symptom risk or has an overly complex one that I am failing to model. For example, fibroid 
volume may interact with other characteristics like fibroid type or location (e.g., under the 
placenta or submucous) or even with blood supply (e.g., the size of the blood vessel feeding the 
tumor).  
To assess model fit, I ran Hosmer-Lemeshow goodness of fit tests for logistic and 
multinomial logistic regression.
136
 The p-values from these tests were as follows: 0.725 (volume 
and bleeding only), 0.659 (volume and polytomous symptoms among Whites), and 0.401 (volume 
and polytomous symptoms among Blacks). A larger p-value is used to indicate that a model fits 
the data well. So, it seems that my models do a better job of describing the relationship between 
volume and symptoms among White women. This is plausible because there are gaps in the 
literature describing the severity-symptom relationship—none have looked at Black and White 
women separately. There may be a different etiology for each race group or different confounders 
should be considered.  
Adjustment for both maternal characteristics and fibroid characteristics in the secondary 
analyses always produced larger (less protective) OR, compared to those adjusted for only 
maternal characteristics (A10, Tables 1 and 2). Despite the non-statistically significant CIs, this 
would seem to indicate a potential effect for volume, independent of fibroid type or location 
(independent of being in the corpus, anterior, or posterior or being intramural or subserosal 
fibroids). Model fit improved for the bleeding only model (p=0.742) and the volume and 
polytomous symptom model among Whites (0.948). The fit decreased for the model using data 
from Black women (0.355). 
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Table 7. Odds Ratios for symptom type due to fibroid volume among non-Hispanic White and Black women 
  
White 
(n=2901) 
Black 
(n=707) 
n Unadjusted Adjusted
1
 n Unadjusted Adjusted
1
 
OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
No Symptoms 
(reference) 
 
No 
Fibroids  
907 REF - REF - 210 REF - REF - 
Fibroid 
Volume  
          
≤5 40     16     
>5 and ≤20 16     14     
 >20 16     11     
            
 
No 
Fibroids 
1254 REF - REF - 247 REF - REF - 
Pain Only 
 
Fibroid 
Volume  
          
≤5 68 1.23 0.82, 1.83 1.38 0.91, 2.07 26 1.38 0.72, 2.64 0.92 0.45, 1.87 
>5 and ≤20 24 1.08 0.57, 2.05 1.14 0.60, 2.19 17 1.03 0.50, 2.14 1.01 0.45, 2.27 
>20 17 0.77 0.39, 1.53 0.85 0.42, 1.71 28 2.16 1.05, 4.45 1.65 0.76, 3.60 
            
 
No 
Fibroids 
498 REF - REF - 108 REF - REF - 
Both 
Symptoms 
 
Fibroid 
Volume  
          
≤5 41 1.87 1.19, 2.93 1.84 1.16, 2.92 8 0.97 0.40, 2.34 0.49 0.19, 1.26 
>5 and ≤20 14 1.59 0.77, 3.29 1.80 0.85, 3.80 6 0.83 0.31, 2.23 0.67 0.23, 1.95 
>20 6 0.68 0.27, 1.76 0.68 0.26, 1.76 16 2.83 1.27, 6.31 1.61 0.67, 3.87 
REF=reference group, n=number 
 
1
Adjusted for age (quadratic), parity, hypertension history, smoking, alcohol use, study site 
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Table 8. Odds Ratios for symptom type due to increasing fibroid number among all race groups 
Outcome Exposure n Unadjusted Adjusted
1
 
OR 95% CI OR 95% CI 
No symptoms 
(reference)  
(n=1381) 
No Fibroids (reference) 1255 REF - REF - 
Fibroids 
126 
    
Bleeding Only 
(n=334) 
No Fibroids 299     
Number of Fibroids (Linear) 35 1.14 1.00, 1.30 1.03 0.82, 1.30 
       
Pain Only 
(n=1885) 
No Fibroids 1681     
Number of Fibroids (Linear) 204 1.12 0.90, 1.40 1.19 1.03, 1.37 
       
Both Symptoms 
(n=792) 
No Fibroids 692     
Number of Fibroids (Linear) 100 1.25 1.07, 1.46 1.20 1.02, 1.41 
REF=reference group, n=number
 
1
Adjusted for age (quadratic), race, parity, hypertension history, smoking, alcohol use, study site 
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 Finally, Table 8 presents the associations between symptoms and number of fibroids (a 
polytomous model). After adjustment for maternal characteristics, increasing number was 
associated with an increased risk of reporting pain only (OR 1.19; CI 1.03, 1.37) and reporting 
both symptoms (OR 1.20; CI 1.02, 1.41). The p-value for the adjusted model’s fit was 0.577, 
suggesting a reasonable fit. The relationship between pain and number of tumors appeared to get 
stronger after adjustment for fibroid characteristics (OR 1.34; CI 0.98, 1.84; A10, Table 3). As 
with fibroid volume, I did not detect a relationship between this measure of severity and bleeding; 
this may be due to imprecision and sample size, but the effect estimate became closer to the null 
value after adjustment. 
Secondary analyses  
Additional secondary analyses of bleeding outcomes are not shown in my dissertation, 
but are briefly described. I explored the relationships between fibroid volume or increasing 
number of fibroids and three bleeding outcomes:  number of bleeding episodes, duration of 
bleeding, and heaviness of bleeding. The models for these bleeding outcomes were limited to 
women who experienced no symptoms (reference group), bleeding only, or pain during bleeding 
(i.e., women with only pain or bleeding and pain independently were dropped). These models 
were not stratified by race. Adjusted models included confounders associated with the bleeding 
only or both symptoms outcomes. 
 As expected, I was underpowered for many of these bleeding outcomes. However, I 
continued to see an effect for increasing number of fibroids. After adjustment for maternal factors 
alone, increased risks were identified for having two or more bleeding episodes, bleeding at least 
two days, and having light bleeding.  
The secondary analyses on intensity of pain were limited to women who had no 
symptoms or those who reported pain during bleeding, but were stratified by race when total 
fibroid volume was an exposure. The final confounders identified for both the pain only and both 
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symptoms outcomes were included in the adjusted models. Small sample sizes prevented 
estimation in many instances. Increasing number of tumors increased risk of moderate or severe 
pain after adjustment for maternal characteristics, but this effect was neutralized (or over-adjusted 
for) when adding fibroid characteristics to the model. 
Discussion, considerations, and next steps 
 The relationship between total fibroid volume and first trimester symptoms is modified 
by maternal race. The most common symptom among both White and Black women was pain. 
For White women, smaller total fibroid volumes were associated with reporting both bleeding and 
pain after adjustment. There was no apparent relationship between volume and symptoms among 
Black women, either due to small sample sizes or unaccounted factors that influence their 
bleeding and pain (e.g., fibroid position, social factors). The fact that Black women did not report 
more symptoms than White women and did not have symptoms associated with increasing fibroid 
volume was surprising. My background research on pain suggested that Black women may be 
more likely to experience and report pain, but this may be outside of pregnancy. Black women are 
more likely to have larger fibroids and these tumors can “outgrow” their blood supply and infarct 
(“die” from the inside out). This situation can cause pain, but my results do not seem to indicate 
this was a particular problem for Black women during the snapshot of time that is the first 
trimester of pregnancy. A previous RFTS study found that fibroid type and location did not differ 
greatly by race (except Black women having more posterior fibroids), so the association between 
volume and both symptoms among White women may not be due to differences in these factors.
8
 
I did find that increasing number of fibroids increased risk of reporting pain and having both 
symptoms—these relationships were not modified by race. Increasing number of fibroids likely 
influences risk through position or types of fibroids, rather than corresponding to an increase in 
volume. There was poor correlation (0.200) between the two measures of severity, even when 
looking at the race groups separately. The results from these Aims did not reveal a clear 
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association between fibroid severity and bleeding, suggesting that this relationship could be 
weaker than expected or overly complex, confounded by unmeasured factors, or that larger 
sample sizes are needed to analyze it.  
 The analyses in this dissertation are among the first to explore the relationship between 
fibroid severity and symptoms during pregnancy. The use of the RFTS is unique because fibroid 
characteristics were uniformly measured across all subjects via ultrasound (as opposed to self-
report or medical record codes). A previous RFTS study examined fibroids and bleeding risk, but 
did not consider disease severity; the population in these analyses also included women who 
experienced miscarriages (which are associated with bleeding symptoms).
5
 Only three studies, all 
clinical, commented on fibroids and pain during pregnancy.
34,120,121
 Information on pain was 
abstracted from charts, rather than self-reported by all women and only two studies described 
fibroid severity.
120,121
 One of these studies noted that prescription analgesics may be prescribed 
more often to women with larger fibroids, but in this instance, prescribing could be driven by the 
higher probability of an awareness of fibroids (if fibroids are documented in medical records, 
they are more likely to by symptomatic/problematic).
121
 
For RFTS participants, the first trimester interview occurs after the first trimester 
ultrasound. It is possible that women in whom fibroids were found discussed their diagnosis with 
healthcare providers, though RFTS sonographers were instructed to not discuss fibroid status with 
participants. Women with fibroids or women who are more likely to talk to their providers may 
recall bleeding or pain episodes differentially than women who do not fall into these groups. A 
concern about pregnancy health or awareness of fibroid symptoms may lead to a woman more 
rigorously documenting her pregnancy experiences.  Similarly, women with a previous fibroid 
diagnosis may recall bleeding and pain differently than women without a diagnosis. The degree 
of this misclassification is difficult to estimate, but sensitivity analyses adjusting for previous 
fibroid diagnosis would be an obvious next step for these analyses for publication. However, as 
noted in the description of the RFTS cohort, women in the first phase were not asked about a 
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previous diagnosis of fibroids. Therefore, including a variable for this information severely limits 
sample size in complete case analyses; a “missing” category would likely need to be included. 
Additionally, the questions relating to both bleeding and pain in RFTS interviews are 
generalized. Reasons for bleeding and pain are not officially ascertained, so it is possible that 
underlying medical conditions rather than the presence or severity of any fibroids are causally 
related to or exacerbating these symptoms during pregnancy. However, this is a limitation of most 
studies—not being able to differentiate between placental bleeding from spotting due to over-
exertion or cramping from gastrointestinal distress. Though the take-home point is, if women 
with fibroids are experiencing more bleeding or pain than women without the tumors, knowledge 
regarding the overall risk is still useful. These symptoms likely impact quality of life (e.g., 
emotional distress, financial burden of NSAIDs or feminine products, limited physical activity) 
and healthcare utilization (e.g., increased visits to providers, prescriptions for analgesics)—
regardless of their etiology. To further explore this issue, future studies could review RFTS 
information on self-reported medication use or comorbid conditions (e.g., prior abdominal 
surgeries or history of depression).  
A consideration for any analysis using RFTS data is the unique composition of the 
cohort. Women in RFTS are more likely to have prior pregnancies, more years of education, and 
higher socioeconomic status than an average United States population of pregnant women. 
Women who joined RFTS may have been motivated by altruism, concerns about specific 
pregnancy conditions, or free ultrasounds and pregnancy tests. All of these qualities may limit the 
generalizability of these results. However, this population is generalizable to women from a 
variety of race groups living in urban and suburban areas in the southeastern United States.   
In order to better understand the life-cycle of fibroids during pregnancy, it is necessary to 
identify disease characteristics associated with adverse health outcomes or with symptoms that 
may negatively impact quality of life. For example, we eventually may learn that larger fibroids 
in certain positions are associated with symptoms because they are more likely to infarct during 
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pregnancy. These analyses demonstrate that fibroids are associated with symptoms among White 
women. However, fibroid severity plays a confusing or complicated role in influencing symptom 
risk. Further analyses are warranted—perhaps among larger cohorts, using longitudinal analyses, 
using more sophisticated modeling techniques for volume (e.g., restricted cubic splines), or 
perhaps after collecting additional information on symptoms (e.g., using daily diaries or 
pictograms to indicate the amount of bleeding). Continuing to study fibroid severity in pregnancy 
may eventually raise physician awareness of the unique concerns and experiences for the 
pregnant woman with fibroids (e.g., increased need of feminine products or analgesics, risk of 
anemia, or emotional distress due to worrying about potential pregnancy loss). Additionally, 
informing fibroid treatment decision-making for women planning a pregnancy may be possible 
(e.g., if anticipated duration/heaviness of bleeding or intensity of pain is such that fibroid removal 
is recommended). Increased knowledge may also help in the development of counseling 
programs or educational materials for these women. Overall, my data indicating that larger tumor 
volume minimally influences symptom risks are reassuring since fibroids are common among 
women with successful pregnancies. 
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CHAPTER V 
THIRD AIM: EXAMINING FIBROID GROWTH AS A MEASURE OF DISEASE 
SEVERITY 
Overview 
The purpose of this Aim is exploratory: to identify any associations between changes in 
total fibroid volume or number of fibroids and maternal or tumor characteristics. Increased fibroid 
volume is associated with labor and delivery complications.
23,25,28
 Identifying factors associated 
with fibroid growth may help physicians anticipate these complications, better tailor clinical care, 
and have more informed discussions with their patients about the natural history of fibroids 
during pregnancy. 
For these analyses, data from the RFTS subcohort was used (those women with repeated 
ultrasounds and interviews). Total fibroid volume measurements from each trimester were used to 
longitudinally model growth. Using the RFTS subcohort allowed for several improvements upon 
the methodological techniques used in previous studies to assess fibroid growth among pregnant 
women: with 216 women with all three ultrasounds, this was the largest sample size of any study; 
the timing and procedures for these ultrasounds were standardized across all participants; and 
information available from interviews allowed me to explore the influence of many 
characteristics on fibroid growth. Lastly, no previous studies of growth during pregnancy have 
attempted to model fibroid growth longitudinally and account for intra-person correlation of 
measurements.  
Hypothesis  
There was no formal hypothesis for this Aim, as the relationships between fibroid 
volumetric or number changes and characteristics such as bleeding or pain have not been 
explored in pregnancy. I suspected those traits that are already linked to severe fibroid disease 
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(e.g., Black race, older age, and higher BMI) would have stronger associations with increases in 
fibroid volume or would explain a higher proportion of variation in these observations. 
Methods 
Study population 
This RFTS subcohort consisted of the first 300 women with fibroids identified at the first 
trimester ultrasound during the second phase of the study and 100 women without fibroids, 
frequency matched on race, age, and gestational age at ultrasound. After the first trimester 
ultrasound, women with fibroids were scheduled to receive additional exams at 14 to 16 (second 
trimester) and 26 to 28 weeks (third trimester) gestational age. The control group only received 
the second trimester ultrasound unless fibroids were identified at this point, then they also had the 
third exam. All women were scheduled for a second CATI (third trimester). Those with first 
trimester losses did not continue with subcohort activities. Women with fibroids in the subcohort 
were told by sonographers about their fibroids and asked if subsequent ultrasounds could be 
scheduled to follow the tumors.  
As in the previous two Aims, the population was limited to those who had singleton live 
births and completed the first trimester CATI. The population was further limited to women who 
had an ultrasound examination in each trimester. Longitudinal modeling may be robust to missing 
data, but this remains true only if certain covariance structures are used and missing outcome 
information is not related to the reason for the missingness.
137,138
 It could be possible that a 
dramatic change in fibroid volume may have affected a woman’s health, ability, or desire to show 
up for subsequent study ultrasounds (she may have chosen to leave the study and only interact 
with her personal physician). Furthermore, only women missing the third trimester ultrasound 
could be added to the population used in these analyses because all women had to have a first 
trimester ultrasound and none of my outcomes could be calculated if the second trimester 
ultrasound was missing (outcome variables are described below). In theory, women missing the 
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second ultrasound would be missing the third trimester ultrasound as well (due to the RFTS 
process of participation). Because women missing their 15-week exams were not scheduled for 
subsequent ultrasounds, missingness is not random. Also, if women in the control group had no 
fibroids at both the first and second ultrasounds, they were not asked to return for the third scan—
here, outcome (no growth of fibroids) is related to outcome missingness in the third trimester. 
Lastly, including women with only the first two ultrasounds would give more weight to the first 
outcome measurements. If different phenomenon influence fibroid changes throughout 
pregnancy, the ability to generalize effect estimates to all of pregnancy is diminished. There were 
154 women who had the first two ultrasounds, but not the third; 141 of whom were in the control 
group and never had fibroids (i.e., their outcome and missingness were related). Therefore, only 
women with complete outcome information were used in these analyses (n=216). Both women 
with and without fibroids identified at the first trimester ultrasound were used if they had all three 
exams (3 women in the control group developed fibroids by the second trimester and 
subsequently returned for a third exam). 
Outcome measurement: change in volume 
 Again, the goal of this Aim was to describe how maternal and fibroid characteristics 
influence changes in total fibroid volume or number of fibroids during pregnancy. Total volume  
was calculated in cc for each woman in each trimester. Volume could be treated as a continuous 
variable, but this caused several problems. First, a one cc change in fibroid volume for a woman 
starting her pregnancy with only two cc is a much more dramatic volumetric change than for a 
woman starting with 25cc—so continuous volume reflects absolute rather than relative changes 
and can be harder to interpret. Furthermore, a decrease in fibroid volume may be a different 
phenomenon than an increase in volume and they probably should be modeled as separate 
outcomes.  
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 I chose to measure changes in fibroid volume during pregnancy as the percent change in 
total fibroid volume between the first and second trimesters and again between the second and 
third trimesters for each woman. A continuous outcome with two time points was the result. 
Figure 6 shows how a variable for “percent change in total volume” was made from the 
informations collected at each ultrasound.  
Figure 6. Schematic detailing the creation of a continous variable for percent change in 
fibroid volume during pregnancy 
 
 
First, I collected the unrounded total fibroid volumes in each trimester. Next, I divided 
the second trimester volume by the first trimester volume (and similarly repeated this between the 
third and second trimesters). For example, if a first trimester volume was 18cc and the second 
trimester was  four cc, the percent change was 22%. This corresponds to a reduction in volume 
because 100% would indicate that 100% of the original volume was accounted for and that there 
was no change (>100% corresponds to growth). When using percent change in volume, two time 
points were created—the change between the first and second trimester (t=1) and the change 
between the second and third trimester (t=2). 
Percent change in volume as a continuous variable was a difficult variable to work with 
because it was skewed and overdispersed; it ranged from 0 (complete reduction in 
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volume/disappearance of fibroids) to 8400 (840% increase) and had a mean of 253 and standard 
deviation of 710 when the data are in in long format. This would be problematic when using non-
multilevel generalized linear models with an identity link. However, in multilevel modeling, the 
primary concern is normality and homoscedasticity of the residuals. To assess this, I ran a basic 
multilevel model for continuous percent change in volume with unstructured covariance and 
unstructured residuals using the xtmixed command in Stata. Visual assessment revealed that 
residuals for this variable were not normally distributed and also displayed heterosckedastcity—
they were more widely dispersed at the first time point (results not shown).  
 Due to the attributes of this variable, I chose to categorize percent change in volume. 
Four distinct categories could be used: no change in volume, complete reduction (disappearance), 
loss of volume (reduction), and increase in volume (growth). Initially, complete reduction was 
considered a separate outcome because I suspected that difficulty in physically visualizing 
fibroids during ultrasounds, rather than biology, might influence these observations. However, 
using this many outcome categories would necessitate non-ordinal polytomous multilevel 
modeling. As of Stata 12.0, this can only be done with the user-written gllamm command, for 
which very few examples using longitudinal/panel data exist in the literature. The command also 
does not offer the ease of modeling control that commands like xtmelogit do. So, percent 
change in volume was made into two dichotomous outcomes: 1) ≤10% reduction compared to 
observations showing no change or growth and 2) ≥10% growth compared to no change or 
reduction. Ideally the reference group might be comprised of only those observations showing no 
change. However, each outcome needs to account for all observations in long format data. 
Women can fall into multiple outcome categories during pregnancy, so leaving growth 
observations out of the reference group for the reduction outcome, might completely eliminate 
some women or one of the observations for some women in the reduction analyses (e.g., those 
who experience growth at both time points).   
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There is very little literature regarding an acceptable margin of error between fibroid 
volume measurements done via ultrasound, either between or within sonographers. However, 
sonographers routinely make measurements in millimeters with a high degree of confidence (e.g., 
crown rump length and biparietal diameter). I chose to use a 10% change as my cutoff for growth 
or reduction. It is possible that a 10% change is too small to detect or is within the margin of error 
for sonography measurements, but a 10% criterion facilitated comparisons with other studies 
assessing growth in pregnancy. I also provide the results for models using a 50% change cut off 
in Appendix 11, Tables 1 and 2, but these are discussed in the results text. 
Outcome measurement: change in number of fibroids 
 Number of fibroids could be modeled as a continuous variable, a count outcome, or a 
categorical outcome. Fibroid number has a small range and is skewed toward lower numbers of 
fibroids; it was not modeled continuously. Ultimately, a Poisson multilevel model was not used 
because of the difficulty in interpreting effect estimates (reported as incidence rate ratios) and the 
inability to easily calculate an intraclass correlation coefficient (ICC). Similar to the percent 
change in volume outcome, two dichotomous outcomes were created to describe the change in 
number of fibroids between trimesters: 1) a decrease in the number of tumors compared to 
observations showing no change or an increase and 2) an increase in number compared to no 
change or a decrease.  
Selection of explanatory variables for growth models 
Figure 7 depicts a DAG representing the suspected causal relationship between total 
fibroid volume at a given point during pregnancy and a subsequent measure of that volume. 
These factors were evaluated for associations with changes in fibroid severity: maternal age, race, 
BMI, parity, diabetes status, hypertension status, tobacco use, alcohol use, and first trimester 
symptoms. Fibroid type and position were also assessed.  
85 
 
Figure 7. Directed acyclic graph depicting the suspected causal relationship between total 
fibroid volume in the first and third trimesters 
 
Factors listed in green denote those measured in Right from the Start. Factors in pink were not available for 
these analyses. The dotted line indicates uncertain evidence. 
 
 
For most women, BMI measurements were available from each ultrasound exam—
allowing for longitudinal measurement of this trait. The analyses in this Aim use two time 
points—the first representing fibroid changes between the first and second trimester and the final 
time point representing changes between the second and third trimesters. For the time-varying 
measure of BMI, BMI at the second and third trimesters were used to correspond with the two 
time points. The relationship between time-varying BMI and change in fibroid severity can be 
seen as cross-sectional; it was suspected that increasing BMI in pregnancy might present 
challenges in visualizing fibroids, so BMI measurements taken at the same time that percent 
change in volume could be calculated were used. To compare with previous studies, a fixed and 
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continuous representation of BMI from the first trimester and a corresponding fixed, categorical 
version were also modeled. 
Several other variables could be considered time-varying.  Responses for alcohol use, 
tobacco use, bleeding, and pain were collected during both the first and third trimester CATI. 
However, responses from the first trimester interview would temporally precede the first outcome 
measurement (percent change in volume cannot be calculated until the second trimester) and the 
responses from the third trimester interview would be assessed in a cross-sectional manner with 
the second measurement of the outcome. To avoid this temporal confusion when interpreting 
effects, all of these characteristics were treated as fixed and not time-varying. In contrast, 
information regarding fibroid characteristics was collected during each ultrasound, like BMI, and 
these traits were modeled as time-varying variables. In these instances, the fibroid classifications 
from the first and second trimesters were used—they temporally precede the outcome 
measurement.  
The linearity of the relationships between all outcomes and all continuous variables 
(BMI, age) was assessed in a manner similar to that used in the first two Aims. With the data in 
wide format, logistic regression and likelihood ratio tests were used to compare models with and 
without quadratic terms for the continuous variables. This was done at each time point (e.g., the 
outcome measured at time=1 and the covariate measured at time=1). None of the continuous 
variables were found to have a non-linear relationship with any outcome at any time point. 
Polynomials of higher orders and splines were not considered, as easy interpretation of effect 
estimates and preserving degrees of freedom was desired (see below for more on df).  
Multilevel modeling approach 
The primary intent of modeling fibroid growth was to build exploratory (i.e., descriptive), 
rather than predictive or causal models. Each of the variables mentioned above was regressed 
independently (univariate modeling) on each of the four primary outcomes: percent change in 
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volume (growth or reduction) and change in number of fibroids (increase or decrease). The 
univariate parameter estimates were reported after an appropriate covariance structure and 
number of adaptive quadrature points was chosen for each variable/model (described below).  
I attempted to run multivariate models containing all maternal characteristics and model 
containing all fibroid characteristics using my 50% growth and reduction models, as well as my 
change in number of fibroids models. The intra-class correlation coefficients (ICC) from these 
models were reported in text, but not the effect estimates of the explanatory variables. Because 
these multivariate models were not constructed to represent causal relationships and the variables 
were not included/excluded to improve model fit, these “adjusted” estimates cannot inform causal 
inference. Some explanatory variables included in the “adjusted” models may in fact act as 
confounders, intermediate variables, or colliders in the causal relationships between other factors 
and fibroid growth. So, adding more variables to the model allowed me to see if the ICC 
changed—if I was able to explain more variation in my outcomes within women. 
Previously, time-varying and “fixed” covariates were mentioned. In actuality, time-
varying traits are those that vary over time within a subject. They are called level-1 (intra-subject) 
characteristics and can explain variation in the odds of growth or reduction both within a person 
and between persons. “Fixed” factors, called level-2 traits, are those that vary between subjects 
and are fixed or unchanging across time points within a person. These variables explain inter-
subject variation in the outcome. The term “fixed” is used to describe non-time-varying (level-2) 
variables in this dissertation. An exception is made when I specifically refer to traditional “fixed 
effect estimates,” as opposed to random effects, in the text immediately below. 
Figure 8 shows equations representing the relationship between time-varying BMI and a 
given outcome when multilevel longitudinal modeling is used. The level-1, within-person 
equation (1) shows an intercept (B0j), two covariates (time and BMI), and an error term (eij) 
measured across time (i) and subjects (j). Next, level-2 equations (2) for each item in the level-1 
equation are written. In addition to the fixed effect estimate for the intercept, I add a random 
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component (u0j, the random intercept). I also allow time to have fixed and random components 
(called a random coefficient or slope). A priori, I decided to include a fixed effect and random 
slope for time in all “univariate” models for the maternal and fibroid characteristics. A random 
slope for time can “be described as a random time-by-individual interaction.”139 This allows for 
the idea that over time, fibroid growth trajectories may vary across women. Finally, in the 
equations below, a random slope for BMI can also be considered in the level-2 equations; this 
means that BMI modifies the trajectory of growth over time. Whether or not this random effect 
remains in the model is discussed in the following sections.  
Substituting the level-2 equations into the level-1 equation results in the reduced form 
below. The level-1 error term is normally distributed and the random effects are multivariate 
normally distributed with a mean of zero and with a structure for the variances (T00, T11, T22) 
and covariances (T10, T21, T20) that may be specified in the modeling process. If we allow a 
unique value to be calculated for each variance and covariance, nine degrees of freedom are used 
in this model (3 fixed effects, 3 variances, and 3 covariances).  
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Figure 8. Multilevel equation for a time-varying covariate (BMI) 
 
 
 
Modeling fixed, non-time-varying, level-2 covariates, like maternal race is similar to 
modeling level-1 variables. When a variable does not vary within a subject (i.e., over time), it is 
only included in the level-2 equations. In Figure 9 below, we see that race has three categories 
(with “White” left out as a reference group) and the indicator variables are included as predictors 
in the random intercept equation and the equation for time. Race is not allowed to have a random 
component. When writing out the reduced form of the equation, an interaction between time and 
race is created. This is interpreted as race modifying the relationship between time and growth. 
This can help account for differential timing in the ultrasounds between race groups and 
therefore, the timing in biological processes could be different between the races when the 
outcomes are measured. This was important because I was forcing my models to have two evenly 
spaced time points. Whether or not this interaction remained in the final model for race is 
described below. The reduced equation in Figure 9 uses 7 df.  
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Figure 9. Multilevel equation for a fixed covariate (maternal race) 
 
 
Model selection 
These analyses use multilevel mixed effects logistic regression modeling. In Stata, the 
xtmelogit command was used. xtmelogit uses adaptive quadrature and allowed me to 
select the number of integration points.
140
 Ideally, integration points should be increased until 
effect estimates stabilize.
141,142
 The xtmelogit command permitted me to select one of four 
covariance structures for the random effects: unstructured, independent, exchangeable, or 
identity.
140
 Unstructured is ideal because an estimate for each variance and covariance is 
produced, but as seen in the above equations, its use requires more df and is computationally 
expensive. Independent structures estimate unique variances, but covariances are held to zero; 
exchangeable structures hold all variances to one equal value and do the same with the 
covariances; and identity structures specify equal variances but hold covariances to zero.
140
 
For each covariate of interest, I ran longitudinal models using each covariance structure. 
Starting with one, three, or five integration points, I added points until the fixed and random 
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effect variance estimates stabilized to four decimal places.
141
 For example, if estimates did not 
change between models run with 3 and 5 integration points, 3 points were considered sufficient. 
To shorten computation time, I used the matrix command (matrix a=e(b)), such that when 
adding integration points to a model,  estimates from the previous model were used as starting 
points.
143
 If fixed effects remained stable, random effect variance changes of up to 4 decimal 
places were considered stable if the variance was less than 1.00*10^(-15).  
Once estimates were stable (i.e., the number of integration points was chosen), then 
random coefficients for level-1 variables or interactions with time for level-2 variables were 
examined. If the random effect variance for a level-1 variable was less than 1.00*10^(-15) or a 
confidence interval could not be calculated by Stata, it was removed (the fixed effect remained) 
and the process of choosing number of integration points in this new model was repeated. For 
level-2 variables, I tested interaction terms collectively for inclusion with a Wald test (p<0.10 
indicating heterogeneity). If the term(s) were removed, the process of selecting integration points 
was repeated.  
The process of selecting integration points and including random slopes or interactions 
was performed for each of the four covariance structures for each characteristic of interest. Once 
the final model for each structure was selected, I extracted predicted values from each final 
regression. Lines using these values were plotted against a Lowess line created by regressing time 
on the raw outcome data. The covariance structure whose line most closely fit the Lowess line 
was selected as the final model for a given covariate. For example, in Figure 10, the dichotomous 
outcome for increase in percent change in volume was plotted against time (observations are 
jittered). The purple line represents the Lowess line for these data. Overlaying this are three lines 
produced from modeling time-varying BMI on growth in models fit with independent, 
exchangeable, or identity covariance structures.  Roughly, this figure illustrates that there was 
more growth between the first and second trimesters (t=1) than between the second and third 
(t=2)—note the downward sloping Lowess line. 
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Figure 10. Visual examination of predicted values from models regressing time-varying 
BMI on fibroid growth, compared to a Lowess regression for time on fibroid growth 
 
 
 
 
 
Unstructured covariance structure was preferred and would have been automatically 
selected if estimates stabilized. However, this rarely occurred and visual examination using 
figures similar to the one above, were used to select a structure from among those whose effects 
stabilized. In Figure 10, the estimates from all structures overlap and are equivalently close to the 
Lowess line. In these cases, the model with the independent structure was chosen and the effect 
estimates from this reported because unique variance estimates are estimated. The conditional 
ICC, as calculated by Stata, was also then reported (estat icc; conditional on random effects 
variables equaling zero). If models with an independent structure would not run—which was rare, 
identity structure was preferred. AIC was not used to select a covariance structure or comment on 
model fit because the utility of AIC in models with non-independent observations is generally not 
justified.
137
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For some variables, it was not possible to run models when a random slope or interaction 
term was included (e.g., Stata stopped the regression or 30 iterations with “not concave” or 
“backed up” warnings were produced). Covariance structures that permitted the examination of 
the random effects variances or Wald tests were preferred. If no covariance structures allowed 
this, then I ran models with these terms removed, but a note was made in Appendix 11. All final 
model selections are presented in this appendix.  
I chose to use the same modeling techniques for my percent change in volumes outcomes 
using a 10% cut off as I did for the 50% cut off. The final selections are listed with the 50% 
growth and reduction results in the appendix, but the corresponding univariate models for 10% 
growth and reduction used the same techniques, only integration points changed to ensure result 
stabilization. 
Comments on sample size and data-sparseness  
 I anticipated that the multivariable analyses in this Aim would be underpowered, as 216 
women completed the three repeated ultrasounds. As previously mentioned, a textbook on 
regression techniques recommends a ratio of 15 subjects or subjects experiencing events (for a 
dichotomous outcome) per degree of freedom in a non-multilevel multivariable model.
133
 The 
number of parameters or covariates determines the degrees of freedom in a model. For example, 
if I modeled a continuous, time-varying BMI with an unstructured covariance, it would require 9 
degrees of freedom. Accordingly, 135 study subjects experiencing fibroid growth would be 
required for a model with only BMI. This rule of thumb is difficult to use in the context of 
longitudinal data (when observations and subjects are separate entities), but it is clear that fully 
adjusted models lack sufficient sample size to produce stable estimates and narrow confidence 
intervals (my final sample size was 216 at each time point). 
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Results  
Population characteristics 
 A description of the RFTS subcohort used in this Aim is presented in Table 9. There were 
216 women who completed all three ultrasound exams and were not missing information on 
fibroid volume or number of tumors. All but three women had fibroids in the first trimester; these 
three women had fibroids visualized on subsequent scans.  
 
 
Table 9. Maternal characteristics: Right from the Start subcohort  
 
Characteristics 
 (n=216) 
 n % 
Age (y)    
    Continuous, median[range] 31 [19-44] 
    <28 64 29.6 
    ≥28 and <31 53 24.5 
    ≥31 and <34 49 22.7 
    ≥34 50 23.2 
    Missing 0  
Race/Ethnicity   
    Non-Hispanic White 125 57.9 
    Non-Hispanic Black 70 32.4 
    Other (Includes Hispanic) 21 9.7 
    Missing 0  
First Trimester BMI    
    Continuous, median[range] 26 [18-56] 
    Underweight  2 0.9 
    Normal weight 91 42.5 
    Overweight  66 30.8 
    Obese 55 25.7 
    Missing 2  
Second Trimester BMI    
    Continuous, median[range] 27 [18-55] 
    Missing 37  
Third Trimester BMI    
    Continuous, median[range] 29 [22-55] 
    Missing 39  
Parity    
    0 108 50.0 
    1 72 33.3 
    2+ 36 16.7 
    Missing 0  
Diabetes   
    No  209 96.8 
    Yes 7 3.2 
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    Missing 0  
Hypertension   
    No 167 77.3 
    Yes 15 6.9 
    Missing* 34 15.7 
First trimester smoking    
    Non-smokers/quit prior to first trimester/ unknown when quit  200 92.6 
    Current smokers 8 3.7 
    Possible first trimester use (quit within 4 months of interview) 8 3.7 
    Missing 0  
First trimester alcohol use   
    Non users/quit prior to first trimester  102 47.2 
    Current users 10 4.6 
    Possible first trimester use (quit within 4 months of interview) 104 48.2 
    Missing 0  
First Trimester symptoms   
    None 56 26.2 
    Pain only 86 40.2 
    Bleeding only 26 12.2 
    Both symptoms 46 21.5 
    Missing 2  
Household Income   
    ≤ $40,000 50 23.8 
    $40,000-80,000 80 38.1 
    ≥$80,000 80 38.1 
    Missing  6  
Education Level   
    ≤High school 23 10.7 
    Some college 39 18.1 
    ≥4 years college 154 71.3 
    Missing  0  
Study Site   
    North Carolina 198 91.7 
    Texas 5 2.3 
    Tennessee 13 6.0 
    Missing  0  
 n=number; y=years; BMI=body mass index; wk=weeks 
*Women with unknown hypertension status were included as a distinct category in regression 
analyses. Women missing information for other variables were dropped from pertinent “complete 
case” analyses. 
 
 
Women in the subcohort had similar characteristics to the study population of the first 
two Aims. The subcohort was more likely to have hypertension (77% here and 61% previously) 
and be from North Carolina (a function of the subcohort recruitment design).  
Table 10 describes the fibroid characteristics of the subcohort. The number of fibroids did 
not change from trimester to trimester, but the range for total fibroid volume did. Total volume 
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appeared to decrease most dramatically between the second and third trimesters. This confirms 
what Figure 10 showed—there was less volumetric growth at the second time point. Fisher’s 
exact test was used to compare fibroid type and position between the first and second trimester. 
Fibroid positions and types are only described for the first and second trimesters because this was 
the information used when creating the level-1 (time-varying) variables for these characteristics. 
Compared to the first trimester, fewer women had any intramural fibroids (a 31% decrease), 
fibroids in the anterior of the uterus (19% decrease), in the posterior (16% decrease), in the 
fundus (12% decrease), and in the uterine corpus (20% decrease) in the second trimester. 
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Table 10. Fibroid characteristics by trimester: Right from the Start subcohort 
 
Fibroid 
Characteristics 
First Trimester Second Trimester Third Trimester P
1
 
 n % n % n % 
Number         
    First trimester 
    median[range]   1[0-7]
2
 1[0-7] 1[0-7]  
Total volume (cm
3
)
 
        
    First trimester 
    median[range]   5[0-265] 5[0-598] 0[0-853]  
 
Percent change in 
volume between 
trimesters 
median[range]    
100[0-26500] 
Between first and 
second trimesters 
88[0-2100] 
Between second 
and third trimesters  
Any subserosal       0.237 
    No 125 57.9 138 63.9    
    Yes 91 42.1 78 36.1    
Any submucous, 
distorting 
endometrium       1.00 
    No 187 86.6 187 86.6    
    Yes 29 13.4 29 13.4    
Any submucous, 
not distorting       0.834 
    No 203 94.0 205 94.9    
    Yes 13 6.0 11 5.1    
Any intramural       <0.001 
    No 115 53.2 181 83.8    
    Yes 101 46.8 35 16.2    
Any pedunculated       1.00 
    No 203 94.0 203 94.0    
    Yes 13 6.0 13 6.0    
Any anterior       <0.001 
    No 94 43.5 133 61.6    
    Yes 122 56.5 83 38.4    
Any posterior       0.001 
    No 97 44.9 132 61.1    
    Yes 119 55.1 84 38.9    
Any in cervix       0.210 
    No 181 83.8 191 88.4    
    Yes 35 16.2 25 11.6    
Any in fundus       0.009 
    No 136 62.7 162 75.0    
    Yes 80 37.0 54 25.0    
Any in corpus       <0.001 
    No 86 39.8 129 59.7    
    Yes 130 60.2 87 40.3    
n=number; cm
3
=cubic centimeters 
1 Fisher’s exact test comparing the counts between first and second trimester fibroid types and positions 
(the time points used for time-varying fibroid characteristics) 
2
3 women had no fibroids in the first trimester, but developed them later in pregnancy 
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Visual examination of the data 
 The longitudinal nature of the subcohort data was explored with spaghetti plots. First, 
total fibroid volume in each trimester was plotted for each woman. I chose to stratify these plots 
by maternal race, as this was a priori, suspected to influence or modify growth trajectories. In 
Figure 11, we see the total volume changes over time by race. Figure 12 removes “outlier” 
women with large volumes and focuses on the majority of women who have 200cc of total 
volume or less. No clear temporal trend for increases or decreases in volume is visible and there 
is not an obvious difference in this relationship between the races. Many women appear to have 
increases in fibroid volume in the beginning of pregnancy, but lose volume later. This is perhaps 
due to the dramatically rising levels of progesterone in early pregnancy and/or an inability to 
visualize all fibroids as a pregnancy progresses.  
 
Figure 11. Fibroid volumes in each trimester (time) for all study subjects, stratified by race 
 
99 
 
 
Figure 12. Fibroid volumes in each trimester (time) for study subjects with 200cc total 
volume or less, stratified by race  
 
 
 
In Figures 13 and 14, I plotted my continuous outcome for percent change in total volume 
against time and stratified by race. Figure 13 “zooms” in on a 5000% increase in volume or less 
(n=6 women removed). For illustrative purposes, Figure 14, focuses on those with a 1000% 
increase in volume or less (as a reminder, 100% indicates no change and <100% indicates 
reduction). Among non-Hispanic White and Black women, some experienced both growth and 
reduction during pregnancy; a few had more growth later in pregnancy than they did in early 
pregnancy. No consistent relationship between volume changes and time existed, but it appeared 
that for many women, volume increased between the first two trimesters (t=1) more dramatically 
than it did between the last two trimesters (t=2). Interestingly, the median percent change for 
White women at time one was 126% (growth) and at time two, 70% (reduction); the ranksum p-
value comparing the distributions of percent change was <0.001. Among Black women the 
medians were 108% and 100%, respectively (p=0.415; results not shown). This suggests growth 
rates may differ by race. 
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Figure 13. Percent change in total volume between trimesters for all study subjects, 
stratified by race  
 
 
 
Figure 14. Percent change in total volume between trimesters for study subjects 
experiencing a 1000% increase or less in volume or a loss of volume, stratified by race 
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Finally, I assessed change in number of fibroids was visually. In Figure 15, one can see 
that number of fibroids can increase or decrease over time for women, regardless of race; there is 
no consistent relationship between number of fibroids and trimester.  
 
Figure 15. Number of fibroids in each trimester for all study subjects, stratified by race 
 
 
 
Results from the multilevel models 
 Fibroid growth, an increase in the percent change in total volume, was the first outcome I 
analyzed. This was a dichotomous outcome: a ≥10% increase in volume was compared with 
observations in which no change in volume or a decrease in volume occurred. There were 115 
women who had increased fibroid volume in their second trimester compared to their first and 38 
women who experienced an increase between the second and third trimesters (see Table 11). 
Table 12 displays the results from the multilevel logistic regression models run for each 
explanatory variable of interest. A random intercept for study subject, a fixed effect for time, and 
a random coefficient for time were included in all models.  
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Table 11. Number of women experiencing changes in total fibroid volume between 
trimesters 
 
Time 
10% Change  
Growth  
n(%) 
No Change 
n(%) 
Reduction  
n(%) 
Disappearance 
n(%) 
Total 
Time 1 115(53) 9(4) 26(12) 66(31) 216 
Time 2 38(18) 68(31) 47(22) 63(29) 216 
 
 
 All but two models for fibroid growth were run with an independent covariance structure 
(the results for having any submucous fibroids distorting the endometrium or those for any 
fibroids in the posterior of the uterus). Of the time-varying or level-1 variables explored (BMI 
and fibroid characteristics), a random coefficient for these traits only remained in the model for 
any fibroids in the posterior of the uterus. Variance estimates for all other random coefficients 
were either <1.00*10^(-15) or Stata could not calculate confidence intervals. Among the fixed or 
level-2 covariates, an interaction term with time was only included in the model for hypertension; 
those odds ratios and confidence intervals reflect the linear combination of the lower order terms 
of interest and their interaction term with time (lincom was used in Stata). The interaction term 
for race and time approached significance (p<0.2). 
 A “null” model, including only time as a predictor and allowing it to have a random 
coefficient, showed that time has an important relationship in predicting the odds of fibroid 
growth (Table 12). The variance for the random coefficient was statistically significant and the 
fixed effect estimate indicates that increasing time (progressing through pregnancy) was 
protective against fibroid growth—in line with the previous figures. A null effect could not be 
dismissed however, upon examining the confidence interval. Fifty-nine percent of the variation in 
fibroid growth was explained by clustering observations by study subject and adjusting for time 
(see the ICC). 
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 For BMI, a similar effect was seen when comparing the continuous level-1 version of the 
variable with a level-2 version that held each participant’s first trimester BMI constant over the 
time points. A one-unit increase in BMI corresponded with a 1% increase in the odds for fibroid 
growth. Categorical BMI could not be modeled likely due to sparse data—modeling this required 
six terms, including three interactions. A null effect was observed for increasing maternal age, 
suggesting it minimally impacts total fibroid volume increases during pregnancy.  
 Null effects could not be ruled out for most covariates tested. In terms of magnitude of 
effect, the following were protective against growth: increasing parity, smoking in the first 
trimester, having diabetes or hypertension, having submucous fibroids distorting the endometrium 
(OR 0.51; CI 0.27, 0.95), and having cervical fibroids. An increased OR for growth was indicated 
among other characteristics, including symptoms of pain and/or bleeding in the first trimester—
this may suggest that symptoms are indicative of active or growing fibroids. 
For the growth models using 50% as a cut off, the results were almost identical to those 
using a 10% cut off (A11, Table 1) I attempted to run two fully adjusted models (using maternal 
characteristics and then fibroid characteristics) for my 50% growth outcome. I tried to use 
unstructured or independent covariance structures and used random coefficients or interactions 
for covariates if they were included in the univariate models. For the maternal characteristics 
model, an independent structure and five integration points was selected; the ICC was very small: 
7.22*10^(-23). The model including all fibroid characteristics used an independent structure and 
three integration points; it had an ICC of 1.42*10^(-17).  This suggests that including all 
covariates that might explain growth does not help explain intra-person variation in 
measurements well, but sparse data is a limitation. 
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Table 12. Associations between fibroid growth (≥10%) and maternal and fibroid 
characteristics from multilevel logistic regression 
Characteristic n
1
 ICC Fixed 
Effect 
Odds 
Ratio 
95% CI 
t=1 
(115) 
t=2 
(38) 
Null Model 
(time is only 
predictor) 
 
 
115 
 
 
38 
 
 
0.593 
 
 
0.18 
 
 
0.06, 0.56 
      
Maternal 
Characteristics 
     
Body Mass Index      
Time Varying
2
 
(continuous, linear) 
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28 
 
<0.001 
 
1.01 
 
0.97, 1.05 
Fixed
3
 
(continuous, linear) 
 
114 
 
38 
 
<0.001 
 
1.01 
 
0.98, 1.05 
Fixed 
(categorical) 
Cannot model/choose covariance structure 
    Underweight      
    Normal      
    Overweight      
    Obese      
Age      
Fixed 
(continuous, linear) 
 
115 
 
38 
 
<0.001 
 
1.01 
 
0.96, 1.05 
Fixed 
(categorical) 
   
<0.001 
  
    <28 38 15  0.54 0.30, 0.97 
    ≥28 and <31 25 6  REF - 
    ≥31 and <34 25 7  0.64 0.36, 1.17 
    ≥34 27 10  0.80 0.45, 1.44 
Race      
Fixed 
(categorical) 
   
<0.001 
  
    White, Non-
Hispanic 
 
68 
 
19 
 REF - 
    Black, Non-
Hispanic 
 
35 
 
16 
  
1.09 
 
0.68, 1.73 
    Other/Hispanic 12 3  1.05 0.50, 2.19 
Parity      
Fixed 
(categorical) 
   
<0.001 
  
    0 65 21  REF - 
    1 35 11  0.67 0.42, 1.08 
    2+ 15 6  0.58 0.31, 1.07 
Smoking      
Fixed 
(categorical) 
   
<0.001 
  
    No 108 34  REF - 
    Yes, exposed 3 2  0.80 0.25, 2.54 
    Possible exposure 4 2  1.11 0.36, 3.37 
Alcohol      
Fixed      
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(categorical) <0.001 
    No 48 17  REF - 
    Yes, exposed 8 0  1.51 0.54, 4.19 
    Possible exposure 59 21  1.40 0.90, 2.17 
Diabetes      
Fixed 
(categorical) 
   
<0.001 
  
    No 115 36  REF - 
    Yes 0 2  0.26 0.05, 1.22 
Hypertension      
Fixed 
(categorical) 
   
<0.001 
  
    No 96 24  REF
4
 - 
    Yes 7 7  0.65 0.22, 1.87 
    Missing 12 7  0.40 0.19, 0.87 
First Trimester 
Symptoms 
     
Fixed 
(categorical) 
     
    None 27 10  REF - 
    Pain only 40 17  1.01 0.58, 1.73 
    Bleeding only 15 4  1.20 0.57, 2.51 
    Both symptoms 31 7  1.51 0.81, 2.80 
Baseline total fibroid  
volume (first trimester) 
 
<0.001 
  
    ≤5 cc (including 0) 70 17  REF - 
    >5 and  ≤20 22 8  0.70 0.41, 1.21 
    >20 23 13  0.78 0.47, 1.32 
Fibroid Position or Type  
(All are time-varying and 
categorical) 
   
Any subserosal   <0.001   
    No 64 20  REF - 
    Yes 51 18  1.40 0.91, 2.15 
Any submucous, 
distorting 
endometrium 
   
 
<0.001 
  
    No 106 31  REF - 
    Yes 9 7  0.51 0.27, 0.95 
Any submucous, not 
distorting 
   
<0.001 
  
    No 106 36  REF - 
    Yes 9 2  1.58 0.64, 3.89 
Any intramural   <0.001   
    No 59 31  REF - 
    Yes 56 7  1.19 0.75, 1.89 
Any pedunculated   <0.001   
    No 106 37  REF - 
    Yes 9 1  1.18 0.49, 2.84 
Any anterior   <0.001   
    No 50 21  REF - 
    Yes 65 17  1.13 0.73, 1.73 
Any posterior   <0.001   
    No 50 22  REF - 
    Yes 65 16  1.28 0.77, 2.13 
Any in cervix      
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    No 99 34  REF - 
    Yes 16 4  0.74 0.40, 1.38 
Any in fundus   <0.001   
    No 71 25  REF - 
    Yes 44 13  1.30 0.83, 2.05 
Any in corpus   <0.001   
    No 45 21  REF - 
    Yes 70 17  1.13 0.73, 1.74 
REF=reference category, ICC=intraclass correlation coefficient, n=number 
1
There were 115 women experiencing at least 10% growth at time=1 and 38 women experiencing it at 
time=2. Total number of women and missingness can be inferred from information in the first tables of this 
Aim.  
2
Time-varying variables use information from the second and third trimesters (Body Mass Index) or the 
first and second trimesters (fibroid characteristics) 
3
Fixed variables use information from the first trimester across time points 
4
Odds ratios and confidence intervals reflect the linear combination of the lower order term of interest and 
its interaction term with time (t=1)  
 
 
Next, I examined fibroid reduction. This was a dichotomous outcome representing a 
≥10% loss in volume compared to observations in which no change in volume or an increase 
occurred. There were 92 women who had decreased fibroid volume in their second trimester 
compared to their first and 110 women who experienced a decrease between the second and third 
trimesters (includes complete disappearance of fibroids). Table 13 shows the results from the 
multilevel logistic regression models run for reduction and each explanatory variable of interest.  
Again, a random intercept for study subject, a fixed effect for time, and a random coefficient for 
time were included in all models.  
 All models but the model for having “any submucous fibroids distorting the 
endometrium” were run with independent covariance structures. Of the time-varying or level-1 
variables explored, a random coefficient only remained in the model for any fibroids in the 
fundus of the uterus. Among the level-2 covariates, an interaction term with time was only 
included in the model for hypertension. 
 The null model, including time as a predictor and allowing it to have a random 
coefficient, indicated that time explained very little variation in the odds of fibroid reduction and 
that the random coefficient should be removed (had it not been decided to include it a priori). 
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Increasing time corresponded to a non-statistically significant increase in the odds of reduction, 
which aligns with the previous results showing time is protective against growth. 
 A null effect was observed for both continuous level-1 BMI and its level-2 version. 
Categorical BMI models would not converge for this outcome. Increasing maternal age did not 
have an effect on fibroid reduction.  
 Increasing odds of reduction were suggested for most factors for which protective effects 
against growth were previously observed: increasing parity, having diabetes or hypertension, 
having submucous fibroids distorting the endometrium (OR 3.36; CI 2.08, 6.35), and having 
cervical fibroids. Smoking was not associated with a risk of reduction. Having fibroids in the 
posterior was associated with loss of fibroid volume (OR 1.91; CI 1.29, 2.83), as were fibroids in 
the anterior (OR 2.02; CI 1.36, 2.99). This supports the idea that uterine stretching and fetal size, 
rather than an inability to visualize fibroids in the posterior, affects reduction.  Symptoms of pain 
and bleeding were protective against reduction, again aligning with the results for the fibroid 
growth models, where increased ORs were noted. 
As with the growth models, the 10% and 50% reduction results were very similar (A11, 
Table 2). I tried to run two fully adjusted models for 50% fibroid reduction using unstructured or 
independent covariance structures (including all maternal characteristics or all fibroid 
characteristics). For the maternal characteristics model, an independent structure and five 
integration points was used; the ICC was 1.10*10^(-19). It was not possible to run a model 
including all fibroid characteristics.  
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Table 13. Associations between fibroid reduction (≥10%)and maternal and fibroid 
characteristics from multilevel logistic regression models 
Characteristic n
1
 ICC Fixed 
Effect 
Odds 
Ratio 
95% CI 
t=1 
(92) 
t=2 
(110) 
Null Model 
(time is only predictor) 
   
 
<0.001 
  
 92 110  1.40 0.96, 2.04 
Maternal 
Characteristics 
     
Body Mass Index      
Time Varying
2
 
(continuous, linear) 
 
74 
 
95 
 
<0.001 
 
0.99 
 
0.96, 1.03 
Fixed
3
 
(continuous, linear) 
 
91 
 
108 
 
<0.001 
 
0.99 
 
0.96, 1.02 
Fixed 
(categorical) 
Cannot model/choose covariance structure 
    Underweight      
    Normal      
    Overweight      
    Obese      
Age      
Fixed 
(continuous, linear) 
 
92 
 
110 
 
<0.001 
 
0.99 
 
0.95, 1.03 
Fixed 
(categorical) 
     
    <28 25 32  1.20 0.72, 2.02 
    ≥28 and <31 24 28  REF - 
    ≥31 and <34 22 28  1.30 0.77, 2.21 
    ≥34 21 22  0.94 0.55, 1.59 
Race      
Fixed 
(categorical) 
   
<0.001 
  
    White, Non-Hispanic 53 69  REF - 
    Black, Non-Hispanic 32 30   
0.83 
 
0.55, 1.26 
    Other/Hispanic 7 11  0.79 0.41, 1.52 
Parity      
Fixed 
(categorical) 
   
<0.001 
  
    0 38 59  REF - 
    1 33 38  1.19 0.78, 1.83 
    2+ 21 13  1.10 0.64, 1.88 
Smoking      
Fixed 
(categorical) 
     
    No 83 106  REF - 
    Yes, exposed 5 2  0.87 0.32, 2.38 
    Possible exposure 4 2  0.67 0.24, 1.88 
Alcohol      
Fixed 
(categorical) 
   
<0.001 
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    No 46 52  REF - 
    Yes, exposed 2 6  0.72 0.28, 1.84 
    Possible exposure 44 52  0.93 0.63, 1.37 
Diabetes      
Fixed 
(categorical) 
   
<0.001 
  
    No 85 110  REF - 
    Yes 7 0  1.14 0.39, 3.33 
Hypertension      
Fixed 
(categorical) 
   
<0.001 
  
    No 66 91  REF
4
 - 
    Yes 8 6  1.75 0.61, 5.05 
    Missing 18 13  1.72 0.82, 3.61 
First Trimester 
Symptoms 
     
Fixed 
(categorical) 
   
<0.001 
  
    None 28 24  REF - 
    Pain only 42 40  1.05 0.65, 1.70 
    Bleeding only 8 15  0.91 0.47, 1.78 
    Both symptoms 14 30  1.06 0.61, 1.84 
Baseline total fibroid  
volume (first trimester) 
 
<0.001 
  
    ≤5 cc (including 0) 70 17  REF - 
    >5 and  ≤20 22 8  1.20 0.74, 1.94 
    >20 23 13  0.89 0.56, 1.41 
Fibroid Position or Type  
(All are time-varying  
and categorical) 
   
Any subserosal   <0.001   
    No 59 57  REF - 
    Yes 33 53  1.34 0.91, 2.00 
Any submucous, 
distorting endometrium 
   
 
<0.001 
  
    No 73 76  REF - 
    Yes 19 34  3.63 2.08, 6.35 
Any submucous, not 
distorting 
   
<0.001 
  
    No 89 103  REF - 
    Yes 3 7  0.81 0.35, 1.88 
Any intramural   <0.001   
    No 50 86  REF - 
    Yes 42 24  1.29 0.83, 1.99 
Any pedunculated   <0.001   
    No 89 99  REF - 
    Yes 3 11  1.36 0.61, 3.01 
Any anterior   <0.001   
    No 39 51  REF - 
    Yes 53 59  2.02 1.36, 2.99 
Any posterior   <0.001   
    No 44 48  REF - 
    Yes 48 32  1.91 1.29, 2.83 
Any in cervix   <0.001   
    No 75 89  REF - 
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    Yes 17 21  2.29 1.30, 4.04 
Any in fundus   <0.001   
    No 60 74  REF - 
    Yes 32 36  1.33 0.88, 2.02 
Any in corpus   <0.001   
    No 39 49  REF - 
    Yes 53 61  1.79 1.19, 2.61 
REF=reference category, ICC=intraclass correlation coefficient, n=number 
1
There were 92 women experiencing at least 10% reduction at time=1 and 110 women experiencing it at 
time=2. Total number of women and missingness can be inferred from information in the first tables of this 
Aim.  
2
Time-varying variables use information from the second and third trimesters (Body Mass Index) or the 
first and second trimesters (fibroid characteristics) 
3
Fixed variables use information from the first trimester across time points 
4
Odds ratios and confidence intervals reflect the linear combination of the lower order term of interest and 
its interaction term with time (t=1)  
 
 
The final outcomes for the third Aim focus on an increase or decrease in the number of 
fibroids visualized between trimesters. Factors associated with an increase in number of fibroids 
are shown first.  The reference group for this outcome included observations in which no change 
in number or a decrease in number occurred. There were 16 women who had more fibroids in the 
second trimester than they did the first and 18 women who experienced and increase between the 
second and third trimesters. Below are the results from the multilevel logistic regression models 
for each explanatory variable of interest (Table 14). A random intercept for study subject, a fixed 
effect for time, and a random coefficient for time were included in all models.  
 A variety of covariance structures were used for these models, they are presented in A11, 
Table 3. Models with unstructured or independent structures often would not run. Furthermore, 
models with interaction terms (for the level-2 predictors) also caused difficulties and these terms 
had to be removed without Wald testing. The random coefficients for the level-1 fibroid 
characteristics often remained in the models. The ICC for the increase in number of fibroids 
models were typically much higher than seen in the models describing changes in total fibroid 
volume. ICC over 10% were identified for the continuous, fixed (level-2) versions of maternal 
BMI and age, and for hypertension, any submucous fibroids distorting the endometrium, and any 
pedunculated fibroids.  
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 The null model, including only time, indicated that increasing time could be protective 
against an increase in number of fibroids, though the confidence interval crosses 1.00. Clustering 
observations by study subject and adjusting for time explained 5% percent of the variation in the 
odds for increasing number of fibroids. 
 As BMI and maternal age increased, there were small increases in the odds of observing 
more fibroids between trimesters. Null effects could not be ruled out for most covariates tested. 
There was consistency among those factors that were protective against volumetric growth: 
increasing parity, smoking in the first trimester, having diabetes or hypertension, having 
submucous fibroids distorting the endometrium, having cervical fibroids, and having fibroids in 
the corpus were protective against an increase in number of tumors. Associations between 
maternal races other than non-Hispanic White and increased fibroid growth were previously 
suggested. Here, Hispanic race/ethnicity was possibly protective against increasing number of 
tumors. First trimester symptoms were again linked to increased tumor burden. Specifically, 
women experiencing bleeding seemed to have an increased number of tumors during pregnancy 
(OR 5.35; CI 1.34, 21.31).  
It was possible to run a final adjusted maternal characteristics model, using an 
independent structure and five integration points; the ICC was very small: 3.94*10^(-13). It was 
not possible to run a model including all fibroid characteristics. 
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Table 14. Associations between an increase in number of fibroids and maternal and fibroid 
characteristics from multilevel logistic regression models 
Characteristic n
1
 ICC Fixed 
Effect 
Odds 
Ratio 
95% CI 
t=1 
(16) 
t=2 
(18) 
Null Model 
(time is only predictor) 
  0.054 0.92 0.34, 2.49 
      
Maternal 
Characteristics 
     
Body Mass Index      
Time Varying
2
 
(continuous, linear) 
13 14 Could not 
be 
calculated 
1.04 0.99, 1.10 
Fixed
3
 
(continuous, linear) 
16 18 0.134 1.04 0.99, 1.09 
Fixed 
(categorical) 
  0.015   
    Underweight 0 0  Could not be calculated 
    Normal 6 5  REF - 
    Overweight 5 4  1.14 0.45, 2.93 
    Obese 5 9  2.31 0.97, 5.52 
Age      
Fixed 
(continuous, linear) 
16 18 0.120 1.05 0.97, 1.13 
Fixed 
(categorical) 
  0.054   
    <28 4 6  REF - 
    ≥28 and <31 3 4  0.82 0.28, 2.42 
    ≥31 and <34 5 3  1.07 0.37, 3.04 
    ≥34 4 5  1.18 0.42, 3.26 
Race      
Fixed 
(categorical) 
  Could not 
be 
calculated 
  
    White, Non-Hispanic 9 9  REF - 
    Black, Non-Hispanic 7 8  1.58 0.72, 3.46 
    Other/Hispanic 0 1  0.30 0.04, 2.49 
Parity      
Fixed 
(categorical) 
  0.052   
    0 11 10  REF - 
    1 4 6  0.67 0.29, 1.58 
    2+ 1 2  0.38 0.10, 1.44 
Smoking      
Fixed 
(categorical) 
  0.053   
    No 15 17  REF - 
    Yes, exposed 1 0  0.78 0.09, 6.94 
    Possible exposure 0 1  0.74 0.08, 6.67 
Alcohol      
Fixed 
(categorical) 
  0.056   
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    No 6 8  REF - 
    Yes, exposed 2 0  1.62 0.29, 9.12 
    Possible exposure 8 10  1.31 0.59, 2.88 
Diabetes      
Fixed 
(categorical) 
  <0.001   
    No 16 17  REF - 
    Yes 0 1  0.86 0.09, 8.08 
Hypertension      
Fixed 
(categorical) 
  0.138   
    No 15 12  REF
4
 - 
    Yes 0 3  1.28 0.33, 4.96 
    Missing 1 3  0.70 0.22, 2.20 
First Trimester 
Symptoms 
     
Fixed 
(categorical) 
  <0.001   
    None 2 2  REF - 
    Pain only 5 9  2.45 0.75, 8.04 
    Bleeding only 5 3  5.35 1.34, 21.31 
    Both symptoms 4 4  2.66 0.73, 9.73 
Fibroid Characteristics  
(All are time-varying 
and categorical) 
     
Any subserosal   0.054   
    No 8 11  REF - 
    Yes 8 7  1.14 0.50, 2.59 
Any submucous, 
distorting endometrium 
  0.147   
    No 14 16  REF - 
    Yes 2 2  0.61 0.20, 1.89 
Any submucous, not 
distorting 
  0.078   
    No 16 17  REF - 
    Yes 0 1  0.35 0.03, 4.12 
Any intramural   0.051   
    No 11 16  REF - 
    Yes 5 2  0.47 0.17. 1.32 
Any pedunculated   0.120   
    No 15 16  REF - 
    Yes 1 2  1.52 0.40, 5.83 
Any anterior   0.063   
    No 11 11  REF - 
    Yes 5 7  0.49 0.19, 1.27 
Any posterior   0.072   
    No 6 14  REF - 
    Yes 10 4  0.67 0.28, 1.62 
Any in cervix   0.075   
    No 13 16  REF - 
    Yes 1 2  0.86 0.24, 3.08 
Any in fundus   0.060   
    No 9 13  REF - 
    Yes 7 5  1.18 0.52, 2.70 
Any in corpus   0.060   
    No 9 10  REF - 
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    Yes 7 8  0.67 0.28, 1.62 
REF=reference category, ICC=intraclass correlation coefficient, n=number 
1
There were 16 women experiencing an increase in number at time=1 and 18 women experiencing it at 
time=2. Total number of women and missingness can be inferred from information in the first tables of this 
Aim.  
2
Time-varying variables use information from the second and third trimesters (Body Mass Index) or the 
first and second trimesters (fibroid characteristics) 
3
Fixed variables use information from the first trimester across time points 
4
Odds ratios and confidence intervals reflect the linear combination of the lower order term of interest and 
its interaction term with time (t=1)  
 
 
Finally, I explored a decrease in the number of fibroids visualized between trimesters. 
The reference group for this outcome included observations in which no change in number or an 
increase in number occurred. Ninety women had fewer fibroids in the second trimester than they 
did the first and 83 women experienced a decrease between the second and third trimesters. Table 
15 shows the results from the multilevel logistic regression models run for each explanatory 
variable of interest.  A random intercept for study subject, a fixed effect for time, and a random 
coefficient for time were included in all models.  
 Most models for decrease in number of tumors were run with independent covariance 
structures. No random coefficients were kept for models of maternal characteristics, but several 
fibroid characteristic models indicated that their inclusion was warranted. No interaction terms 
for level-2 covariates were kept. Similar to the models for changes in fibroid volume, the ICC for 
the decrease in number of fibroids models were small.  
 The null model including only time indicated that increasing time might not have a strong 
relationship with a decrease in number of fibroids. As BMI and maternal age increased, there was 
a null effect or small increase suggested in the odds of observing fewer fibroids between 
trimesters.  Null effects could not be ruled out for most covariates tested. In line with previous 
results, effect estimates for factors that were protective against volumetric growth and an increase 
in number of fibroids suggested an increase in the odds of having fewer fibroids (increasing 
parity, having diabetes or hypertension, having submucous fibroids distorting the endometrium, 
having cervical fibroids, and having fibroids in the corpus). Interestingly, smoking in the first 
115 
 
trimester or having first trimester pain or pain and bleeding indicated possible decreased odds of 
having fewer fibroids, which contradicts previous results.  
It was possible to run a final adjusted maternal characteristics model, using an 
independent structure and three integration points; the ICC was 1.95*10^(-24). It was not possible 
to run a model including all fibroid characteristics. 
 
Table 15. Associations between a decrease in number of fibroids and maternal and fibroid 
characteristics from multilevel logistic regression models 
 
Characteristic n
1
 ICC Fixed 
Effect 
Odds 
Ratio 
95% CI 
t=1 
(90) 
t=2 
(83) 
Null Model 
(time is only 
predictor) 
  <0.001 0.87 0.59, 1.28 
      
Maternal 
Characteristics 
     
Body Mass Index      
Time Varying
2
 
(continuous, linear) 
75 73 <0.001 1.01 0.98, 1.04 
Fixed
3
 
(continuous, linear) 
90 82 <0.001 1.00 0.97, 1.03 
Fixed 
(categorical) 
  <0.001   
    Underweight 1 0  0.45 0.05, 4.45 
    Normal 36 41  REF - 
    Overweight 30 20  0.83 0.53, 1.32 
    Obese 23 21  0.91 0.56, 1.47 
Age      
Fixed 
(continuous, linear) 
90 83 <0.001 1.02 0.98, 1.06 
Fixed 
(categorical) 
  <0.001   
    <28 23 21  REF - 
    ≥28 and <31 27 22  1.64 0.97, 2.79 
    ≥31 and <34 17 19  1.11 0.64, 1.92 
    ≥34 23 21  1.50 0.88, 2.57 
Race      
Fixed 
(categorical) 
  <0.001   
    White, Non-
Hispanic 
48 52  REF - 
    Black, Non-
Hispanic 
34 24  1.06 0.70, 1.62 
    Other/Hispanic 8 7  0.83 0.42, 1.65 
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Parity      
Fixed 
(categorical) 
  <0.001   
    0 40 40  REF - 
    1 33 28  1.25 0.81, 1.92 
    2+ 17 15  1.36 0.79, 2.34 
Smoking      
Fixed 
(categorical) 
  <0.001   
    No 82 79  REF - 
    Yes, exposed 4 2  0.89 0.34, 2.50 
    Possible exposure 4 2  0.89 0.34, 2.50 
Alcohol      
Fixed 
(categorical) 
  <0.001   
    No 48 39  REF - 
    Yes, exposed 2 6  0.90 0.35, 2.29 
    Possible exposure 40 38  0.81 0.54, 1.20 
Diabetes      
Fixed 
(categorical) 
  <0.001   
    No 84 83  REF - 
    Yes 6 0  1.13 0.38, 3.31 
Hypertension      
Fixed 
(categorical) 
  <0.001   
    No 67 69  REF - 
    Yes 8 6  1.27 0.60, 2.70 
    Missing 15 8  0.74 0.43, 1.29 
First Trimester 
Symptoms 
     
Fixed 
(categorical) 
  <0.001   
    None 27 20  REF - 
    Pain only 37 28  0.84 0.52, 1.37 
    Bleeding only 9 15  1.19 0.61, 2.30 
    Both symptoms 17 19  0.89 0.51, 1.56 
Fibroid 
Characteristics  
(All are time-
varying and 
categorical) 
     
Any subserosal   <0.001   
    No 51 40  REF - 
    Yes 39 43  1.77 1.19, 2.63 
Any submucous, 
distorting 
endometrium 
  <0.001   
    No 73 58  REF - 
    Yes 17 25  2.42 1.45, 4.01 
Any submucous, not 
distorting 
  <0.001   
    No 86 76  REF - 
    Yes 4 7  1.26 0.51, 3.11 
Any intramural   <0.001   
    No 41 57  REF - 
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    Yes 49 26  2.64 1.70, 4.13 
Any pedunculated   <0.001   
    No 87 78  REF - 
    Yes 3 5  0.65 0.23, 1.53 
Any anterior   <0.001   
    No 35 38  REF - 
    Yes 55 45  2.01 1.35, 2.98 
Any posterior   <0.001   
    No 39 30  REF - 
    Yes 51 53  2.50 1.63, 3.83 
Any in cervix   <0.001   
    No 72 66  REF - 
    Yes 18 17  2.63 1.19, 5.79 
Any in fundus   <0.001   
    No 55 53  REF - 
    Yes 35 30  1.64 1.08, 2.49 
Any in corpus   <0.001   
    No 29 32  REF - 
    Yes 61 51  2.76 1.80, 4.23 
REF=reference category, ICC=intraclass correlation coefficient, n=number 
1
There were 90 women experiencing a decrease in number at time=1 and 83 women experiencing it at 
time=2. Total number of women and missingness can be inferred from information in the first tables of this 
Aim.  
2
Time-varying variables use information from the second and third trimesters (Body Mass Index) or the 
first and second trimesters (fibroid characteristics) 
3
Fixed variables use information from the first trimester across time points 
 
Secondary analyses 
Baseline tumor volume or for my analyses, baseline total volume may influence rate of 
growth or reduction. I briefly mentioned the idea that larger fibroids can outgrow their blood 
supply, so it is reasonable to wonder if larger fibroids grow less or even shrink. Or, one might 
expect that small fibroids will be harder to visualize in later pregnancy—a perceived reduction in 
volume. These two processes could also counteract each other and drive an effect estimate for 
baseline volume on growth toward the null. I ran multilevel models for the effect of first trimester 
total fibroid volume on 10% growth and reduction (Tables 12 and 13). There was no clear 
relationship between baseline volume (categorized) and volumetric changes during pregnancy. 
I also noted in my spaghetti plots that rates of volumetric growth seemed to change over 
time (more growth between the first two trimesters). For my secondary analyses, I built linear 
regression models for the effect of prior total fibroid volume on subsequent total volume. For 
example, I ran an unadjusted regression of first trimester volume on second trimester and I then 
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ran this model adjusted for all maternal characteristics. I repeated this process for the effect of 
first trimester volume on third and also for second trimester volume on third.  
Building these linear regression models was difficult, owing to the odd distributions of 
total volume. I ended up log transforming all of my outcomes, removing an outlier (a woman who 
had a large total fibroid volume that kept increasing in each trimester), and using robust standard 
errors. Even with these modifications, the residuals for these models showed non-normality and 
heteroskedasticity—in part due to the large number of women with no tumor volume as 
pregnancies progressed (zero was changed to 0.01cc to allow for the outcome log 
transformations).  
I also determined that the relationship between prior and subsequent volume did not look 
linear. Quadratic modeling for volume could not adequately account for the relationships and I 
did not want to use splines or higher order terms because I was concerned about ease of 
interpretation. As an example, Figure 16 shows the problems with modeling first trimester 
volume on second. In the top panel, we can see the relationship is curved, but both linear and 
quadratic modeling over-simplify it. In the middle panel, I present the deviations in normality of 
the residuals (adjusted) and at the bottom, the heteroskedasticity of the residuals (adjusted). The 
models for the other time points had similar problems. This means that interpreting the effect of 
prior volume should be done cautiously, as assumptions are violated. Nonetheless, the effect of 
first trimester volume on second was OR 1.031 (CI 1.022, 1.039, adjusted); the effect of first 
trimester volume on third was OR 1.042 (CI 1.031, 1.052, adjusted); and the effect of second 
trimester volume on third was OR 1.028 (CI 1.016, 1.040, adjusted). Increases in prior volume do 
seem to be associated with small increases in subsequent volume, but the effects are consistent 
across time. When considered with my spaghetti plots, this may mean that most women 
experience growth early in pregnancy, but it is independent of initial total fibroid volume.  
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Figure 16. Figures used to evaluate the fit of an adjusted linear regression model for the 
effect of first trimester total fibroid volume on second trimester total fibroid volume 
 
 
 
Top panel: linearity of the first and second trimester volume relationship. Middle panel: Assessing the 
distribution of residuals for normality. Bottom Panel: Assessing the residuals for heteroskedasticity. 
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Discussion, considerations, and next steps 
Maternal and fibroid characteristics are related to fibroid disease changes—although, the 
magnitude of these relationships and the biologic mechanisms cannot be parsed out of the results 
in this dissertation. These analyses found that BMI and maternal age likely have a small or null 
effect on changes in fibroid volume or number of tumors. Treating these variables as level-1 or 
level-2 predictors did not change these conclusions, but categorizing them into quartiles or 5-year 
increments might. Unlike my study, DeVivo and colleagues found that among their 38 women, 
maternal pre-pregnancy BMI had a fairly strong association with volume increases in early 
pregnancy (OR 1.20) and age was protective against growth between the first and third 
trimesters.
10
 
Several factors were protective against an increase in volumetric growth and an increase 
in number of fibroids: increasing parity, having diabetes or hypertension, having submucous 
fibroids distorting the endometrium, having cervical fibroids, and having fibroids in the corpus. 
Effects in the opposite direction were often seen when examining fibroid reduction or a decrease 
in the number of tumors. DeVivo and colleagues noted that parity was protective against a 10% 
increase in size between the first and second trimester (unadjusted OR 0.13, CI 0.03, 0.94; change 
in volume of any tumor within a woman).
10
 Following from conclusions made by Laughlin and 
colleagues about post-partum fibroid regression, the association with parity and “less severe” 
tumor burden may be due to a differential ability of parous and nulliparous uteri to restructure and 
vascularize during pregnancy.
81
 This contrasts with the study by Peddada and associates (who 
used mixed-effects models on data from non-pregnant women), that concluded that mean fibroid 
growth rates were not statistically different between nulliparous and parous women.
63
 
DeVivo and associates, like myself, used a 10% change in volume criterion.
10
 Ultimately, 
I think future studies looking at intra- and inter-sonographer reliability and accuracy of fibroid 
measurements in pregnancy would inform whether this is a realistic cut off point. However, my 
results for 50% changes in volume told stories similar to my 10% models. One of the most 
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interesting comparisons between the De Vivo study and mine was the effect of baseline volume.   
DeVivo and colleagues also noted no association between initial fibroid size and increases in 
volume throughout pregnancy, which is reassuring to compare with my longitudinal results 
looking at total fibroid volume.
10
 Peddada and colleagues, who followed individual tumors via 
magnetic resonance imaging for a year, agree with this conclusion.
63
 Initial fibroid size was not 
related to mean growth rates.
63
 My secondary analyses using linear regression to estimate the 
effect of prior total fibroid volume indicated that increasing volume might correspond to 
increases in subsequent volume, but the reliability of these models is questionable.  
Smoking, which may be protective against fibroids outside of pregnancy, was protective 
against volumetric growth during pregnancy in my analyses, but its relationship with changes in 
tumor number was less clear. Strong associations with increasing percent change in fibroid 
volume were suggested for first trimester symptoms of bleeding and pain among the RFTS 
subcohort. Interactions between time and race—potentially indicating different biologic processes 
or timing of ultrasounds—were not significant when regressing on any of the outcomes. 
As noted in the background section, several studies commented on fibroid growth 
between trimesters or ultrasounds. The largest of these studies used data from  107 women, but all 
noted increases in growth were less pronounced as pregnancies progressed, as did I.
9,11,32
 In my 
work, multilevel longitudinal modeling was used—which allowed for adjustment by time and the 
inclusion of a random effect for time. However, the results from the Aim 3 call into question the 
importance of time and longitudinal modeling for changes in fibroid severity during pregnancy. 
The spaghetti plots indicated that time may not have a clear linear relationship with volume or 
number of fibroids. Although results from the null model for fibroid growth indicated that time 
was an important predictor and helped explain variation, this relationship was not seen between 
time and the other fibroid severity outcomes (reduction, change in number). In the other 
multilevel models, interactions between time and level-2 covariates were often not statistically 
significant, nor were the variance estimates for the random coefficients for time (results not 
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shown). Time likely has an important fixed effect, but perhaps not a random one (it depends on 
one’s modeling intent).  
It could be argued that marginal models like generalized estimating equations, or even 
logistic regressions performed at each time point could be used to model changes in fibroid 
severity. The former would allow clustering by study subject, but not impose a temporal order on 
the observations. Logistic regression stratified by time would save degrees of freedom without the 
multiple observations within subjects and there would be no need to estimate a covariance 
structure. Logistic regression could also be warranted if a researcher felt that each time point in 
pregnancy should be treated differently (i.e., unique mechanisms affect severity in early 
pregnancy). This bears consideration in future analyses when one considers that hormone level 
increases are most dramatic in early pregnancy (especially progesterone).  
Stratifying models by time point has some problems. Dichotomizing fibroid severity 
outcomes has repercussions: the reference groups for each of my outcomes were composed of 
women who experienced no change in severity or had the opposite change in severity. This could 
diminish the magnitude of one’s odds ratios and bias estimates toward a null value. Ideally, 
outside of using linear multilevel modeling, a non-ordinal polytomous outcome would be used in 
multilevel modeling or if stratifying on time point, containing a category for growth, one for 
reduction, and a reference group for women whose severity did not change.  
Although these were the first analyses to use longitudinal modeling of fibroid growth in 
pregnancy, the models reported here were used to identify factors that may be associated with 
changes in severity or explain variation in severity. These univariate associations were a 
necessary next step in exploring fibroid changes during pregnancy. These were not fully 
predictive or adjusted causal models. Using the information reported here, researchers can begin 
to build predictive models or causal models for these characteristics. These analyses should raise 
questions about how and why fibroids grow and how this impacts pregnancy.  
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One of the most interesting ideas developed in my dissertation is that fibroid-related 
symptoms may be associated with developing more severe disease later in pregnancy. Symptoms 
may indicate active or changing fibroids. For example, angiogenesis associated with the 
formation of new fibroids may first manifest as spotting in early pregnancy. Eventually, 
anticipating the needs for medication or counseling among pregnant women with fibroids may be 
possible and information about symptoms may be used to predict the development of larger 
fibroids that may cause labor or delivery complications.  
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CHAPTER VI 
CONCLUSION 
My dissertation describes the nature of fibroid disease among pregnant women. My work 
shows that non-linear relationships between total fibroid volume and the risks for bleeding and 
pain in the first trimester exist—and that these relationships differ by maternal race. Increasing 
number of tumors increased risk of self-reported pain and pain and bleeding together for all race 
groups. The results from my analyses show that not only are fibroid disease and related symptoms 
unique among race groups, but that fibroid severity is dynamic within individual women. It is 
possible that changes in fibroid volume and changes in number of tumors are separate biologic 
processes—with different implications for pregnancy or labor complications. 
Longitudinal models were used to identify maternal and fibroid characteristics associated 
with fibroid growth during pregnancy. As in previous studies, increases in disease severity, as 
defined by an increase in total fibroid volume, were noted for many women at the beginning of 
pregnancy (regardless of race). Nulliparity and first trimester symptoms were possible risk factors 
for increases in total volume and number of tumors—suggesting that experiencing symptoms is 
indicative of fibroid formation or growth.  
The relationship between these characteristics and changes in disease severity may be 
dependent upon timing during pregnancy. Previous studies have tried to examine changes in 
tumor size between trimesters, but it is difficult to compare these with my results, because this 
dissertation appears to be the first analysis to use longitudinal modeling during pregnancy. 
Ultimately, large studies with sufficient samples sizes and ideally, more measurements during 
pregnancy, will be needed to create adjusted causal models that can account for intra-subject 
correlation of measurements.  
Although the impact of fibroids on prescription drug use and labor and delivery 
complications has been explored, we know very little about the natural history of the disease 
during pregnancy and the quality of life for pregnant women with fibroids. No recommendations 
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for treating or anticipating symptoms specifically among pregnant women with fibroids exist, nor 
are there guidelines for clinicians about anticipating medical complications due to changes in 
fibroid severity during pregnancy.  As of now, we do not know enough about fibroids during 
pregnancy to develop healthcare recommendations about anticipating the needs or medical 
problems of women with fibroids, especially during pregnancy. By continuing to study disease 
severity in pregnancy, it eventually may be possible to raise physician awareness of the unique 
concerns and experiences of these women (e.g., increased need of feminine products or 
analgesics, risk of anemia, or emotional distress due to worrying about potential pregnancy loss). 
Additionally, informing fibroid treatment decision-making for women planning a pregnancy may 
be possible (e.g., if anticipated duration/heaviness of bleeding or pain is such that fibroid removal 
is recommended). Increased knowledge also may help in the development of counseling 
programs or educational materials for these women.   
The impact of fibroid-associated symptoms on quality of life was not specifically 
explored here. Women with larger or more numerous fibroids may report bleeding or pain 
differently than women with less “severe” disease, but whether this translates into emotional 
distress, increased visits to providers, is limiting of physical activity, or leads to increased use of 
sanitary products or NSAIDs, is a logical next analysis. This dissertation demonstrates that 
uterine fibroid disease is complex and its severity should be contextualized in terms of all of the 
following:  tumor burden, changes in tumor burden, symptoms, healthcare utilization, and 
medical complications. 
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APPENDIX 
A 1. Studies examining fibroid growth during pregnancy 
First Author, year 
of Publication 
Study Setting Population Identification of 
Fibroids 
Measurement of 
Fibroid Growth 
N Results 
 
Muram29, 1980 Retrospective chart 
review, Ottawa 
General Hospital, 
1976 to1978 
Obstetric patients 
with at least 1 
ultrasound who 
were followed until 
the end of 
pregnancy, women 
with therapeutic 
abortions excluded. 
 
Mixed races, 7% 
Black women 
Ultrasound 
documented 
spherical mass of at 
least 3cm.  
 
Only largest fibroid 
in each woman 
considered. 
Presumed to be 
percent change in 
diameter.  
 
Number or timing 
of repeat 
ultrasounds not 
described.  
41 women with 
fibroids  
In 38 women, there was no size change. In 
2 women, fibroids grew by 20 to 25% and 
in 1 woman, a 20% reduction. 
Lev-Toaff9, 1987 Likely 
retrospective chart 
review, presumed 
to be one or more 
university 
hospitals, 
Philadelphia. 
Pregnant women 
referred for 
ultrasound. 
 
Black and White 
women, 79.6% 
Black. 
Fibroids (no 
criteria provided) 
detected by 
ultrasound and 
confirmed 
surgically or with 
palpation. 
A change of 
≥1.0cm in at least 2 
out of 3 diameter 
measurements. 
 
2 to 4 ultrasounds 
at 4 to 12 week 
intervals. 
162 fibroids in 71 
women 
In the 1st trimester, fibroids increased or 
remained the same (role of initial volume 
unclear).  
 
In 2nd trimester, 30% of fibroids 2 to 6cm 
in diameter increased, 15% decreased. For 
larger fibroids, 14% increased and 48% 
decreased. 
 
In the 3rd trimester, 5% of small fibroids 
increased, 35% decreased. Of large 
fibroids, 12% increased and 60% 
decreased.  
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First Author, year 
of Publication 
Study Setting Population Identification of 
Fibroids 
Measurement of 
Fibroid Growth 
N Results 
 
Aharoni30, 1988 Prospective, 
Setting not 
described, 
presumed to be an 
obstetrics and 
gynecology 
hospital 
department, Israel 
No demographic 
information other 
than age provided. 
Women known to 
have fibroid before 
pregnancy or upon 
routine ultrasound 
before 20 weeks 
gestation. 
Ultrasounds every 
3 to 8 weeks.  
 
Fibroid volume 
measured as an 
ellipsoid. 
 
Percent volumetric 
change for each 
fibroid calculated. 
 
Growth curves 
(volume versus 
gestational age) for 
each fibroid 
presented. 
32 fibroids in 29 
women 
7 fibroids (22%) increased by more than 
10% but less than 25% of initial volume. 
 
19 fibroids (59%) increased or decreased 
in size by less than 10% of initial volume. 
 
6 fibroids (19%) decreased by 10-20% of 
their initial volume. 
 
Davis31, 1990 Presumed to be 
retrospective, 
Cedars-Sinai 
Medical Center, 
Los Angeles, 1986 
to 1988 
Pregnant women 
with a history of 
fibroids matched 
on race, age, and 
parity to pregnant 
women without 
fibroids.  
 
Mixed races, 37% 
Black 
Muram29 criteria, 
using ultrasounds 
from 20 to 24 
weeks. 
Ultrasound at 20 to 
24 weeks and two 
additional 
ultrasounds at 6 to 
8 week intervals 
for women with 
fibroids.  
 
Methods for 
detecting/deter-
mining volumetric 
change not 
discussed. 
81 women with 
fibroids at initial 
ultrasound returned 
for remaining two 
exams. 
One woman with a single fibroid showed 
volume change between first and second 
assessment 
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First Author, year 
of Publication 
Study Setting Population Identification of 
Fibroids 
Measurement of 
Fibroid Growth 
N Results 
 
Rosati32, 1992 Prospective, 
presumed to be an 
obstetrics and 
gynecology 
hospital 
department, Rome, 
Italy 
No demographic 
information other 
than age provided. 
Muram 29criteria, 
fibroids with 
diameter of 3cm or 
more.  
 
Limited to women 
with one fibroid. 
Ultrasounds every 
2 weeks to 4 
weeks, beginning 
in the first 
trimester. 
 
Fibroid volume 
determined using 
the formula for an 
ellipsoid. 
 
Difference between 
volumes from first 
and last ultrasound 
measurements in 
each trimester used 
to calculate mean 
percentage 
difference in 
volume. Means for 
each trimester 
compared with t-
tests.  
36 women with 
single fibroids 
Comparisons of mean percentage 
difference in volume between all 
trimesters were statistically significant 
(p<0.05).  
 
During the first and second trimester, 
fibroid volume increased (8 +/- 7% and 2 
+/- 5%, respectively). Fibroid volume in 
the third trimester decreased (-0.5 +/- 4%). 
32% of fibroids grew during pregnancy. 
Mean growth was 12+/- 6%. 
 
60% of fibroids had <10% change in 
volume from beginning to end of 
pregnancy. 
 
Growth was not related to initial fibroid 
volume (results not shown). 
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First Author, 
year of 
Publication 
Study Setting Population Identification of 
Fibroids 
Measurement of 
Fibroid Growth 
N Results 
 
Strobelt
33
, 1994
 
 Prospective, 
prenatal clinic, 
Monza, Italy, 
1983 to 1989 
Excluded women 
who had 
pregnancy 
termination, 
miscarriage, 
myomectomy 
during 
pregnancy, less 
than three 
ultrasounds, first 
ultrasound 
preformed after 
20 weeks 
gestation.  
 
No demographic 
information other 
than age 
provided. 
Muram
 29
criteria, 
fibroids with 
average diameter 
of 1cm or more 
included.  
 
Women had 
known fibroids 
before 
pregnancy, 
fibroids detected 
by early 
pregnancy 
ultrasound 
performed for 
clinical 
indications, or 
routine 
ultrasounds 
between 16-20 
weeks.   
Ultrasounds 
every 2 weeks 
until 20 weeks 
gestation, 
monthly 
thereafter. 
 
Only largest 
fibroid followed 
if multiple 
present. 
 
10% change in 
average diameter 
size, no change, 
or “disappeared.” 
134 women with 
fibroids 
20 women (15%) had a fibroid grow 
during entire pregnancy. 
 
Fibroids greater than 5cm more likely 
to increase in size than ones  less than 
5cm (26% versus 10%, p=0.03). 
 
Fibroids less than 5cm less likely to 
be visualized at follow-up 
ultrasounds.  
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First Author, 
year of 
Publication 
Study Setting Population Identification of 
Fibroids 
Measurement of 
Fibroid Growth 
N Results 
 
De Vivo 
10
, 2001 Prospective, 
university 
hospital, 
Messina, Italy, 
2008 
Women with 
singleton 
pregnancies who 
had diagnosis of 
fibroids and 
Down Syndrome 
screening. 
Women with 
miscarriage and 
incomplete 
obstetric follow-
up excluded. 
 
Limited to White 
women. 
At least 1 fibroid 
≥1cm in 
diameter, timing 
of initial 
diagnosis unclear 
(before referral or 
during 
screening).  
Fibroid volume 
formula 
provided. 
 
Initial scan and 
fibroid diagnosis 
presumed to be 
11 to14 weeks 
gestation, 
followed by 
scans at 20 to 22 
and 32 to 34 
weeks. 
 
Percent increase 
in volume 
calculated. 
42 fibroids in 38 
women. 
71% of fibroids increased (>10%) 
between first 2 time points. 66% 
increased between last 2 time points. 
Remainders of women were grouped 
together as “decreased or stayed the 
same.” 
 
Used regression techniques to assess 
bivariate associations between risk 
factors and increase in growth. Did 
not build a multivariate model. 
Hammoud 
11
, 
2006 
Retrospective 
chart review, 
presumed to be 
obstetrics and 
gynecology 
department(s) at 
University of 
Utah and/or 
Wayne State 
University, 1994 
to 2004 
Patients seen for 
2 or more 
obstetric 
ultrasounds. 
 
89% African 
American, 6% 
Caucasian, 5% 
other races. 
Diagnostic 
criteria not 
described.  
 
Initial 
ultrasounds 
targeted between 
16 to 20 weeks 
gestation. 
 
 
Formula for 
volume 
calculations 
provided. 
 
Only largest 
fibroid of each 
patient followed. 
 
Percentage and 
mean/median 
change in volume 
between ≤19, 20 
to 30, and 31 to 
42 weeks 
calculated. 
107 women with 
fibroids  
40% of fibroids increased by more 
than 10% of initial volume between 
1st and 2nd period. 13% increased or 
decreased in size by less than 10%. 
47% decreased by >10% of their 
initial volume.  
 
18% increased between and 2nd and 
3
rd
 scans. 18% had no change between 
and 2nd and 3rd. 64% decreased 
between and 2nd and 3rd. 
 
88% of fibroids with mean diameter 
>4cm at 2nd period decreased in size 
between 2nd and 3rd time points; only 
20% of smaller fibroids decreased. 
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First Author, 
year of 
Publication 
Study Setting Population Identification of 
Fibroids 
Measurement of 
Fibroid Growth 
N Results 
 
Neiger
12
, 2006 Retrospective 
chart review, 
presumed to be 
Obstetrics and 
Gynecology 
department at 
Wright State 
University, Ohio, 
2001 to 2003 
Singleton 
pregnancies 
referred for 
ultrasound, with 
at least 2 
ultrasounds 
performed.  
 
Mixed races, 
36% Black. 
Diagnostic 
criteria not 
described. 
Fibroid size 
determined by 
average diameter. 
 
Criteria for 
determining size 
change not 
discussed. 
 
Mean gestational 
age was 14 
weeks for first 
ultrasound, with 
repeat scans 
every1 to 17 
weeks (average 
of 6). 
137 fibroids in 72 
women. 
“On average, no significant change in 
size” of fibroids during pregnancy.  
 
Average change in size by week of 
gestation shown as a Figure, but not 
discussed. 
 
Fibroid shape and location changed 
during pregnancy. 
cm=centimeter 
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A 2. Ultrasound report form completed by sonographers at six weeks estimated gestational 
age, Right from the Start  
 
 
 
 
 
 
 
 
Sonographer: __________________________  NO SHOW            (check, fax page 1 to RFTS) 
Sonography Site: ________    Print Requested        (check) 
 
FIRST TRIMESTER ULTRASOUND REPORT 
 
Date 
of US 
       DOB        
Participant 
Initials 
 
  M M D D Y Y   M M D D Y Y    
 
 
Weight _____________ lbs           Height _________ft_________ in 
 
 
At today’s ultrasound you will be assessing gestation and looking for uterine fibroids.  Please conduct a 
thorough examination of the entire myometrium using transvaginal and transvesical/abdominal 
approaches as required.  Complete the entire form. 
 
1. Measure weight and height - round to the nearest pound for weight and to the nearest ½ inch for height. 
For ½ pounds, round up to nearest pound (150.5 = 151 pounds); for ¼ inch, round up to nearest ½ inch (5’ 
5 ¼” = 5’ 5 ½”). 
 
2. Provide a digital image of the fetal pole with caliper markings. (If a fetal pole is not seen, 
provide a digital image and measurements of most clearly identified intrauterine/gestational structure (i.e. 
gestational sac with diameters, decidual reaction without gestational sac, etc.).  
 
3. If you have any technical comments related to performing the ultrasound, please make a note.   DO NOT 
record comments related to pregnancy well being or fetal anatomy.  A comment section has been provided 
under questions 3,4,5,6 and 7. 
4. Provide a still photo or digital image on CD of the ultrasound to the participant. (Add a RFTS disclaimer 
label on the back of the photo or CD).  
5. Prepare a digital cine loop.  Record a full slow transverse sweep of the uterus moving from the woman’s 
right to left side and a longitudinal sweep of the uterus from the anterior to posterior portion of the uterus.  
6. Store all digital images on a CD labeled with the participant’s study number (RSID) and date and type of 
the ultrasound (first trimester). 
 
7. If fibroids are present, for each fibroid, record the following (If an indeterminate area is noted complete as 
much information as you can about the area): 
· Note all characteristics of each fibroid – check all that apply. 
· Provide three perpendicular diameters of each fibroid (or indeterminate area) (length, width and height).  
Please take 3 independent measurements and record the average mm value on page 3 of this form. 
· Use the Addendum form if more than six fibroids are identified. 
· Record on a CD a digital image of each fibroid or indeterminate area with caliper marks.  Label each 
fibroid image with the fibroid number that corresponds to the measurements recorded on page 3 of this 
form. If a fibroid is pedunculated, provide a digital image of the fibroid and stalk. 
· Draw and label each fibroid or indeterminate area seen today on the uterine diagrams on page 4. 
· (UNC/WHI ONLY) Inform the participant about the follow-up ultrasounds, schedule 15-week US appointment.  
  15 week US appointment: Date: ________________ Time: ___________ Site: _________ 
8. (UNC/WHI ONLY) If a woman does not show for her appointment, attempt to call and reschedule by the 
end of the day.  If unable to reach, rescheduling will be handled by RFTS staff in main office. 
rescheduled US appointment: Date: _____________Time:___________ Site: ________ 
 
Multiple Gestations?   (circle) 
 
NO       YES ®  How many? ______ 
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A 3. Ultrasound report form completed by sonographers at 15 (and 27) weeks estimated 
gestational age, Right from the Start (second study phase) 
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A 4: Questions asked about bleeding during the first trimester computer-assisted telephone 
interview, Right from the Start  
 
 
 
 
 
 
 
 
H8a. Since you got pregnant, have you had any bleeding or spotting with 
blood?  
No  skip to H14.   Yes   
Don't know  skip to H14.  Refused  skip to H14. 
 
H8b. Did the bleeding or spotting start at the time you expected your 
menstrual period? 
No  Yes  Don't know  Refused 
 
[Ask questions H9a. through H12. for the first episode, then repeat these 
questions for a second or third episode.] 
H9a. As best as you can remember, when did you start to bleed or spot for 
the (first, second, third) time? 
Month: ____  Day: ______ [If doesn’t remember day ask H9b.]  
Year: _______ H10a  
 Don’t know H10a 
 Refused H10a 
 
1st episode 2nd episode 3rd episode 
month: ____  
day: ______ [if doesn’t 
remember day ask 
H9b.] 
year: _______  
 don’t know 
 refused 
month: ____  
day: ______ [if doesn’t 
remember day ask 
H9b.] 
year: _______  
 don’t know 
 refused 
month: ____  
day: ______ [if 
doesn’t remember day 
ask H9b.] 
year: _______  
 don’t know 
 refused 
 
H9b. Do you remember what week in [month] that was, the first, second, 
third, fourth or fifth? 
1st episode 2nd episode 3rd episode 
_____1
st
 
____2
nd
 
____ 3
rd
 
_____ 4
th 
_______  
5
th
 
 don’t know 
  refused 
_____1
st
 
____2
nd
 
____ 3
rd
 
_____ 4
th 
_______  
5
th
 
 don’t know 
  refused 
_____1
st
 
____2
nd
 
____ 3
rd
 
_____ 4
th 
_______  
5
th
 
 don’t know 
 refused 
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H10a. As you answer the next question, I would like you to compare this 
spotting or bleeding to the amount of bleeding you usually have with 
your normal menstrual period. On the day of your heaviest spotting 
or bleeding in the [first, second, third] episode, would you describe 
the bleeding as light spotting so that you only noticed it when you 
wiped, lighter than the heavy flow of your menstrual period, like the 
heavy flow of your menstrual period, or more than the heavy flow of 
your menstrual period? [If a woman answers “It was light” clarify if she 
means light spotting or lighter than heavy flow] 
 
1st episode 2nd episode 3rd episode 
light spotting 
lighter than heavy flow 
like heavy flow 
more than heavy flow 
don't know 
refused 
light spotting 
lighter than heavy flow 
like heavy flow 
more than heavy flow 
don't know 
refused 
light spotting 
lighter than heavy flow 
like heavy flow 
more than heavy flow 
don't know 
refused 
 
H10b. What color was the blood, was it generally red, pink or more of a 
brown color? 
1st episode 2nd episode 3rd episode 
red 
pink 
brown 
don't know 
refused 
red 
pink 
brown 
don't know 
refused 
red 
pink 
brown 
don't know 
refused 
 
H10c. How many days did this [spotting/bleeding] last? If your spotting or 
bleeding stopped for at least two days and then started again, 
consider this as a separate episode of spotting or bleeding. 
1st episode 2nd episode 3rd episode 
_____  days 
don't know 
refused 
_____  days 
don't know 
refused 
_____  days 
don't know 
refused 
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Italic text indicates instructions presented to the interviewer 
Bold text is read aloud by the interviewer to the participant 
 
 
 
 
 
 
 
 
 
 
H11a. Did you have any pain during the time you had spotting or bleeding 
the (first, second, third) time? 
1st episode 2nd episode 3rd episode 
Yes 
No  skip to H12. 
don't know  skip to 
H12. 
refused  skip to H12. 
Yes 
No  skip to H12. 
don't know  skip to 
H12. 
refused  skip to H12. 
Yes 
No  skip to H14. 
don't know  skip to 
H14. 
refused  skip to H14. 
 
H11b. Overall, would you describe the pain as mild, moderate or severe? 
1st episode 2nd episode 3rd episode 
mild 
moderate 
severe 
don't know  
refused 
mild 
moderate 
severe 
don't know  
refused 
mild 
moderate 
severe 
don't know  
refused 
 go to H13 
 
H12. Did you have a (second, third) time during this pregnancy when you 
had spotting or bleeding? By (second, third) we mean that you had at 
least two days where you had no spotting or bleeding before it started 
again. [If her spotting or bleeding stopped for at least two days and then 
started again, consider this as a separate episode of spotting or bleeding.] 
2
nd
 episode 3
rd
 episode 
no  --> H14. 
yes  --> H9a. 
don't know --> H14. 
refused--> H14. 
no  --> H14. 
yes  --> H9a. 
don't know --> H14. 
refused --> H14. 
 
H13. How many more times did you have bleeding or spotting with blood? 
[Enter 0 if none.] 
_____ more times  Don’t know  Refused 
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A 5: Questions asked about pain during the first trimester computer-assisted telephone 
interview, Right from the Start  
 
 
Italic text indicates instructions presented to the interviewer 
Bold text is read aloud by the interviewer to the participant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H7a. Have you had any abdominal pain or cramping since your last 
menstrual period? Probe: Have you had any stomach or belly 
pain? [Mark yes even if she has been told that the pain is normal. 
Pain should be associated with pregnancy, not a stomach flu or 
other illness.] 
No  skip to H8a.   Yes   
Don't know  skip to H8a.  Refused  skip to H8a. 
 
H7b. When did you first have pain? [Likely that pain is intermittent] 
Month: ____  Day: ______ [If doesn’t remember day ask 
H7c.] Year: _______ H8a 
 Don’t know H8a 
 Refused H8a 
 
H7c. Do you remember what week in [month] that was, the first, 
second, third, fourth or fifth? 
___1
st
 ____2
nd
 ___ 3
rd
 ____ 4
th
 ___ 5
th
   
 Don’t know 
 Refused 
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A 6: Questions asked about bleeding during the third trimester computer-assisted telephone 
interview, Right from the Start  
 
 
 
 
 
 
 
 
 
 
H8a. In your first trimester interview, you told us that you had not 
experienced bleeding or spotting with blood at that time during your 
pregnancy. Since your first interview on __________, have you had 
any bleeding or spotting with blood? [note: do include bleeding or 
spotting associated with miscarriage] 
 
[If H8a= "Don't know or Refused" at first trimester interview] Since your first 
interview on ________, have you had any bleeding or spotting with 
blood? 
  
Yes  skip to H9a.     No  skip to H15. 
   
Don't know  skip to H15.                                       Refused  skip to 
H15.      
 
H8ayes. In your first trimester interview, you told us that you last had 
bleeding or spotting on [insert date of last episode from FTI].  Since 
that date, have you had any more episodes of bleeding or spotting 
with blood? [note: do include bleeding or spotting associated with 
miscarriage] 
 Yes [ask questions H9a-H12 for up to three additional episodes in this 
questionnaire. We do want to know H13.] 
 No  skip to H15. 
 Don't know  skip to H15. 
 Refused  skip to H15. 
 
 [Ask questions H9a. through H12. for the first episode, then repeat these 
questions for a second or third episode.] [For questions H9a and H13, read 
“Since your first trimester interview” if no bleeding was reported in FTI.  If she 
reported bleeding in FTI, reference date of last episode reported.] 
H9a. As best as you can remember, [since your first trimester 
interview/since your last episode on _______ [date]], when did you 
start to bleed or spot for the [first, second, third] time? 
month: ____  day: ______ [if doesn’t remember day ask H9b.]   
year: _______  H10a 
 Don’t know  H10a 
 Refused  H10a 
 
Michels 
157 
 
 
 
 
 
 
 
 
1st episode 2nd episode 3rd episode 
month: ____  
day: ______ [if doesn’t 
remember day ask 
H9b.] 
year: _______  
 Don’t know 
 Refused 
month: ____  
day: ______ [if doesn’t 
remember day ask 
H9b.] 
year: _______  
 Don’t know 
 Refused 
month: ____  
day: ______ [if 
doesn’t remember day 
ask H9b.] 
year: _______  
 Don’t know 
 Refused    
 
H9b. Do you remember what week in [month] that was, the first, second, 
third, fourth or fifth? 
1st episode 2nd episode 3rd episode 
_____1
st
 
____2
nd
 
____ 3
rd
 
_____ 4
th 
_______  
5
th
 
Don’t know 
Refused 
_____1
st
 
____2
nd
 
____ 3
rd
 
_____ 4
th 
_______  
5
th
 
Don’t know 
Refused 
_____1
st
 
____2
nd
 
____ 3
rd
 
_____ 4
th 
_______  
5
th
 
Don’t know 
Refused 
 
H10a. As you answer the next question, I would like you to compare this 
spotting or bleeding to the amount of bleeding you usually have with 
your normal menstrual period. On the day of your heaviest spotting 
or bleeding in the [first, second, third] episode, would you describe 
the bleeding as light spotting so that you only noticed it when you 
wiped, lighter than the heavy flow of your menstrual period, like the 
heavy flow of your menstrual period, or more than the heavy flow of 
your menstrual period? [If a woman answers “It was light” clarify if she 
means light spotting or lighter than heavy flow] 
 
1st episode 2nd episode 3rd episode 
light spotting 
lighter than heavy flow 
like heavy flow 
more than heavy flow 
don't know 
refused 
light spotting 
lighter than heavy flow 
like heavy flow 
more than heavy flow 
don't know 
refused 
light spotting 
lighter than heavy flow 
like heavy flow 
more than heavy flow 
don't know 
refused 
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H10b. What color was the blood, was it generally red, pink or more of 
a brown color? 
1st episode 2nd episode 3rd episode 
red 
pink 
brown 
don't know 
refused 
red 
pink 
brown 
don't know 
refused 
red 
pink 
brown 
don't know 
refused 
 
H10c. How many days did this [spotting/bleeding] last? If your spotting or 
bleeding stopped for at least two days and then started again, 
consider this as a separate episode of spotting or bleeding. 
1st episode 2nd episode 3rd episode 
_____  days 
don't know 
refused 
_____  days 
don't know 
refused 
_____  days 
don't know 
refused 
 
H11a. Did you have any pain during the time you had spotting or bleeding 
the [first, second, third] time? 
1st episode 2nd episode 3rd episode 
Yes 
No  skip to H12. 
Don't know  skip to 
H12. 
Refused  skip to 
H12. 
Yes 
No  skip to H12. 
Don't know  skip to 
H12. 
Refused  skip to 
H12. 
Yes 
No  skip to H12. 
Don't know  skip to 
H12. 
Refused  skip to 
H12. 
 
H11b. Overall, would you describe the pain as mild, moderate or 
severe? 
1st episode 2nd episode 3rd episode 
mild 
moderate 
severe 
don't know  
refused 
mild 
moderate 
severe 
don't know  
refused 
mild 
moderate 
severe 
don't know  
refused 
 go to H13 
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Italic text indicates instructions presented to the interviewer 
Bold text is read aloud by the interviewer to the participant 
 
 
 
 
 
H12. Since your first trimester interview, did you have a [second, third] 
time when you had spotting or bleeding? By [second, third] we mean 
that you had at least two days where you had no spotting or bleeding 
before it started again. [If her spotting or bleeding stopped for at least 
two days and then started again, consider this as a separate episode of 
spotting or bleeding.] 
2
nd
 episode 3
rd
 episode 
yes  --> H9a. 
no  --> H15. 
don't know --> H15. 
refused --> H15. 
yes  --> H9a. 
no  --> H15. 
don't know --> H15. 
refused --> H15. 
 
H13. Since your first trimester interview/since your last episode on ______ 
[date], how many more times did you have bleeding or spotting with 
blood? [Enter 0 if none.] 
_____ more times  Don’t know  Refused 
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A 7: Questions asked about pain during the second trimester computer-assisted telephone 
interview, Right from the Start  
 
Italic text indicates instructions presented to the interviewer 
Bold text is read aloud by the interviewer to the participant 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H7a. In your first trimester interview on __________ [date], you said you 
had not experienced any abdominal pain or cramping. Since then, 
have you had any abdominal pain or cramping? Probe: Have you had 
any stomach or belly pain? [Mark “Yes” even if she has been told that 
the pain is normal. The pain should be associated with pregnancy, not a 
stomach flu or other illness] 
 
[If H7a="Don't know or Refused" at first trimester interview] Since your first 
trimester interview on ________ [date], have you had any abdominal 
pain or cramping? 
Yes     No  skip to H8a. 
Don't know  skip to H8a.             Refused  skip to H8a. 
 
H7b. When did you first have pain? [likely that pain is intermittent] 
month: ____  day: ______ [if doesn’t remember day ask H7c.]
 year: _______  H7d 
 Don’t know  H7d 
 Refused  H7d 
 
H7c. Do you remember what week in [month] that was, the first, second, 
third, fourth or fifth? 
___1
st
 ____2
nd
 ___ 3
rd
 ____ 4
th
 ___ 5
th
   
 Don’t know 
 Refused 
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A 8: Directed acyclic graphs (DAGs) 
 
Figure 1. DAG  for bleeding and fibroid severity  
 
 
Factors listed in green denote those measured in Right from the Start. Factors in pink are not measured in 
these analyses. The dotted line indicates uncertain evidence. 
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Figure 2. DAG for pain and fibroid severity 
 
 
 
Factors listed in green denote those measured in Right from the Start. Factors in pink are not measured in 
these analyses. The dotted line indicates uncertain evidence. 
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Figure 3. DAG for study site as a potential confounder 
 
 
SES=socioeconomic status 
Study site is related to fibroid severity and symptoms through ecologic or community-level factors and 
individual-level factors.  Above, green denotes the community-level and pink, the individual-level. Right 
from the Start captures information on study site, individual measures of SES (e.g., income, education), and 
some community and individual-level exposures that are related to study site but not used in these analyses 
(e.g., care setting, medication use). 
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A 9. Methods section tables for Aims 1 and 2 
 
Table 1. Likelihood ratio test results for effect modification by maternal race and fibroid 
severity 
 
 
Potential Confounder 
Bleeding Only 
(n=334) 
Pain Only 
(n=1885) 
Both Symptoms 
(n=792) 
 
Likelihood 
Ratio Test 
P-value 
 
 
 
Likelihood 
Ratio Test 
P-value 
 
 
 
Likelihood Ratio 
Test 
P-value 
 
 
Race*Volume Categories 0.686 0.017 0.039 
Race*Number of Fibroids (Linear) 0.231 0.402 0.738 
With the exception of models for bleeding outcomes, results were stratified by maternal race when fibroid 
volume was the exposure of interest. 
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Table 2. Confounding assessment, step 1: unadjusted associations between potential 
confounders and the primary exposure (any fibroids) among the entire study population 
 
 
Potential Confounder 
 
Unadjusted 
Odds Ratio 
Is factor 
associated 
with the 
exposure? 
Age (y)    
    Linear 1.13 Yes 
    Quadratic (Linear + Quadratic terms) 1.03 Yes 
Race/Ethnicity  Yes 
    Non-Hispanic White Reference  
    Non-Hispanic Black 2.79  
    Other 1.22  
BMI    
    Linear 1.04 Yes 
    Quadratic (Linear + Quadratic terms) 1.13 Yes 
Parity   Yes 
    0 Reference  
    1 0.94  
    2+ 1.10  
Diabetes  Yes 
    No  Reference  
    Yes 1.42  
Hypertension  Yes 
    No Reference  
    Yes 1.67  
    Missing 0.71  
First trimester smoking   Yes 
    Non-smokers/quit prior to first trimester/ unknown when quit  Reference  
    Current smokers 0.75  
    Possible first trimester use (quit within 4 months of interview) 0.49  
First trimester alcohol use  Yes 
    Non users/quit prior to first trimester  Reference  
    Current users 1.14  
    Possible first trimester use (quit within 4 months of interview) 0.81  
Study Site  Yes 
    North Carolina Reference  
    Texas 0.21  
    Tennessee 0.78  
Final list of factors associated with fibroids:  
Age (linear and quadratic), race, BMI (linear and quadratic), parity, diabetes history,  
hypertension history, first trimester smoking, first trimester alcohol use, study site 
y=years, BMI=body mass index 
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Table 3. Confounding assessment, step 2: unadjusted associations between potential 
confounders and outcomes (symptoms) among women without fibroids 
 
Potential 
Confounder 
Bleeding Only 
(n=334) 
Pain Only 
(n=1885) 
Both Symptoms 
(n=792) 
 
Unadjusted 
Odds Ratio 
Is factor 
associated 
with the 
outcome? 
 
Unadjusted 
Odds Ratio 
Is factor 
associated 
with the 
outcome? 
 
Unadjusted 
Odds Ratio 
Is factor 
associated 
with the 
outcome? 
Age (y)   Yes  Yes  Yes 
    Linear 1.02  NA  NA  
    Quadratic 
(Linear + Quadratic 
terms) 
NA  1.13  1.45  
Race/Ethnicity  Yes  Yes  Yes 
    Non-Hispanic 
White 
Reference  -  -  
    Non-Hispanic 
Black 
0.90  0.85  0.94  
    Other 0.97  0.95  1.15  
BMI   No  No  Yes 
    Linear 0.99  1.00  NA  
    Quadratic 
(Linear + Quadratic 
terms) 
NA  NA  0.94  
Parity   Yes  Yes  Yes 
    0 Reference  -  -  
    1 0.74  0.49  0.50  
    2+ 0.92  0.50  0.56  
Diabetes  Yes  Yes  No 
    No  Reference  -  -  
    Yes 1.14  0.72  0.93  
Hypertension  Yes  Yes  Yes 
    No Reference  -  -  
    Yes 0.97  1.13  1.06  
    Missing* 0.57  0.79  0.51  
First trimester 
smoking  
 Yes  Yes  Yes 
    Non-
smokers/quit prior 
to first trimester/ 
unknown when quit  
Reference  -  -  
    Current smokers 0.54  1.14  0.81  
    Possible first 
trimester use (quit 
within 4 months of 
interview) 
0.98  1.60  1.53  
First trimester 
alcohol use 
 Yes  Yes  Yes 
    Non users/quit 
prior to first 
trimester  
Reference  -  -  
    Current users 1.24  1.40  1.86  
    Possible first 
trimester use (quit 
1.06  1.28  1.19  
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within 4 months of 
interview) 
Study Site  Yes  Yes  Yes 
    North Carolina Reference  -  -  
    Texas 0.60  0.62  0.61  
    Tennessee 0.80  0.88  0.86  
Final list of 
factors associated 
with each 
outcome:  
 
 
Age (linear), race, 
parity, diabetes history,  
hypertension history, 
first trimester smoking, 
first trimester alcohol 
use, study site 
 
Age (quadratic), race, 
parity, diabetes history,  
hypertension history, 
first trimester smoking, 
first trimester alcohol 
use, study site 
 
Age (quadratic), race, 
BMI (quadratic), parity,  
hypertension history, 
first trimester smoking, 
first trimester alcohol 
use, study site 
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Table 4. Confounding assessment, step 3: a 1% change-in-estimate approach to determine 
the final inclusion of potential confounders (maternal characteristics) for each outcome 
(symptom profile) 
 
 
Potential Confounder 
Bleeding Only 
(n=334) 
Pain Only 
(n=1885) 
Both Symptoms 
(n=792) 
 
Odds 
Ratio 
for Any 
Fibroids 
vs. No 
Fibroids 
 
1% 
change? 
 
Odds 
Ratio 
for Any 
Fibroids 
vs. No 
Fibroids 
 
1% 
change? 
 
Odds 
Ratio 
for Any 
Fibroids 
vs. No 
Fibroids 
 
1% 
change? 
Unadjusted Odds 
Ratio for Any 
Fibroids vs. No 
Fibroids 
1.1659 
≤1.1542 
or 
≥1.1776 
1.2087 
≤1.1966 
or 
≥1.2208 
1.4394 
≤1.4250 
or 
≥1.4538 
Linear Age 1.1004 Yes NA - NA - 
Quadratic Age NA - 1.3194 Yes 1.4968 Yes 
Race  1.1752 No 1.2356 Yes 1.4564 Yes 
Linear BMI NA - NA - NA - 
Quadratic BMI NA - NA - 1.4505 No 
Parity  1.1586 No 1.2266 Yes 1.3871 Yes 
Diabetes history 1.1663 No 1.2117 No NA - 
Hypertension history 1.1237 Yes 1.1839 Yes 1.3615 Yes 
First trimester smoking 1.1643 No 1.2258 Yes 1.4537 No 
First trimester alcohol 
use 
1.1477 Yes 1.2251 Yes 1.4374 No 
Study Site 1.1131 Yes 1.3893 Yes 1.3893 Yes 
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Table 5. Confounding assessment, step 4: a 10% change-in-estimate approach to determine 
the final inclusion of potential confounders (fibroid characteristics) for each outcome 
(symptom profile) 
 
 
Potential Confounder 
Bleeding Only 
(n=334) 
Pain Only 
(n=1885) 
Both Symptoms 
(n=792) 
 
Odds 
Ratio 
for Any 
Fibroids 
vs. No 
Fibroids 
 
10% 
change? 
 
Odds 
Ratio 
for Any 
Fibroids 
vs. No 
Fibroids 
 
10% 
change? 
 
Odds 
Ratio 
for Any 
Fibroids 
vs. No 
Fibroids 
 
10% 
change? 
Unadjusted Odds 
Ratio for Any 
Fibroids vs. No 
Fibroids 
1.1659 
≤1.0493 
or 
≥1.2825 
1.2087 
≤1.0878 
or 
≥1.3296 
1.4394 
≤1.2955 
or 
≥1.5833 
Any fibroids in the 
fundus? 
1.2537 No 1.1441 No 1.4838 No 
Only fibroids in the 
fundus? 
1.1929 No 1.1630 No 1.5272 No 
Any fibroids in the 
corpus?
1
 
1.1753 No 1.4633 Yes 1.5960 Yes 
Only fibroids in the 
corpus?
1
 
1.3156 Yes 1.4374 Yes 1.6241 Yes 
Any fibroids in the 
cervix? 
1.0029 Yes 1.1562 No 1.3000 No 
Only fibroids in the 
cervix? 
1.0581 No 1.1983 No 1.3411 No 
Any fibroids in the 
anterior? 
1.6144 Yes 1.4214 Yes 1.6392 Yes 
Any fibroids in the 
posterior? 
0.9478 Yes 1.1197 No 1.1408 Yes 
Any intramural 
fibroids? 
1.6049 Yes 1.1857 No 1.5202 No 
Any submucous 
fibroids (not distorting 
the endometrium)? 
1.1287 No 1.2046 No 1.4326 No 
Any submucous 
fibroids (distorting the 
endometrium)? 
1.0882 No 1.2443 No 1.3770 No 
Any subserosal 
fibroids?  
0.9775 Yes 1.2273 No 1.4161 No 
Any pedunculated 
fibroids? 
1.1447 No 1.1661 No 1.3789 No 
1Due to potential collinearity, variables like “Any fibroids in the corpus” and “Only fibroids in the corpus” 
were never included together in adjusted models (even if both resulted in a 10% change-in-estimate). 
Instead, only the variable for “Any fibroids in the corpus” was used. 
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A 10. Secondary results tables for Aims 1 and 2 
 
Table 1. Associations between risk of bleeding and total fibroid volume, adjusted for 
maternal and fibroid characteristics 
 
  
All Race Groups 
(n=1,715) 
n Adjusted
1
 
OR 95% CI 
No Symptoms 
(reference) 
(n=1,381) 
No Fibroids  1255 REF - 
Fibroid 
Volume  
   
≤5 63   
>5 and ≤20 31   
 >20 32   
     
 No Fibroids 299 REF - 
Bleeding Only 
(n=334) 
Fibroid 
Volume  
   
≤5 15 1.36 0.35, 5.26 
>5 and ≤20 10 1.91 0.50, 7.36 
>20 10 1.61 0.38, 6.74 
     
1
Adjusted for age (linear), hypertension history, alcohol use, study site, fibroids only in the corpus, fibroids 
only in the cervix, any fibroids in the anterior, any fibroids in the posterior, any intramural fibroids, any 
subserosal fibroids.   
 
 
 
 
 
 
 
 
 
 
 
 
 
171 
 
Table 2. Associations between risk of symptoms (not including bleeding only) and total fibroid volume, adjusted for maternal and fibroid 
characteristics and stratified by race 
 
  
White 
(n=2901) 
Black 
(n=707) 
n Adjusted
1
 n Adjusted
1
 
OR 95% CI OR 95% CI 
No Symptoms 
(reference) 
(n=979) 
No Fibroids  907 - - 210 - - 
Fibroid 
Volume  
      
    ≤5 cc 40   16   
    >5 and  ≤20 16   14   
     >20 16   11   
        
 No Fibroids 1254 - - 247 - - 
Pain Only 
(n=1363) 
Fibroid 
Volume  
      
    ≤5 cc 68 1.93 0.88, 4.26 26 1.17 0.31, 4.41 
    >5 and  ≤20 24 1.65 0.62, 4.42 17 1.35 0.33, 5.46 
    >20 17 1.27 0.44, 3.68 28 2.09 0.50, 8.70 
        
 No Fibroids 498 - - 108 - - 
Both 
Symptoms 
(n=559) 
Fibroid 
Volume  
      
    ≤5 cc 41 1.30 0.52, 3.27 8 0.65 0.13, 3.23 
    >5 and  ≤20 14 1.18 0.37, 3.74 6 0.90 0.17, 4.67 
    >20 6 0.42 0.10, 1.68 16 2.07 0.41, 10.45 
1
Adjusted for age (quadratic), parity, hypertension history, smoking, alcohol use, study site, any fibroids in the corpus, any fibroids in the anterior, any fibroids in 
the posterior.   
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Table 3. Associations between risk of symptoms and number of fibroids, adjusted for 
maternal and fibroid characteristics 
 
Outcome Exposure n Adjusted
1
 
OR 95% CI 
No symptoms 
(reference)  
(n=1381) 
No Fibroids (reference) 1255 REF - 
Fibroids 126   
Bleeding Only 
(n=334) 
No Fibroids 299 REF - 
Number of Fibroids (Linear) 35 1.43 0.88, 2.32 
     
Pain Only 
(n=1885) 
No Fibroids 1681 REF - 
Number of Fibroids (Linear) 204 1.34 0.98, 1.84 
     
Both Symptoms 
(n=792) 
No Fibroids 692 REF - 
Number of Fibroids (Linear) 100 1.26 0.87, 1.81 
1
Adjusted for age (quadratic), race, parity, hypertension history, first trimester smoking, first trimester 
alcohol use, study site; any fibroids in the uterine corpus, any in the cervix, any in the posterior, any in the 
anterior, any intramural fibroids, any subserosal fibroids  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Michels 
173 
 
 
A 11. Secondary results tables for Aim 3 
 
Table 1. Final model selections and associations between fibroid growth (≥50%) and 
maternal and fibroid characteristics from multilevel logistic regression models 
 
Characteristic Covariance 
Structure 
Number of 
Integration 
Points 
Random 
Coefficient 
kept? 
Interaction 
with time 
kept? 
ICC Fixed 
Effect 
Odds 
Ratio 
95% CI 
Null Model 
(time is only 
predictor) 
Unstructured 7 Yes1  0.659 0.19 1.76*10^ 
(-5), 
1995.84 
        
Maternal 
Characteristics 
       
Body Mass 
Index 
       
Time Varying2 
(continuous, 
linear) 
Independent  3 No  <0.001 1.03 1.00, 1.07 
Fixed3 
(continuous, 
linear) 
Independent  3  No <0.001 1.04 1.00, 1.07 
Fixed 
(categorical) 
Cannot model/choose covariance structure    
    Underweight        
    Normal        
    Overweight        
    Obese        
Age        
Fixed 
(continuous, 
linear) 
Independent  3  No <0.001 1.01 0.97, 1.06 
Fixed3 
(categorical) 
Independent  3  No <0.001   
    <28      0.68 0.37, 1.26 
    ≥28 and <31      REF - 
    ≥31 and <34      0.63 0.33, 1.19 
    ≥34      0.87 0.48, 1.61 
Race        
Fixed 
(categorical) 
Independent  3  No <0.001   
    White, Non-
Hispanic 
     REF - 
    Black, Non-
Hispanic 
     1.14 0.70, 1.86 
  Other/Hispanic      1.03 0.47, 2.27 
Parity        
Fixed 
(categorical) 
Independent  3  No <0.001   
    0      REF - 
    1      0.70 0.42, 1.16 
    2+      0.79 0.42, 1.50 
Smoking        
Fixed 
(categorical) 
Independent  3  No <0.001   
    No      REF - 
    Yes, exposed      0.93 0.28, 3.13 
    Possible      1.31 0.42, 4.14 
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exposure 
Alcohol        
Fixed 
(categorical) 
Independent  3  No <0.001   
    No      REF - 
    Yes, exposed      1.49 0.51, 4.34 
    Possible 
exposure 
     1.44 0.90, 2.29 
Diabetes        
Fixed 
(categorical) 
Independent  3  No <0.001   
    No      REF - 
    Yes      0.43 0.09, 2.03 
Hypertension        
Fixed 
(categorical) 
Independent  3  Yes4 <0.001   
    No      REF - 
    Yes      0.86 0.29, 2.52 
    Missing      0.40 0.17, 0.93 
First Trimester 
Symptoms 
       
Fixed 
(categorical) 
Independent  3  No <0.001   
    None      REF - 
    Pain only      1.26 0.70, 2.26 
    Bleeding 
only 
     1.31 0.59, 2.91 
    Both 
symptoms 
     1.59 0.82, 3.08 
Fibroid 
Characteristics  
(All are time-
varying and 
categorical) 
       
Any subserosal Independent  3 No  <0.001   
    No      REF - 
    Yes      1.22 0.77, 1.92 
Any 
submucous, 
distorting 
endometrium 
Identity 3 No  <0.001   
    No      REF - 
    Yes      0.38 0.18, 0.80 
Any 
submucous, not 
distorting 
Independent  3 No  <0.001   
    No      REF - 
    Yes      1.73 0.69, 4.29 
Any intramural Independent  3 No  <0.001   
    No      REF - 
    Yes      1.06 0.65, 1.72 
Any 
pedunculated 
Independent  3 No  <0.001   
    No      REF - 
    Yes      1.03 0.40, 2.65 
Any anterior Independent  3 No  <0.001   
    No      REF - 
    Yes      1.14 0.73, 1.81 
Any posterior Exchangeable 7 Yes  0.110   
    No      REF - 
    Yes      1.01 0.59, 1.71 
Any in cervix Independent  3 No  <0.001   
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    No      REF - 
    Yes      0.70 0.36, 1.37 
Any in fundus Independent  3 No  <0.001   
    No      REF - 
    Yes      1.35 0.84, 2.17 
Any in corpus Independent  3 No  <0.001   
    No      REF - 
    Yes      0.88 0.56, 1.40 
REF=reference category, ICC=intraclass correlation coefficient 
1
 A priori, it was decided to include a random coefficient for time when modeling all covariates 
2
 Time-varying variables use information from the second and third trimesters (Body Mass Index) or the 
first and second trimesters (fibroid characteristics) 
3
 Fixed variables use information from the first trimester across all time points 
4
 Odds ratios and confidence intervals reflect the linear combination of the lower order term of interest and 
its interaction term with time (t=1)  
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Table 2. Final model selections and associations between fibroid reduction (≥50%) and 
maternal and fibroid characteristics from multilevel logistic regression models 
 
 
 
Characteristic Covariance 
Structure 
Number of 
Integration 
Points 
Random 
Coefficient 
kept? 
Interaction 
with time 
kept? 
ICC Fixed 
Effect 
Odds 
Ratio 
95% CI 
Null Model 
(time is only 
predictor) 
Independent 3 No1  <0.001 1.08 0.73, 1.61 
        
Maternal 
Characteristics 
       
Body Mass 
Index 
       
Time Varying2 
(continuous, 
linear) 
Independent 3 No  <0.001 1.01 0.98, 1.04 
Fixed3 
(continuous, 
linear) 
Independent 3  No <0.001 1.01 0.98, 1.04 
Fixed 
(categorical) 
Independent 3  No <0.001   
    Underweight      0.60 0.06, 5.89 
    Normal      REF - 
    Overweight      0.93 0.58, 1.49 
    Obese      1.11 0.68, 1.81 
Age        
Fixed 
(continuous, 
linear) 
Independent 3  No <0.001 0.99 0.95, 1.02 
Fixed 
(categorical) 
Independent 3  No <0.001   
    <28      REF - 
    ≥28 and <31      1.46 0.86, 2.48 
    ≥31 and <34      1.05 0.60, 1.83 
    ≥34      0.93 0.53, 1.62 
Race        
Fixed 
(categorical) 
Independent 3  No <0.001   
    White, Non-
Hispanic 
     REF - 
    Black, Non-
Hispanic 
     0.95 0.62, 1.46 
    
Other/Hispanic 
     0.45 0.21, 0.99 
Parity        
Fixed 
(categorical) 
Independent 3  No <0.001   
    0      REF - 
    1      1.23 0.79, 1.90 
    2+      1.38 0.79, 2.39 
Smoking        
Fixed 
(categorical) 
Independent 3  No <0.001   
    No      REF - 
    Yes, exposed      1.08 0.38, 3.03 
    Possible 
exposure 
     0.82 0.28, 2.40 
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Alcohol        
Fixed 
(categorical) 
Independent 3  No <0.001   
    No      REF - 
    Yes, exposed      0.59 0.20, 1.68 
    Possible 
exposure 
     0.99 0.66, 1.48 
Diabetes        
Fixed 
(categorical) 
Independent 3  No4 <0.001   
    No      REF - 
    Yes      1.84 0.63, 5.36 
Hypertension        
Fixed 
(categorical) 
Independent 3  Yes5 <0.001   
    No      REF - 
    Yes      1.43 0.49, 4.24 
    Missing      1.91 0.90, 1.04 
First Trimester 
Symptoms 
       
Fixed3 
(categorical) 
Independent 3  No <0.001   
    None      REF - 
    Pain only      0.77 0.47, 1.26 
    Bleeding only      0.82 0.41, 1.62 
    Both 
symptoms 
     0.91 0.51, 1.60 
Fibroid 
Characteristics  
(All are time-
varying and 
categorical) 
       
Any subserosal Independent 3 No  <0.001   
    No      REF - 
    Yes      0.91 0.61, 1.37 
Any submucous, 
distorting 
endometrium 
Independent 3 No  <0.001   
    No      REF - 
    Yes      3.69 2.18, 6.24 
Any submucous, 
not distorting 
Identity 3 No  <0.001   
    No      REF - 
    Yes      0.73 0.30, 1.81 
Any intramural Independent 3 No  <0.001   
    No      REF - 
    Yes      1.31 0.84, 2.04 
Any 
pedunculated 
Independent 3 No  <0.001   
    No      REF - 
    Yes      0.52 0.21, 1.33 
Any anterior Independent 3 No  <0.001   
    No      REF - 
    Yes      1.36 0.91, 2.03 
Any posterior Independent 3 No  <0.001   
    No      REF - 
    Yes      1.51 1.01, 2.26 
Any in cervix Independent 3 No  <0.001   
    No      REF - 
    Yes      1.59 0.92, 2.77 
Any in fundus Independent 5 Yes  <0.001   
    No      REF - 
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    Yes      0.82 0.49, 1.38 
Any in corpus Independent 3 No  <0.001   
    No      REF - 
    Yes      1.90 1.26, 2.86 
REF=reference category, ICC=intraclass correlation coefficient. 
1
 A priori, it was decided to include a random coefficient for time when modeling all covariates 
2
 Time-varying variables use information from the second and third trimesters (Body Mass Index) or the 
first and second trimesters (fibroid characteristics) 
3
 Fixed variables use information from the first trimester across time points 
4
 Models with an interaction term would not run, so the term was removed to allow for the selection of 
integration points and a covariance structure 
5
 Odds ratios and confidence intervals reflect the linear combination of the lower order term of interest and 
its interaction term with time (t=1)  
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Table 3. Multilevel logistic regression model selections for an increase in number of fibroids 
associated with maternal or fibroid characteristics  
 
 
Characteristic Covariance 
Structure 
Number of 
Integration 
Points 
Random 
Coefficient 
kept? 
Interaction 
with time 
kept? 
Null Model 
(time is only predictor) 
Identity1  5 Yes2  
     
Maternal 
Characteristics 
    
Body Mass Index     
Time Varying3 
(continuous, linear) 
Identity 3 No1  
Fixed4 
(continuous, linear) 
Independent 7  No 
Fixed 
(categorical) 
Exchangeable 5  No1 
    Underweight     
    Normal     
    Overweight     
    Obese     
Age     
Fixed 
(continuous, linear) 
Independent 5  No 
Fixed 
(categorical) 
Identity1 5  No 
    <28     
    ≥28 and <31     
    ≥31 and <34     
    ≥34     
Race     
Fixed 
(categorical) 
Independent 9  No1 
    White, Non-Hispanic     
    Black, Non-Hispanic     
    Other/Hispanic     
Parity     
Fixed 
(categorical) 
Identity1 5  No 
    0     
    1     
    2+     
Smoking     
Fixed 
(categorical) 
Identity 7  No1 
    No     
    Yes, exposed     
    Possible exposure     
Alcohol     
Fixed 
(categorical) 
Identity1 5  No 
    No     
    Yes, exposed     
    Possible exposure     
Diabetes     
Fixed 
(categorical) 
Independent 7  No1 
    No     
    Yes     
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Hypertension     
Fixed 
(categorical) 
Independent 7  No 
    No     
    Yes     
Missing     
First Trimester 
Symptoms 
    
Fixed 
(categorical) 
Independent 7  No 
    None     
    Pain only     
    Bleeding only     
    Both symptoms     
Fibroid 
Characteristics  
(All are time-varying 
and categorical) 
    
Any subserosal Identity 5 Yes  
    No     
    Yes     
Any submucous, 
distorting endometrium 
Independent 5 No  
    No     
    Yes     
Any submucous, not 
distorting 
Identity 5 Yes  
    No     
    Yes     
Any intramural Identity1 5 Yes  
    No     
    Yes     
Any pedunculated Independent 5 No  
    No     
    Yes     
Any anterior Identity 5 Yes  
    No     
    Yes     
Any posterior Identity 5 Yes  
    No     
    Yes     
Any in cervix Identity 5 Yes  
    No     
    Yes     
Any in fundus Identity 5 Yes  
    No     
    Yes     
Any in corpus Identity 5 Yes  
    No     
    Yes     
REF=reference category, ICC=intraclass correlation coefficient. 
1
 Difficulty in modeling: either an independent covariance structure, a random coefficient, or an interaction 
term with time prevented models from running. In the first case, identity matrix was preferred. In the latter 
two cases, the terms were removed to allow integration points and a covariance structure to be chosen.  
2
 A priori, it was decided to include a random coefficient for time when modeling all covariates 
3
 Time-varying variables use information from the second and third trimesters (Body Mass Index) or the 
first and second trimesters (fibroid characteristics) 
4
 Fixed variables use information from the first trimester across time points 
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Table 4. Multilevel logistic regression model selections for a decrease in number of fibroids 
associated with maternal or fibroid characteristics 
 
 
Characteristic Covariance 
Structure 
Number of 
Integration 
Points 
Random 
Coefficient 
kept? 
Interaction 
with time 
kept? 
Null Model 
(time is only predictor) 
Independent 3 No1  
     
Maternal 
Characteristics 
    
Body Mass Index     
Time Varying2 
(continuous, linear) 
Independent 3 No  
Fixed3 
(continuous, linear) 
Independent 3  No 
Fixed 
(categorical) 
Independent 3  No 
Underweight     
Normal     
Overweight     
Obese     
Age     
Fixed 
(continuous, linear) 
Independent 3  No 
Fixed 
(categorical) 
Independent 3  No 
<28     
≥28 and <31     
≥31 and <34     
≥34     
Race     
Fixed 
(categorical) 
Independent 3  No 
White, Non-Hispanic     
Black, Non-Hispanic     
Other/Hispanic     
Parity     
Fixed 
(categorical) 
Independent 5  No 
0     
1     
2+     
Smoking     
Fixed 
(categorical) 
Independent 3  No 
No     
Yes, exposed     
Possible exposure     
Alcohol     
Fixed 
(categorical) 
Independent 3  No 
No     
Yes, exposed     
Possible exposure     
Diabetes     
Fixed Independent 3  No4 
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(categorical) 
No     
Yes     
Hypertension     
Fixed 
(categorical) 
Independent 3  No 
No     
Yes     
Missing     
First Trimester 
Symptoms 
    
Fixed 
(categorical) 
Independent 3  No 
None     
Pain only     
Bleeding only     
Both symptoms     
Fibroid 
Characteristics 
(All are time-varying 
and categorical) 
    
Any subserosal Independent 3 No  
No     
Yes     
Any submucous, 
distorting endometrium 
Independent 3 No  
No     
Yes     
Any submucous, not 
distorting 
Independent 5 Yes  
No     
Yes     
Any intramural Independent 3 No  
No     
Yes     
Any pedunculated Independent 3 No  
No     
Yes     
Any anterior Independent 3 No  
No     
Yes     
Any posterior Independent 3 Yes  
No     
Yes     
Any in cervix Independent 3 Yes  
No     
Yes     
Any in fundus Identity 3 No  
No     
Yes     
Any in corpus Independent 3 Yes  
No     
Yes     
REF=reference category, ICC=intraclass correlation coefficient. 
1
 A priori, it was decided to include a random coefficient for time when modeling all covariates 
2
 Time-varying variables use information from the second and third trimesters (Body Mass Index) or the 
first and second trimesters (fibroid characteristics) 
3
 Fixed variables use information from the first trimester across time points 
 
